Sids


Sudden infant death syndrome

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Sudden Infant Death Syndrome

Safe to Sleep Public Education Campaign, NICHD

Classification and external resources

ICD-10

R95 Added new codes R95.0 for SIDS with mention of autopsy and R95.9 for SIDS without mention of autopsy – For implementation January 2013 (http://www.who.int/classifications/icd/ICD-10Updates2009.pdf).

ICD-9

798.0

OMIM

272120

DiseasesDB

12633

MedlinePlus

001566

eMedicine

emerg/407 ped/2171

MeSH

D013398

Sudden Infant Death Syndrome (SIDS) is marked by the sudden death of an infant that is not predicted by medical history and remains unexplained after a thorough forensic autopsy and detailed death scene investigation.[1] As infants are at the highest risk for SIDS during sleep, it is sometimes referred to as cot death or crib death.

Typically the infant is found dead after having been put to bed, and exhibits no signs of having suffered.[2]

The cause of SIDS is unknown, but some characteristics associated with the syndrome have been identified. The unique signature characteristic of SIDS is its log-normal age distribution that spares infants shortly after birth — the time of maximal risk for almost all other causes of non-trauma infant death. Other notable characteristics are its disproportionate affliction of male infants and the fact that caregivers are unaware in the preceding 24 hours that the infant is at risk of imminent sudden death. Many risk factors and medical causal relationships are proposed for SIDS. Infants sleeping on their bellies or exposed to tobacco smoke are at greater risk than infants sleeping on their backs or unexposed to tobacco smoke. Genetics also play a role, as SIDS is more prevalent in males.[3][4]

SIDS prevention strategies include safe sleep practices, such as putting the infant to sleep on his or her back, in a well-ventilated room, on a firm mattress separate from but close to caregivers. In particular, the “back to sleep” campaign is credited with leading to a measurable reduction in SIDS rates. Pacifiers at bedtime and naptime can help reduce risk. Not smoking during pregnancy is another way to reduce SIDS risk.[5][6] Despite the gradual expansion of medical knowledge on SIDS causes and risk factors, definitive diagnosis remains difficult; infanticide and child abuse cases may be misdiagnosed as SIDS due to lack of evidence, and caretakers of SIDS victims are sometimes falsely accused of foul play.[7][8] Accidental suffocations are also sometimes misdiagnosed as SIDS and vice versa.[9]

Contents
[hide] 1 Definition
2 Risk factors 2.1 Prenatal
2.2 Postnatal

3 Hypotheses 3.1 Bacterial infections
3.2 Bed sharing
3.3 Brain disorders
3.4 Central respiratory pattern deficiency
3.5 Cervical spinal injury from birth trauma
3.6 Child abuse
3.7 Genetics
3.8 Inner ear damage
3.9 Nitrogen dioxide
3.10 Toxic gases
3.11 Vaccination
3.12 Vitamin C

4 Differential diagnosis
5 Prevention 5.1 Air circulation with fan use
5.2 Bedding
5.3 Breastfeeding
5.4 Bumper pads
5.5 Concerns regarding recommendations
5.6 Pacifiers
5.7 Secondhand smoke reduction
5.8 Sleep positioning
5.9 Sleep sacks

6 Epidemiology
7 See also
8 References
9 Further reading
10 External links

Definition [edit]

SIDS is a diagnosis of exclusion and should be applied to only those cases in which an infant’s death is sudden and unexpected, and remains unexplained after the performance of an adequate postmortem investigation, including:
1.an autopsy (by an experienced pediatric pathologist, if possible);
2.investigation of the death scene and circumstances of the death;
3.exploration of the medical history of the infant and family.

After investigation, some of these infants deaths are found to be caused by accidental suffocation, hyperthermia or hypothermia, neglect or some other defined cause.[10]

Australia and New Zealand are shifting to the term “sudden unexpected death in infancy” (SUDI) for professional, scientific and coronial clarity.

The term SUDI is now often used instead of sudden infant death syndrome (SIDS) because some coroners prefer to use the term ‘undetermined’ for a death previously considered to be SIDS. This change is causing diagnostic shift in the mortality data.[11]

In addition, the U.S. Centers for Disease Control and Prevention (CDC) has recently proposed that such deaths be called “sudden unexpected infant deaths” (SUID) and that SIDS is a subset of SUID.[12]

Risk factors [edit]

The cause of SIDS is unknown. Although studies have identified risk factors for SIDS, such as putting infants to bed on their stomachs, there has been little understanding of the syndrome’s biological process or its potential causes. The frequency of SIDS does appear to be influenced by the infant’s age or ethnicity, and the education or socioeconomic status of the infant’s parents.

Listed below are several risk factors associated with increased probability of the syndrome.

Prenatal [edit]
Maternal age — SIDS rates decrease with increasing maternal age, with teenage mothers at greatest risk.[13]
Delayed or inadequate prenatal care [13]
Exposure to nicotine from maternal smoking — SIDS rates are higher for infants of mothers who smoke during pregnancy.[13][14]

Postnatal [edit]
Low birth weight — in the United States from 1995–98, the SIDS death rate for infants weighing 1000–1499 g was 2.89/1000; for a birth weight of 3500–3999 g, it was only 0.51/1000).[15][16]
Exposure to tobacco smoke;[17]
Prone sleeping position (lying on the stomach);[18][19]
No breastfeeding;[20]
Elevated or reduced room temperature;[21]
Excesses of bedding, clothing, soft sleep surfaces, or stuffed animals;[22]
Anemia.[23] (note, however, that per item 6 in the list of epidemiologic characteristics below, extent of anemia cannot be evaluated at autopsy because “total hemoglobin can only be measured in living infants.”[24])
Sharing a bed with parents or other siblings may increase risk for SIDS, but the mechanism remains unclear.[25]
Age of infant — SIDS incidence rises from zero at birth, is highest from two to four months of age, and declines toward zero after the infant’s first year.[26]
Male sex — male children have a ~50% higher risk of SIDS than female children.[27]
Premature birth — increases risk of SIDS death roughly fourfold.[13][15] From 1995–1998 the U.S. SIDS rate for births at 37–39 weeks of gestation was 0.73/1000; the SIDS rate for births at 28–31 weeks of gestation was 2.39/1000)[15]
Mold (this hypothesis has been disproven by research subsequent to Cleveland study in the 1990′s; infant pulmonary hemorrhage is most closely linked to premature birth; prematurity and water-damaged homes would both coincide with poverty)http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4909a3.htm — can cause bleeding in the lungs and a variety of other uncommon conditions that may be fatal; the presence of mold correlates positively with increased incidence of SIDS[citation needed]. Mold-related illness is often misdiagnosed as a virus, influenza, and/or an asthma-like condition.[28]

Hypotheses [edit]

Bacterial infections [edit]

In a British study released May 29, 2008, researchers discovered that the common bacterial infections Staphylococcus aureus and Escherichia coli appear to be risk factors in some cases of SIDS. Both bacteria were present in greater-than-usual concentrations in infants who died from SIDS.[29] SIDS cases peak between eight and ten weeks after birth, a time when antibodies passed from mother to child are starting to disappear, but have not yet been replenished by the infant’s own antibodies.

Bed sharing [edit]

A 2005 policy statement by the American Academy of Pediatrics (AAP) on sleep environment and the risk of SIDS deemed bed-sharing unsafe, recommending that infants sleep in a separate crib, bassinet, or cradle in the same room as a parent.[30] In 2011, the AAP issued an expansion of its recommendations for a safe infant sleeping environment, in which it again recommended “room-sharing without bed-sharing”, stating that such an arrangement can decrease the risk of SIDS by up to 50%. Furthermore, it recommended against devices marketed to make bed-sharing “safe”, such as in-bed co-sleepers.[31]

One trial compared 20 infants who shared their parents’ bed one night and slept separately the next. The children’s heart rate and oxygen saturation were monitored and analyzed together with eight hours of infrared video recording of their sleep. Although the bed-sharing infants spent some parts of the night with their airways (both mouth and nose) covered, “no consistent effect on either oxygen saturation levels or heart rate was revealed, even during prolonged bouts of airway covering.” The authors concluded that “although numerous authors have suggested that bed-sharing infants face risks because of airway covering by bed-clothes or parental bodies, the present trial does not lend support to this hypothesis”.[32]

Brain disorders [edit]

According to a 2006 study in the Journal of the American Medical Association (JAMA), some babies who die of SIDS have abnormalities in the brain stem (medulla oblongata) of underdeveloped serotonin receptors (which help control functions like breathing, blood pressure and arousal) and abnormalities in serotonin signaling. According to the National Institutes of Health, this finding was the strongest evidence at that time that structural differences in a specific part of the brain may contribute to the risk of SIDS.[33] This abnormality can continue postpartum until the end of the baby’s first year, possibly accounting for the increased SIDS risk in premature infants and declining risk in children over 12 months of age. The authors noted that males have fewer serotonin receptors than females, perhaps contributing to the greater frequency of SIDS in males, but their follow-up 2010 paper failed to reconfirm that gender difference.[34]

Another 2006 study showed that a possible cause of SIDS parents leaving their infants in an angled (feet up, head down) position known as the Trendelenburg position.[35] This position can cause the brain stem to fall; in severe cases, the brain becomes “crushed”. Recommended positions for resting infants include Fowler’s position and Sims’ position.[citation needed]

A 2010 study suggests Interleukin-2, a neuromodulator, as the potential mechanism of SIDS. Intense neuronal IL-2 immunoreactivity in brainstems of SIDS victims was found, which could be responsible for decreased cardiorespiratory and arousal responses.[36]

Central respiratory pattern deficiency [edit]

Ongoing research in the pediatric/neonatal community has begun to associate apnea-like breathing cessations in animal models with unusual neural architecture or signal transduction in central pattern generator circuits, including the pre-Bötzinger complex.[37]

Cervical spinal injury from birth trauma [edit]

During birth, if the infant’s head is traumatically turned side to side, upper cervical spinal injury can result. Difficulty breathing is a classic sign of upper spinal cord and brainstem injury.[38] When infants with undiagnosed upper cervical spinal cord injury are continually placed on their stomachs for sleep, they are forced to turn their heads to the side to breathe.

Child abuse [edit]

Several instances of infanticide have been uncovered where the diagnosis was originally SIDS.[7][8] This has led some researchers to estimate that 5% to 20% of SIDS deaths are actually infanticides.[39][40][41][42] In 1997 The New York Times, covering the book The Death of Innocents: A True Story of Murder, Medicine and High-Stakes Science, wrote:

The misdiagnosis of infanticide as SIDS “happens all over,” Ms. Talan, a medical reporter at Newsday, said. “A lot of doctors and police don’t know how to handle it. They don’t take it as seriously as they should.” As a result of the book’s revelations, people are starting to scrutinize possible cases of this “perfect crime,” which involves no physical evidence and no witnesses.[43]

A United Kingdom pediatrician, Roy Meadow believes that many cases diagnosed as SIDS are really the result of child abuse on the part of a parent. During the 1990s and early 2000s, a number of mothers of multiple apparent SIDS victims were convicted of homicide to various extents, on the basis of Meadow’s opinion. In 2003 a number of high-profile acquittals brought Meadow’s theories into disrepute. Several hundred murder convictions were reviewed, leading to several high-profile cases being reopened and convictions overturned. Meadow’s medical license was revoked in 2005,[44] after which he appealed to the High Court, which ruled in his favour in February 2006. The General Medical Council appealed to the Court of Appeal and in October 2006 by a majority decision, with the Master of the Rolls, Sir Anthony Clarke, dissenting, the Court of Appeal upheld the decision of the High Court in part, ruling that Meadow’s misconduct was not sufficiently serious to merit the punishment which he had received.

The Royal Statistical Society issued a media release refuting the expert testimony in one UK case in which the conviction was subsequently overturned.[45]

Genetics [edit]

There is a consistent 50% male excess in SIDS per 1000 live births of each sex. Given a 5% male excess birth rate, there appears to be 3.15 male SIDS cases per 2 female, for a male fraction of 0.61.[3][4] This value of 61% in the US is an average of 57% black male SIDS, 62.2% white male SIDS and 59.4% for all other races combined. Note that when multiracial parentage is involved, infant “race” is arbitrarily assigned to one category or the other; most often it is chosen by the mother. The X-linkage hypothesis for SIDS and the male excess in infant mortality have shown that the 50% male excess could be related to a dominant X-linked allele, occurring with a frequency of 1⁄3 that is protective of transient cerebral anoxia. An unprotected XY male would occur with a frequency of 2⁄3 and an unprotected XX female would occur with a frequency of 4⁄9. The ratio of 2⁄3 to 4⁄9 is 1.5 to 1, which matches the observed male 50% excess rate of SIDS.

Although many researchers have found autosomal and mitochondrial genetic risk factors for SIDS, they cannot explain the male excess because such gene loci have the same frequencies for males and females. Supporting evidence for an X-linkage is found by examining other causes of infant respiratory death, such as suffocation by inhalation of food or other foreign objects. Although food is prepared identically for male and female infants, there is a similar 50% male excess of death from such causes, indicating that males are more susceptible to the cerebral anoxia created by such incidents in exactly the same proportion as found in SIDS.[46][original research?]

The 2006 JAMA study which indicated a relationship between fewer serotonin binding sites and SIDS noted that the boys “had significantly fewer serotonin binding sites than girls”,[33] but the authors could not reproduce that result in their 2010 paper.[34] This neurological imbalance decreases with age, but the increased male SIDS risk of approximately 61% persists throughout each month in the first year of life.[47] Furthermore, this cannot explain the identical male overrepresentation in other respiratory mortality causes, such as respiratory distress syndrome or suffocation from inhalation of food or foreign objects cited above, that also exists for ages of 1–14 years in the U.S. from 1979 to 2005.[15][original research?]

Inner ear damage [edit]

Records of hearing tests (oto-acoustic emissions/OAEs) administered to certain infants show that those who later died of SIDS had differences in the pattern of these tests compared with normal babies. The OAE signal-to-noise ratio was reduced in the right ears of SIDS babies (Rubens DD et al. Early Human Development 84, 225-9 (2008)).[48] It should be noted this was a small study (n=31 cases and 31 controls) with serious limitations (several significant factors were not controlled), and has been criticised from various perspectives.[49] The authors’ suggestion for the cause of SIDS is that the deaths are caused by disturbances in respiratory control other than suffocation. The vestibular apparatus of the inner ear has been shown to play an important role in respiratory control during sleep; this inner ear damage could be linked to SIDS. The authors speculate that the damage occurs during delivery, particularly when prolonged contractions create greater blood pressure in the placenta. The right ear is directly in the “line of fire” for blood entering the fetus from the placenta, and thus could be more susceptible to damage. If the findings are relevant, it may be possible to take corrective measures. Researchers are beginning animal studies to explore the connection.[50]

Nitrogen dioxide [edit]

A 2005 study by researchers at the University of California, San Diego, found that “SIDS may be related to high levels of acute outdoor NO2 exposure during the last day of life.”[51] While nitrogen dioxide (NO2) exposure may be one of many possible risk factors, it is not considered causal, and the report cautioned that further studies were needed to replicate the result.

Toxic gases [edit]

In 1989, a controversial piece of research by UK scientist Barry Richardson claimed that all cot deaths were the result of toxic nerve gases being produced through the action of fungus in mattresses on compounds of phosphorus, arsenic and antimony. These chemicals are frequently used to make mattresses fire-retardant.[citation needed]

Support for this hypothesis was based on the observation that the risk of cot death rises from one sibling to the next.[citation needed] Richardson claimed that parents are more likely to buy new bedding for their first child, and to reuse that bedding for later children. The more frequently used the bedding, the more chance that fungus has become resident in the material; thus, a higher chance of cot death. A paper by Peter Fleming and Peter Blair[52] references evidence from other studies that both supports and refutes the increasing occurrence of SIDS with mattress sharing, suggesting that this is still inconclusive.

Dr. Jim Sprott recommends new parents either buy bedding free of the toxic compounds or wrap the mattresses in a barrier film to prevent escape of the gases. Sprott claims that no case of cot death has ever been traced to a properly manufactured or wrapped mattress.[53]

However, a final report of “The Expert Group to Investigate Cot Death Theories: Toxic Gas Hypothesis”, published in May 1998, concluded that “there was no evidence to substantiate the toxic gas hypothesis that antimony- and phosphorus-containing compounds used as fire retardants in PVC and other cot mattress materials are a cause of SIDS. Neither was there any evidence to believe that these chemicals could pose any other health risk to infants.”[54] The report also states that “in normal cot-like conditions it is not possible to generate toxic gas from antimony in mattresses” and that “babies have also been found to die on wrapped mattresses.”

According to Dr. Sprott, as of 2006, the New Zealand government has not reported any SIDS deaths when babies have slept on mattresses wrapped according to his method. While the Limerick report claims that babies have been found to die on wrapped mattresses, Dr. Sprott argues that a chemical analysis of the bedding should be performed. He additionally claims that this part of the report was flawed:

In February 2000 Dr. Peter Fleming (a co-author of the Limerick Report and principal author of the UK CESDI Report) conceded that the claim that three babies in the United Kingdom had died of cot death on polythene-covered mattresses could not be substantiated.[55]

Vaccination [edit]

Vaccination does not increase the risk of SIDS, and may reduce the risk slightly.[56][57]

According to the US Centers for Disease Control and Prevention:

From 2 to 4 months old, babies begin their primary course of routine vaccinations. This is also the peak age for sudden infant death syndrome (SIDS). The timing of these two events has led some people to believe they might be related. However, studies have concluded that vaccines are not a risk factor for SIDS.[57]

Vitamin C [edit]

In the 1970s, high doses of vitamin C were touted as a preventive measure for SIDS,[58] although the claim was controversial even then.[59][60] Subsequent studies failed to support a preventive role for vitamin C in SIDS.[61] To the contrary, a 2009 study found that high levels of vitamin C were strongly associated with SIDS, possibly through a pro-oxidant interaction with iron.[62]

Differential diagnosis [edit]

Some conditions that are often undiagnosed and could confused with or comorbid with SIDS include:
medium-chain acyl-coenzyme A dehydrogenase deficiency (MCAD deficiency);[63]
infant botulism;[64]
long QT syndrome (accounting for less than 2% of cases);[65]
Helicobacter pylori bacterial infections;[66]
shaken baby syndrome and other forms of child abuse;[67][68]
overlying.[69]

For example, an infant with MCAD deficiency could have died by “classical SIDS” if found swaddled and prone with head covered in an overheated room where parents were smoking. Genes indicating susceptibility to MCAD and Long QT syndrome do not protect an infant from dying of classical SIDS. Therefore, presence of a susceptibility gene, such as for MCAD, means the infant may have died either from SIDS or from MCAD deficiency. It is currently impossible for the pathologist to distinguish between them.

A 2010 study looked at 554 autopsies of infants in North Carolina that listed SIDS as the cause of death, and suggested that many of these deaths may have been due to accidental suffocation. The study found that 69% of autopsies listed other possible risk factors that could have led to death, such us unsafe bedding or sleeping with adults.[70]

Prevention [edit]

Air circulation with fan use [edit]

According to a study of nearly 500 babies published in the October 2008 Archives of Pediatrics & Adolescent Medicine, using a fan to circulate air correlates with a lower risk of sudden infant death syndrome. This is plausible because a prone sleeping baby with nose to the sleeping surface could rebreathe some of its exhaled breath which is enriched in CO2 and depleted in oxygen. A fan could increase the mixing of the exhalation into the room air and lessen the risk of SIDS related to infant hypoxia. Researchers took into account other risk factors and found that fan use was associated with a 72% lower risk of SIDS. Only 3% of the babies who died had a fan on in the room during their last sleep, the mothers reported. That compared to 12% of the babies who lived. Using a fan reduced risk most for babies in poor sleeping environments.[6] Author De-Kun li said that “the baby’s sleeping environment really matters” and that “this seems to suggest that by improving room ventilation we can further reduce risk.”[71]

However, Dr. John Olssen at East Carolina University has pointed out that this study had a number of methodological flaws, such as selection and recall bias, low enrollment numbers, and dissimilar study groups. Olssen argues that although fan use is probably not harmful, it should not be recommended as a means to reduce the risk of SIDS.[72]

Bedding [edit]

Product safety experts advise against using pillows, overly soft mattresses, sleep positioners, bumper pads, stuffed animals, or fluffy bedding in the crib and recommend instead dressing the child warmly and keeping the crib “naked.”[73][74]

Blankets should not be placed over an infant’s head.[75] It has been recommended that infants should be covered only up to their chest with their arms exposed. This reduces the chance of the infant shifting the blanket over his or her head.

Breastfeeding [edit]

A 2003 study published in Pediatrics, which investigated racial disparities in infant mortality in Chicago, found that previously or currently breastfeeding infants in the study had 1/5 the rate of SIDS compared with non-breastfed infants, but that “it became nonsignificant in the multivariate model that included the other environmental factors”. These results are consistent with most published reports and suggest that other factors associated with breastfeeding, rather than breastfeeding itself, are protective.”[76] More recent studies however claim to show a significantly reduced incidence of SIDS in breastfed infants. [77][78][79]

Bumper pads [edit]

Bumper pads may be a contributing factor, claims Health Canada, the Canadian government’s health department. They issued an advisory[80] recommending against the use of bumper pads, stating:

The presence of bumper pads in a crib may also be a contributing factor for Sudden Infant Death Syndrome (SIDS). These products may reduce the flow of oxygen rich air to the infant in the crib. Furthermore, proposed theories indicate that the re-breathing of carbon dioxide plays a role in the occurrence of SIDS.

Concerns regarding recommendations [edit]

Dr. Rafael Pelayo from Stanford University and a number of other pediatric sleep researchers in the US have stated that they believe that the American Academy of Pediatrics’ recommendations regarding cosleeping and pacifier use may have unintended consequences. They have stated that the SIDS prevention strategy of the American Academy of Pediatrics which keeps infants at a low arousal threshold and reduces the time in quiet sleep may be unhealthy for children. They state that slow-wave sleep is the most restorative form of sleep and limiting this sleep in the first 12 months of life may have unintended consequences to both the sleep and the infant.[81]

According to a 1998 study by British researchers that compared back-sleeping infants to stomach-sleeping infants, there were developmental differences at 6 months of age between the two groups. At 6 months of age, the stomach-sleeping infants had higher gross-motor scores, social-skills scores, and total-development skills scores than the back-sleeping infants. The differences were apparent at the 5% statistical significant level. But, at 18 months, the differences were no longer apparent. The researchers deemed the lower-development scores of back-sleeping infants at 6 months of age to be transient and stated that they do not believe the back-sleeping recommendations should be changed.[82] Other scientists have stated that the conclusion that the negative effects of back-sleep at 18 months of age is transient is based upon very little evidence and that no long-term randomized trials have been completed.[83]

Other side effects of the back-sleeping position include increased rates of shoulder retraction, positional plagiocephaly, and positional torticollis.[84] Some scientists dispute that plagiocephaly is a negative side effect. Dr. Peter Fleming, who is co-author of the study that deemed delays at 6 months of age to be transient, has stated that he does not think plagiocephaly is a negative side effect of back-sleep. In an interview with the Guardian, Dr. Fleming stated “I do not think it is a medical problem—it is more of a cosmetic one. Mothers may feel it is a syndrome and a problem when it really is nonsense.”[85] A research study on children with plagiocephaly plus a confounding condition such as premature birth or failure to thrive, found that 26% had mild to severe psychomotor delay. This study also showed that 10% of infants with plagiocephaly had mild to severe mental development delay.[86]

Because of the delays caused by back-sleep, some medical professionals have suggested that the “normal” ages at which children had previously attained developmental milestones should be pushed back. This would enable medical professionals to consider “normal” children who previously were considered developmentally delayed.[87]

Additional studies have reported that the following negative conditions are associated with the back-sleep position: increase in sleep apnea; decrease in sleep duration; strabismus; social skills delays; deformational plagiocephaly; and temporomandibular jaw difficulties.[84] In addition, the following are symptoms that are associated with sleep apnea: growth abnormalities; failure-to-thrive syndrome in infants; neurocognitive abnormalities; daytime sleepiness; emotional problems; decrease in memory; decrease in learning; and a delay in nonverbal skills. The conditions associated with deformational plagiocephaly include visual impairments;; cerebral dysfunction, delays in psychomotor development and decreases in mental functioning. The conditions associated with gross motor milestone delays include speech and language disorders. In addition, it has been hypothesized that delays in motor skills can have a negative impact on the development of social skills.[88][89] In addition, other studies have reported that the prone position prevents subluxation of the hips; increases psychomotor development;, prevents scoliosis; lessens the risk of gastroesophageal reflux; decreases infant screaming periods; causes less fatigue in infants; and increases the relief of infant colic.[90] In addition, prior to the “Back to Sleep” campaign, many babies self-treated their own torticollis by turning their heads from one side to the other while sleeping in the prone position.[91] Supine-sleeping infants cannot self-treat their own torticollis.

Pacifiers [edit]

According to a 2005 meta-analysis, most studies favor pacifier use.[5] According to the American Academy of Pediatrics, pacifier use seems to reduce the risk of SIDS, although the mechanism by which this happens is unclear.[92] SIDS experts and policy makers haven’t recommended the use of pacifiers to reduce the risk of SIDS because of several problems associated with pacifier use, like increased risk of otitis, gastrointestinal infections and oral colonization with Candida species.[92] A 2005 study indicated that use of a pacifier is associated with up to a 90% reduction in the risk of SIDS depending on the ambient factors, and it reduced the effect of other risk factors.[93] It has been speculated that the raised surface of the pacifier holds the infant’s face away from the mattress, reducing the risk of suffocation. If a postmortem investigation does not occur or is insufficient, a suffocated baby may be misdiagnosed with SIDS.

A 2010 study at Monash University suggests pacifiers can prevent SIDS by changing sleep patterns. They believe a pacifier ensures the baby remains in a light sleep and is more easily aroused if he or she feels uncomfortable.[94] The most recent 2011 study confirms that pacifier usage also reduces SIDS risks from other known SIDS risk factors[95]

Secondhand smoke reduction [edit]

According to the US Surgeon General’s Report, secondhand smoke is connected to SIDS.[96] Infants who die from SIDS tend to have higher concentrations of nicotine and cotinine (a biological marker for secondhand smoke exposure) in their body fluids than those who die from other causes.[97] Parents who smoke can significantly reduce their children’s risk of SIDS by either quitting or smoking only outside and leaving their house completely smoke-free.

The maternal pregnancy smoking rate decreased by 38% between 1990 and 2002.[98]

Sleep positioning [edit]

Main article: Back to Sleep

A plot of SIDS rate from 1988 to 2006
Sleeping on the back has been recommended by (among others) the American Academy of Pediatrics (starting in 1992) to avoid SIDS, with the catchphrases “Back To Bed” and “Back to Sleep”. The incidence of SIDS has fallen sharply in a number of countries in which the back-to-bed recommendation has been widely adopted, such as the U.S. and New Zealand.[99]

Among the theories supporting the Back-to-Sleep recommendation is the idea that small infants with little or no control of their heads may, while face down, inhale their exhaled breath (high in carbon dioxide) or smother themselves on their bedding; the brain-stem anomaly research (above) suggests that babies with that particular genetic makeup do not react “normally” by moving away from the pooled CO2, and thus smother. Another theory[100] is that babies sleep more soundly when placed on their stomachs, and are unable to rouse themselves when they have an incidence of sleep apnea, which is thought to be common in infants.

Hospital neonatal-intensive-care-unit (NICU) staff commonly place preterm newborns on their stomach, although they advise parents to place their infants on their backs after going home from the hospital.[101]

Many have started to link the introduction of the Back-to-Sleep recommendation to the increased number of children suffering from Plagiocephaly and Brachycephaly. This is likely due to babies spending more time on their backs.[102] However, these theories are currently unproven.[citation needed]

Sleep sacks [edit]

In colder environments where bedding is required to maintain a baby’s body temperature, the use of a “baby sleep bag” or “sleep sack” is becoming more popular. This is a soft bag with holes for the baby’s arms and head. A zipper allows the bag to be closed around the baby. A study published in the European Journal of Pediatrics in August 1998[103] has shown the protective effects of a sleep sack as reducing the incidence of turning from back to front during sleep, reinforcing putting a baby to sleep on its back for placement into the sleep sack and preventing bedding from coming up over the face which leads to increased temperature and carbon dioxide rebreathing. They conclude in their study “The use of a sleeping-sack should be particularly promoted for infants with a low birth weight.” The American Academy of Pediatrics also recommends them as a type of bedding that warms the baby without covering its head.[104]

Epidemiology [edit]

SIDS was responsible for 0.543 deaths per 1,000 live births in the US in 2005.[15] It is responsible for far fewer deaths than congenital disorders and disorders related to short gestation, though it is the leading cause of death in healthy infants after one month of age.]]

SIDS deaths in the US decreased from 4,895 in 1992 to 2,247 in 2004.[105] But, during a similar time period, 1989 to 2004, SIDS being listed as the cause of death for sudden infant death (SID) decreased from 80% to 55%.[105] According to Dr. John Kattwinkel, chairman of the Centers for Disease Control and Prevention (CDC) Special Task Force on SIDS “A lot of us are concerned that the rate (of SIDS) isn’t decreasing significantly, but that a lot of it is just code shifting”.[105]

A set of 14 epidemiologic characteristics associated with SIDS have been identified:[106][107]
1.A characteristic 4-parameter lognormal age distribution;
2.Increased risk associated with prone sleep position;
3.Prone and supine SIDS have same age and gender distributions;
4.Male and female SIDS have same age distribution;
5.Total sudden respiratory deaths at home have same age and gender distributions;[108]
6.No evidence of cause of death at forensic autopsy and death scene investigation;
7.SIDS spares infants at birth[?];
8.Seasonality: winter maximum, summer minimum;
9.Increasing SIDS rate with Live Birth Order;
10.Consistent male excess of approximately 50%;
11.Low increased risk of SIDS in subsequent siblings of SIDS;
12.Parental smoking is a risk factor for SIDS;
13.Apparent Life Threatening Events (ALTE) are not a risk factor for subsequent SIDS;
14.SIDS risk is greatest during sleep.

See also [edit]
Women and smoking: Unique gender differences and health effects for Females

References [edit]

1.^ “Centers for Disease Control and Prevention, Sudden Infant Death”. Retrieved March 13, 2013.
2.^ Randall B (1996). “Witnessed sudden infant death syndrome”. Journal of Sudden Infant Death Syndrome and Infant Mortality 1: 55–57.
3.^ a b See CDC WONDER online database and http://www3.who.int/whosis/menu.cfm?path=whosis,inds,mort&language=english for data on SIDS by gender in the US and throughout the world.
4.^ a b Mage DT, Donner EM (September 2004). “The fifty percent male excess of infant respiratory mortality”. Acta Paediatr. 93 (9): 1210–5. doi:10.1080/08035250410031305. PMID 15384886.
5.^ a b “Fig 4. Meta-analysis of studies examining the relationship of a pacifier used during the last sleep in SIDS victims versus controls”. American Academy of Pediatrics. Retrieved 2008-11-06.
6.^ a b Coleman-Phox K, Odouli R, Li DK (October 2008). “Use of a fan during sleep and the risk of sudden infant death syndrome”. Arch Pediatr Adolesc Med 162 (10): 963–8. doi:10.1001/archpedi.162.10.963. PMID 18838649.
7.^ a b Glatt, John (2000). Cradle of Death: A Shocking True Story of a Mother, Multiple Murder, and SIDS. Macmillan. ISBN 0-312-97302-0.
8.^ a b Havill, Adrian (2002). While Innocents Slept: A Story of Revenge, Murder, and SIDS. Macmillan. ISBN 0-312-97517-1.
9.^ Krous HF (June 2012). “A commentary on changing infant death rates and a plea to use sudden infant death syndrome as a cause of death”. Forensic Sci Med Pathol. doi:10.1007/s12024-012-9354-x. PMID 22715066.
10.^ “Centers for Disease Control and Prevention, Sudden Unexpected Infant Death and Sudden Infant Death Syndrome”. Retrieved March 14, 2013.
11.^ NZ Ministry of Health
12.^ http://www.cdc.gov/SIDS/index.htm
13.^ a b c d Sullivan FM, Barlow SM. (2001). “Review of risk factors for Sudden Infant Death Syndrome”. Paediatric Perinatal Epidemiology 15 (2): 144–200. doi:10.1046/j.1365-3016.2001.00330.x. PMID 11383580.
14.^ Lavezzi AM, Corna MF, Matturri L (July 2010). “Ependymal alterations in sudden intrauterine unexplained death and sudden infant death syndrome: possible primary consequence of prenatal exposure to cigarette smoking”. Neural Dev 19 (5): 17. doi:10.1186/1749-8104-5-17. PMC 2919533. PMID 20642831.
15.^ a b c d e CDC WONDER online database
16.^ Hunt CE (November 2007). “Small for gestational age infants and sudden infant death syndrome: a confluence of complex conditions”. Arch. Dis. Child. Fetal Neonatal Ed. 92 (6): F428–9. doi:10.1136/adc.2006.112243. PMC 2675383. PMID 17951549.
17.^ Office of the Surgeon General of the United States Report on Involuntary Exposure to Tobacco Smoke (PDF)
18.^ Willinger M, Hoffman HJ, Hartford RB (May 1994). “Infant sleep position and risk for sudden infant death syndrome: report of meeting held January 13 and 14, 1994, National Institutes of Health, Bethesda, MD”. Pediatrics 93 (5): 814–9. PMID 8165085.
19.^ “Secret to SIDS unlocked by researchers”. Sydney Morning Herald. 21 October 2010. Retrieved 21 October 2010.
20.^ McKenna JJ, McDade T (June 2005). “Why babies should never sleep alone: a review of the co-sleeping controversy in relation to SIDS, bedsharing and breast feeding”. Paediatr Respir Rev 6 (2): 134–52. doi:10.1016/j.prrv.2005.03.006. PMID 15911459.
21.^ Moon RY, Horne RS, Hauck FR (November 2007). “Sudden infant death syndrome”. Lancet 370 (9598): 1578–87. doi:10.1016/S0140-6736(07)61662-6. PMID 17980736.
22.^ Fleming PJ, Levine MR, Azaz Y, Wigfield R, Stewart AJ (June 1993). “Interactions between thermoregulation and the control of respiration in infants: possible relationship to sudden infant death”. Acta Paediatr Suppl 82 (Suppl 389): 57–9. doi:10.1111/j.1651-2227.1993.tb12878.x. PMID 8374195.
23.^ Poets CF, Samuels MP, Wardrop CA, Picton-Jones E, Southall DP (April 1992). “Reduced haemoglobin levels in infants presenting with apparent life-threatening events—a retrospective investigation”. Acta Paediatr. 81 (4): 319–21. doi:10.1111/j.1651-2227.1992.tb12234.x. PMID 1606392.
24.^ Giulian GG, Gilbert EF, Moss RL (April 1987). “Elevated fetal hemoglobin levels in sudden infant death syndrome”. N Engl J Med 316 (18): 1122–6. doi:10.1056/NEJM198704303161804. PMID 2437454.
25.^ McIntosh CG, Tonkin SL, Gunn AJ (2009). “What is the mechanism of sudden infant deaths associated with co-sleeping?”. N. Z. Med. J. 122 (1307): 69–75. PMID 20148046.
26.^ Mage DT (1996). “A probability model for the age distribution of SIDS”. J Sudden Infant Death Syndrome Infant Mortal 1: 13–31.
27.^ Mage DT, Donner M. A genetic basis for the sudden infant death syndrome sex ratio, Med Hypotheses 1997;48:137-142.
28.^ Weinberg ED (June 2000). “Association of primary Pneumocystis carinii infection and sudden infant death syndrome”. Clin. Infect. Dis. 30 (6): 991. doi:10.1086/313796. PMID 10880335.
29.^ Weber, M.; Klein, N.; Hartley, J.; Lock, P.; Malone, M.; Sebire, N. (2008). “Infection and sudden unexpected death in infancy: a systematic retrospective case review”. The Lancet 371 (9627): 1848–53. doi:10.1016/S0140-6736(08)60798-9. PMID 18514728.
30.^ Task Force on Sudden Infant Death Syndrome (November 2005). “The changing concept of sudden infant death syndrome: diagnostic coding shifts, controversies regarding the sleeping environment, and new variables to consider in reducing risk”. Pediatrics 116 (5): 1245–55. doi:10.1542/peds.2005-1499. PMID 16216901.
31.^ Task Force on Sudden Infant Death Syndrome; Moon, R. Y. (2011). “SIDS and Other Sleep-Related Infant Deaths: Expansion of Recommendations for a Safe Infant Sleeping Environment”. Pediatrics 128 (5): 1030–1039. doi:10.1542/peds.2011-2284. PMID 22007004.
32.^ Ball H (September 2009). “Airway covering during bed-sharing”. Child Care Health Dev 35 (5): 728–37. doi:10.1111/j.1365-2214.2009.00979.x. PMID 19531119.
33.^ a b Paterson DS, Trachtenberg FL, Thompson EG, et al. (November 2006). “Multiple serotonergic brainstem abnormalities in sudden infant death syndrome”. JAMA 296 (17): 2124–32. doi:10.1001/jama.296.17.2124. PMID 17077377.
34.^ a b Duncan JR, Paterson DS, Hoffman JM, Mokler DJ, Borenstein NS, Belliveau RA, Krous HF, Haas EA, Stanley C et al. (Feb 2010). “Brainstem serotonergic deficiency in sudden infant death syndrome”. JAMA 303 (5): 430–7.
35.^ Maggio AB, Schäppi MG, Benkebil F, Posfay-Barbe KM, Belli DC (November 2006). “Increased incidence of apparently life-threatening events due to supine position”. Paediatric and Perinatal Epidemiology 20 (6): 491–6; discussion 496–7. doi:10.1111/j.1365-3016.2006.00753.x. PMID 17052284.
36.^ Kadhim H, Deltenre P, De Prez C, Sébire G. (August 2010). “Interleukin-2 as a neuromodulator possibly implicated in the physiopathology of sudden infant death syndrome”. FNeurosci Lett. 480 (2): 122–6. doi:10.1016/j.neulet.2010.06.021. PMID 20542085.
37.^ Katz DM (2005). “Regulation of respiratory neuron development by neurotrophic and transcriptional signaling mechanisms”. Respiratory physiology & neurobiology 149 (1–3): 99–109. doi:10.1016/j.resp.2005.02.007. PMID 16203214.
38.^ ICPA — SIDS Research
39.^ Spinelli, Margaret (2003). Infanticide: Psychosocial and Legal Perspectives on Mothers Who Kill. American Psychiatric Pub. p. 27. ISBN 1-58562-097-1.
40.^ Stanton J, Simpson A (December 2001). “Murder misdiagnosed as SIDS: a perpetrator’s perspective”. Arch Dis Child. 85 (6): 454–9. doi:10.1136/adc.85.6.454. PMC 1719021. PMID 11719326.
41.^ Emery JL (October 1993). “Child abuse, sudden infant death syndrome, and unexpected infant death”. Am J Dis Child. 147 (10): 1097–100. PMID 8213682.
42.^ “Investigation of SIDS”. N Engl J Med. 315 (26): 1675–7. December 1986. doi:10.1056/NEJM198612253152611. PMID 3785340.
43.^ Carol Strickland (1997-10-19). “Investigating a Rash of SIDS Deaths, Exposing Infanticide”. The New York Times. Retrieved 2008-04-20.
44.^ “Sir Roy Meadow struck off by GMC”. BBC News. 2005-07-15.
45.^ “About Statistics and the Law” (Website). Royal Statistical Society. (2001-10-23) Retrieved on 2007-09-22
46.^ See the data found at http://wonder.cdc.gov for 9ICD 911–912 and 10ICD W79-W80 for death rates from inhalation of food and foreign objects by sex.
47.^ Osmond C, Murphy M (October 1988). “Seasonality in the sudden infant death syndrome”. Paediatr Perinat Epidemiol 2 (4): 337–45. doi:10.1111/j.1365-3016.1988.tb00228.x. PMID 3072532.
48.^ Thomas H. Maugh II (2007). – [http://scholar.google.co.uk/scholar?hl=en&lr=&q=intitle%3AHearing+loss+may+foretell+SIDS+risk&as_publication=&as_ylo=2007&as_yhi=2007&btnG=Search Scholar search Hearing loss may foretell SIDS risk]. Los Angeles Times.[dead link]
49.^ Alastruey J, Sherwin SJ, Parker KH, Rubens DD (January 2010). “Reply to ‘Cord clamp insult may predispose to SIDS’”. Early Human Development 86 (1): 67. doi:10.1016/j.earlhumdev.2009.12.002. PMID 20071109.
50.^ Alastruey J, Sherwin SJ, Parker KH, Rubens DD (July 2009). “Placental transfusion insult in the predisposition for SIDS: a mathematical study”. Early Hum. Dev. 85 (7): 455–9. doi:10.1016/j.earlhumdev.2009.04.001. PMID 19446412.
51.^ Klonoff-Cohen H, Lam PK, Lewis A (July 2005). “Outdoor carbon monoxide, nitrogen dioxide, and sudden infant death syndrome”. Arch Dis Child. 90 (7): 750–3. doi:10.1136/adc.2004.057091. PMC 1720470. PMID 15970620.
52.^ Fleming PJ, Blair PS, Mitchell EA (November 2002). “Mattresses, microenvironments, and multivariate analyses”. BMJ 325 (7371): 981–2. doi:10.1136/bmj.325.7371.981. PMC 1124537. PMID 12411332.
53.^ “Cot Life 2000 aims to eliminate cot”. Cotlife2000.co.nz. Retrieved 2009-10-15.
54.^ See FSID Press release.
55.^ cotlife2000.co.nz Errors and fallacies in the UK Limerick Report: an overview, Cot Life 2000
56.^ Vennemann MM, Butterfass-Bahloul T, Jorch G, et al. (January 2007). “Sudden infant death syndrome: no increased risk after immunisation”. Vaccine 25 (2): 336–40. doi:10.1016/j.vaccine.2006.07.027. PMID 16945457.
57.^ a b Sudden Infant Death Syndrome (SIDS) and Vaccines http://www.cdc.gov/vaccinesafety/Concerns/sids_faq.html
58.^ Kalokerinos A, Dettman G (July 1976). “Sudden death in infancy syndrome in Western Australia”. Med. J. Aust. 2 (1): 31–2. PMID 979792.
59.^ Donovan J (September 1979). “Vitamin C and cot death: where is the evidence?”. Med. J. Aust. 2 (6): 311. PMID 522763.
60.^ Holborow P (April 1980). “Sudden infant death syndrome”. Am. J. Clin. Nutr. 33 (4): 730–1. PMID 7361687. “There has been some controversy about the role of Vitamin C in cot death.”
61.^ Cheraskin E (October 1995). “Vitamin C, smoking and SIDS”. J R Soc Health 115 (5): 332. doi:10.1177/146642409511500519. PMID 7473510.
62.^ Dick A, Ford R (November 2009). “Cholinergic and oxidative stress mechanisms in sudden infant death syndrome”. Acta Paediatr. 98 (11): 1768–75. doi:10.1111/j.1651-2227.2009.01476.x. PMC 2773533. PMID 19706020.
63.^ Yang Z, Lantz PE, Ibdah JA (December 2007). “Post-mortem analysis for two prevalent beta-oxidation mutations in sudden infant death”. Pediatr Int 49 (6): 883–7. doi:10.1111/j.1442-200X.2007.02478.x. PMID 18045290.
64.^ Nevas M, Lindström M, Virtanen A, et al. (January 2005). “Infant botulism acquired from household dust presenting as sudden infant death syndrome”. J. Clin. Microbiol. 43 (1): 511–3. doi:10.1128/JCM.43.1.511-513.2005. PMC 540168. PMID 15635031.
65.^ Millat G, Kugener B, Chevalier P, et al. (May 2009). “Contribution of long-QT syndrome genetic variants in sudden infant death syndrome”. Pediatr Cardiol 30 (4): 502–9. doi:10.1007/s00246-009-9417-2. PMID 19322600.
66.^ Stray-Pedersen A, Vege A, Rognum TO (October 2008). “Helicobacter pylori antigen in stool is associated with SIDS and sudden infant deaths due to infectious disease”. Pediatr. Res. 64 (4): 405–10. doi:10.1203/PDR.0b013e31818095f7. PMID 18535491.
67.^ Bajanowski T, Vennemann M, Bohnert M, Rauch E, Brinkmann B, Mitchell EA (July 2005). “Unnatural causes of sudden unexpected deaths initially thought to be sudden infant death syndrome”. Int. J. Legal Med. 119 (4): 213–6. doi:10.1007/s00414-005-0538-8. PMID 15830244.
68.^ Du Chesne A, Bajanowski T, Brinkmann B (1997). “[Homicides without clues in children]“. Arch Kriminol (in German) 199 (1–2): 21–6. PMID 9157833.
69.^ Williams, F. L.; Lang, G. A.; Mage, D. T. (2001). “Sudden unexpected infant deaths in Dundee, 1882-1891: overlying or SIDS?”. Scottish medical journal 46 (2): 43–47. PMID 11394337. edit
70.^ http://www.charlotteobserver.com/sids/
71.^ Carla K. Johnson (Associated Press writer) (2008-09-08). “Fan use linked to lower risk of sudden baby death”. Toronto Star. Retrieved 2008-11-09., also in Live Science
72.^ Vanderford J, Olsson J (May 2009). “Should we really encourage fan use?”. Arch Pediatr Adolesc Med 163 (5): 490; author reply 490–1. doi:10.1001/archpediatrics.2009.79. PMID 19414701.
73.^ Smartmoney.com on bedding
74.^ “What Can Be Done?”. American SIDS Institute.
75.^ Mitchell, E.; Thompson, J.; Becroft, D.; Bajanowski, T.; Brinkmann, B.; Happe, A.; Jorch, G.; Blair, P. et al. (2008). “Head covering and the risk for SIDS: findings from the New Zealand and German SIDS case-control studies”. Pediatrics 121 (6): e1478–e1483. doi:10.1542/peds.2007-2749. PMID 18519451. edit
76.^ Hauck FR, Herman SM, Donovan M, Iyasu S, Merrick Moore C, Donoghue E, Kirschner RH, Willinger M (2003). “Sleep environment and the risk of sudden infant death syndrome in an urban population: the Chicago Infant Mortality Study”. Pediatrics 111 (5 Part 2): 1207–14. PMID 12728140.
77.^ Chen A, Rogan W (May 2004). “Breastfeeding and the Risk of Postneonatal Death in the United States”. Pediatrics 113 (5): 435–9. PMID 10617723.
78.^ Vennemann MM, Bajanowski T, Brinkmann B, et al. (March 2009). “Does breastfeeding reduce the risk of sudden infant death syndrome?”. Pediatrics 123 (3): e406–10. doi:10.1542/peds.2008-2145. PMID 19254976.
79.^ Hauck F, Thompson J, Tanabe K, et al. (July 2011). “Breastfeeding and Reduced Risk of Sudden Infant Death Syndrome: A Meta-analysis”. Pediatrics 128 (1): e103–10. doi:10.1542/peds.2010-300. PMID 21669892.
80.^ “Policy Statement for Bumper Pads in Cribs — Consumer Product Safety”. Retrieved 2007-06-27.
81.^ Pelayo R, Owens J, Mindell J, Sheldon S (March 2006). “Bed sharing with unimpaired parents is not an important risk for sudden infant death syndrome: to the editor”. Pediatrics 117 (3): 993–4; author reply 994–6. doi:10.1542/peds.2005-2748. PMID 16510694.
82.^ Dewey C, Fleming P, Golding J (January 1998). “Does the supine sleeping position have any adverse effects on the child? II. Development in the first 18 months.ALSPAC Study Team”. Pediatrics 101 (1): E5. doi:10.1542/peds.101.1.e5. PMID 9417169.
83.^ Pelligra R, Doman G, Leisman G (July 2005). “A reassessment of the SIDS Back to Sleep Campaign”. Scientific World Journal 5: 550–7. doi:10.1100/tsw.2005.71. PMID 16075152.[dead link]
84.^ a b Jones MW (2004). “Supine and Prone Infant Positioning: A Winning Combination”. J Perinat Educ 13 (1): 10–20. doi:10.1624/105812404826388. PMC 1595182. PMID 17273371.
85.^ Carter H (July 8, 2003). “Flat Out”. The Guardian.
86.^ Kordestani RK, Patel S, Bard DE, Gurwitch R, Panchal J (January 2006). “Neurodevelopmental delays in children with deformational plagiocephaly”. Plast Reconstr Surg. 117 (1): 207–18; discussion 219–20. doi:10.1097/01.prs.0000185604.15606.e5. PMID 16404269.
87.^ Stevens P, “The Flip Side of Back to Sleep”, The O&P Edge.
88.^ von Hofsten C (June 2004). “An action perspective on motor development”. Trends Cogn. Sci. (Regul. Ed.) 8 (6): 266–72. doi:10.1016/j.tics.2004.04.002. PMID 15165552.
89.^ Sigmundsson H, Haga M (October 2000). “[Children and motor competence]“. Tidsskr. Nor. Laegeforen. (in Norwegian) 120 (25): 3048–50. PMID 11109395.
90.^ Högberg U, Bergström E (April 2000). “Suffocated prone: the iatrogenic tragedy of SIDS”. Am J Public Health 90 (4): 527–31. doi:10.2105/AJPH.90.4.527. PMC 1446204. PMID 10754964.
91.^ Graham JM, Gomez M, Halberg A, et al. (February 2005). “Management of deformational plagiocephaly: repositioning versus orthotic therapy”. J. Pediatr. 146 (2): 258–62. doi:10.1016/j.jpeds.2004.10.016. PMID 15689920.
92.^ a b “The Changing Concept of Sudden Infant Death Syndrome: Diagnostic Coding Shifts, Controversies Regarding the Sleeping Environment, and New Variables to Consider in Reducing Risk”. American Academy of Pediatrics. Retrieved 2008-11-06.
93.^ Li DK, Willinger M, Petitti DB, Odouli R, Liu L, Hoffman HJ (2006). “Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control study”. BMJ 332 (7532): 18–22. doi:10.1136/bmj.38671.640475.55. PMC 1325127. PMID 16339767.
94.^ “Dummies may protect babies babies from cot death”. Sydney Morning Herald. 8 October 2010. Retrieved 12 October 2010.
95.^ Moon RY, Tanabe KO, Yang DC, Young HA, Hauck FR (April 2011). “Pacifier Use and Sids: Evidence for a Consistently Reduced Risk”. Matern Child Health J 16 (3): 609–14. doi:10.1007/s10995-011-0793-x. PMID 21505778.
96.^ Chapter 5; pages 180–194, secondhand smoke is connected to SIDS.
97.^ Bajanowski, T.; Brinkmann, B.; Mitchell, E.; Vennemann, M.; Leukel, H.; Larsch, K.; Beike, J.; Gesid, G. (2008). “Nicotine and cotinine in infants dying from sudden infant death syndrome”. International journal of legal medicine 122 (1): 23–28. doi:10.1007/s00414-007-0155-9. PMID 17285322. edit
98.^ Centers for Disease Control and Prevention (CDC) (October 2004). “Smoking during pregnancy—United States, 1990–2002″. MMWR Morb Mortal Wkly Rep. 53 (39): 911–5. PMID 15470322.
99.^ Mitchell EA, Hutchison L, Stewart AW (July 2007). “The continuing decline in SIDS mortality”. Arch Dis Child. 92 (7): 625–6. doi:10.1136/adc.2007.116194. PMC 2083749. PMID 17405855.
100.^ Blyth, T.; McKenzie, S. (2003). “SIDS, smoking, and arousal thresholds: conclusions not supported by data”. Archives of disease in childhood. Fetal and neonatal edition 88 (2): F162; author reply F162. doi:10.1136/fn.88.2.F162. PMC 1721504. PMID 12598514. edit
101.^ Aris C, Stevens TP, Lemura C, et al. (October 2006). “NICU nurses’ knowledge and discharge teaching related to infant sleep position and risk of SIDS”. Adv Neonatal Care 6 (5): 281–94. doi:10.1016/j.adnc.2006.06.009. PMID 17045948.
“Erratum”. Adv Neonatal Care 6 (6): 340. December 2006. doi:10.1016/j.adnc.2007.01.001.
102.^ “What is tummy time?”. Retrieved 2013-02-22.
103.^ L’Hoir MP, Engelberts AC, van Well GT, et al. (1998). “Risk and preventive factors for cot death in The Netherlands, a low-incidence country”. Eur. J. Pediatr. 157 (8): 681–8. doi:10.1007/s004310050911. PMID 9727856.
104.^ “The Changing Concept of Sudden Infant Death Syndrome: Diagnostic Coding Shifts, Controversies Regarding the Sleeping Environment, and New Variables to Consider in Reducing Risk”. American Academy of Pediatrics. Retrieved 2008-11-06.
105.^ a b c Bowman L, Hargrove T. Exposing Sudden Infant Death In America. Scripps Howard News Service. http://dailycamera.com/news/2007/oct/08/saving-babies-exposing-sudden-infant-death-in/
106.^ Mage DT, Donner EM (2004). “Is SIDS at Borkmann’s Point?”. Medical Hypotheses and Research 1 (2/3): 131–7.
107.^ Mage DT, Donner EM (2011). “The universal age distribution of the Sudden Infant Death Syndrome”. Scandinavian Journal of Forensic Science 17 (1): 4–8.
108.^ Carpenter RG, Gardner A (1982). “Variations in unexpected infant death rates relating to age, sex and season”. Studies on Medical and Population Subjects 45. London: HMSO. pp. 23–31.

Further reading [edit]
Ottaviani, G. (2007). Crib death. Sudden unexplained death of infants: the pathologist’s viewpoint. Berlin Heidelberg, Germany: Springer. ISBN 978-3-540-49370-9.
Joan Hodgman; Toke Hoppenbrouwers (2004). SIDS. Calabasas, Calif: Monte Nido Press. ISBN 0-9742663-0-2.
Lewak N. “Book Review: SIDS”. Arch Pediatr Adolesc Med 158 (4): 405.

External links [edit]
SIDS at the Open Directory Project

Categories: Causes of death
Ailments of unknown etiology
Pediatrics
Infancy
Children and death

Navigation menu

Create account
Log in

Article
Talk

Read
Edit
View history

Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikimedia Shop

Interaction

Help
About Wikipedia
Community portal
Recent changes
Contact Wikipedia

Toolbox

Print/export

Languages

العربية
Català
Česky
Dansk
Deutsch
Español
فارسی
Français
Bahasa Indonesia
Italiano
עברית
Magyar
Nederlands
日本語
Norsk bokmål
Polski
Português
Română
Русский
Simple English
Suomi
Svenska
Українська
中文
Edit links

Vulnerability of fourth ventricle choroid plexus in sudden unexplained fetal and infant death syndromes related to smoking mothers.

Lavezzi AM, Matturri L, Del Corno G, Johanson CE.

Source

Lino Rossi Research Center for the Study and Prevention of Unexpected Perinatal Death and SIDS, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy. Electronic address: anna.lavezzi@unimi.it.

Abstract

The human choroid plexuses in the ventricular system represent the main source of cerebrospinal fluid secretion and constitute a major barrier interface that controls the brain’s environment. The present study focused on the choroid plexus of the fourth ventricle, the main cavity of the brainstem containing important nuclei and/or structures mediating autonomic vital functions. In serial sections of 84 brainstems of subjects aged from 17 gestational weeks to 8 postnatal months of life, the deaths due to both known and unknown causes, we examined the cytoarchitecture and the developmental steps of the fourth ventricle choroid plexus to determine whether this structure shows morphological and/or functional alterations in unexplained perinatal deaths (Sudden Infant Death Syndrome and Sudden Intrauterine Unexplained Death Syndrome). High incidence of histological and immunohistochemical alterations (prevalence of epithelial dark cells, the presence of cystic cells in the stroma, decreased number of blood capillaries, hyperexpression of substance P and apoptosis) were prevalently observed in unexplained death victims (p<0.05 vs. controls). A significant correlation was found between maternal smoking in pregnancy and choroidal neuropathological parameters (p February 2013 – Volume 45 – Issue > Advances in the Genetic Investigation of Sids

Text sizing:A A A

Pathology:
February 2013
doi: 10.1097/01.PAT.0000426790.72010.a0
Forensic Pathology: PDF Only
Advances in the Genetic Investigation of Sids
Christodoulou, John

Abstract
With the recognition through epidemiological studies that the prone sleeping position is a major cause of SIDS, simple measures have led to a significant reduction in its incidence. However, SIDS is still a major cause of infant mortality in the Western world, and in most cases detailed post-mortem examination fails to shed light on a possible aetiology. It is being increasingly recognised that apparent SIDS may be the consequence of a primary underlying genetic disorder, including inborn errors of metabolism (most especially fatty acid oxidation disorders), genetic defects of cardiac conduction (particularly a range of channelopathies), and hypertrophic cardiomyopathies. In addition, polymorphisms in a number of genes have been implicated in the pathogenesis and incidence of SIDS, although the magnitude of their importance remains to be established.

A synopsis of the well-established genetic causes of SIDS will be given in this presentation, along with a brief overview of association studies implicating specific genetic polymorphisms with SIDS. Together, these data raise the question of whether it is timely to consider a ‘molecular post-mortem’ for SIDS cases where an underlying aetiology remains unknown.

(C) 2013 Royal College of Pathologists of Australasia

Content referenced by

http://en.wikipedia.org/wiki/Sudden_infant_death_syndrome

http://www.ncbi.nlm.nih.gov/pubmed?term=sids

http://www.ihop-net.org/UniPub/iHOP/index.html?field=all&search=sids&organism_id=0

https://www.google.ca/#q=top+research+hospitals+sids&hl=en&ei=25aaUb3tLoS4qgHQ6oHoBg&start=30&sa=N&bav=on.2,or.r_cp.r_qf.&bvm=bv.46751780,d.aWM&fp=f4d6a1dd52c39eab&biw=1034&bih=526

http://scholar.google.ca/scholar?as_ylo=2013&q=sids&hl=en&as_sdt=0,5

Posted in Uncategorized | Leave a comment

Heart Disease


Cardiovascular disease

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Cardiovascular disease

Classification and external resources

Micrograph of a heart with fibrosis (yellow) and amyloidosis (brown). Movat’s stain.

ICD-10

I51.6

ICD-9

429.2

DiseasesDB

28808

MeSH

D002318

Cardiovascular disease (also called heart disease) is a class of diseases that involve the heart or blood vessels (arteries, capillaries, and veins).[1]

Cardiovascular disease refers to any disease that affects the cardiovascular system, principally cardiac disease, vascular diseases of the brain and kidney, and peripheral arterial disease.[2] The causes of cardiovascular disease are diverse but atherosclerosis and/or hypertension are the most common. Additionally, with aging come a number of physiological and morphological changes that alter cardiovascular function and lead to subsequently increased risk of cardiovascular disease, even in healthy asymptomatic individuals.[3]

Cardiovascular disease is the leading cause of deaths worldwide, though since the 1970s, cardiovascular mortality rates have declined in many high-income countries.[4] At the same time, cardiovascular deaths and disease have increased at a fast rate in low- and middle-income countries.[5] Although cardiovascular disease usually affects older adults, the antecedents of cardiovascular disease, notably atherosclerosis, begin in early life, making primary prevention efforts necessary from childhood.[6] There is therefore increased emphasis on preventing atherosclerosis by modifying risk factors, such as healthy eating, exercise, and avoidance of smoking.

Contents
[hide] 1 Types
2 Risk factors 2.1 Age
2.2 Sex
2.3 Air pollution

3 Pathophysiology
4 Screening
5 Prevention 5.1 Diet
5.2 Supplements
5.3 Medication

6 Management
7 Epidemiology
8 Research
9 References
10 External links

Types [edit]

Disability-adjusted life year for inflammatory heart diseases per 100,000 inhabitants in 2004.[7]

no data

less than 70

70-140

140-210

210-280

280-350

350-420

420-490

490-560

560-630

630-700

700-770

more than 770
Coronary heart disease (also ischaemic heart disease or coronary artery disease)
Cardiomyopathy – diseases of cardiac muscle
Hypertensive heart disease – diseases of the heart secondary to high blood pressure
Heart failure
Cor pulmonale – a failure of the right side of the heart
Cardiac dysrhythmias – abnormalities of heart rhythm
Inflammatory heart disease Endocarditis – inflammation of the inner layer of the heart, the endocardium. The structures most commonly involved are the heart valves.
Inflammatory cardiomegaly
Myocarditis – inflammation of the myocardium, the muscular part of the heart.

Valvular heart disease
Cerebrovascular disease – disease of blood vessels that supplies to the brain such as stroke
Peripheral arterial disease – disease of blood vessels that supplies to the arms and legs
Congenital heart disease – heart structure malformations existing at birth
Rheumatic heart disease – heart muscles and valves damage due to rheumatic fever caused by streptococcal bacteria infections

Risk factors [edit]

Epidemiology suggests a number of risk factors for heart disease: age, gender, high blood pressure, high serum cholesterol levels, tobacco smoking, excessive alcohol consumption, family history, obesity, lack of physical activity, psychosocial factors, diabetes mellitus, air pollution.[2] While the individual contribution of each risk factor varies between different communities or ethnic groups the consistency of the overall contribution of these risk factors to epidemiological studies is remarkably strong.[8] Some of these risk factors, such as age, gender or family history, are immutable; however, many important cardiovascular risk factors are modifiable by lifestyle change, drug treatment or social change.

Age [edit]

Calcified heart of older woman with Cardiomegaly taken at the Instituto Nacional de Cardiología, Mexico.
Age is an important risk factor in developing cardiovascular diseases. It is estimated that 87 percent of people who die of coronary heart disease are 60 and older.[9] At the same time, the risk of stroke doubles every decade after age 55.[10]

Multiple explanations have been proposed to explain why age increases the risk of cardiovascular diseases. One of them is related to serum cholesterol level.[11] In most populations, the serum total cholesterol level increases as age increases. In men, this increase levels off around age 45 to 50 years. In women, the increase continues sharply until age 60 to 65 years.[11]

Aging is also associated with changes in the mechanical and structural properties of the vascular wall, which leads to the loss of arterial elasticity and reduced arterial compliance and may subsequently lead to coronary artery disease.[12]

Sex [edit]

Men are at greater risk of heart disease than pre-menopausal women.[13] However, once past menopause, a woman’s risk is similar to a man’s.[13]

Among middle-aged people, coronary heart disease is 2 to 5 times more common in men than in women.[11] In a study done by the World Health Organization, sex contributes to approximately 40% of the variation in the sex ratios of coronary heart disease mortality.[14] Another study reports similar results that gender difference explains nearly half of the risk associated with cardiovascular diseases[11] One of the proposed explanations for the gender difference in cardiovascular disease is hormonal difference.[11] Among women, estrogen is the predominant sex hormone. Estrogen may have protective effects through glucose metabolism and hemostatic system, and it may have a direct effect on improving endothelial cell function.[11] The production of estrogen decreases after menopause, and may change the female lipid metabolism toward a more atherogenic form by decreasing the HDL cholesterol level and by increasing LDL and total cholesterol levels.[11] Women who have experienced early menopause, either naturally or because they have had a hysterectomy, are twice as likely to develop heart disease as women of the same age group who have not yet gone through menopause.[citation needed]

Among men and women, there are differences in body weight, height, body fat distribution, heart rate, stroke volume, and arterial compliance.[12] In the very elderly, age related large artery pulsatility and stiffness is more pronounced in women.[12] This may be caused by the smaller body size and arterial dimensions independent of menopause.[12]

Air pollution [edit]

Particulate matter has been studied for its short- and long-term exposure effects on cardiovascular disease. Currently, PM2.5 is the major focus, in which gradients are used to determine CVD risk. For every 10 μg/m3 of PM2.5 long-term exposure, there was an estimated 8-18% CVD mortality risk.[15] Women had a higher relative risk (RR) (1.42) for PM2.5 induced coronary artery disease than men (0.90) did.[15] Overall, long-term PM exposure increased rate of atherosclerosis and inflammation. In regards to short-term exposure (2 hours), every 25 μg/m3 of PM2.5 resulted in a 48% increase of CVD mortality risk.[16] Additionally, after only 5 days of exposure, a rise in systolic (2.8 mmHg) and diastolic (2.7 mmHg) blood pressure occurred for every 10.5 μg/m3 of PM2.5.[16] Other research has implicated PM2.5 in irregular heart rhythm, reduced heart rate variability (decreased vagal tone), and most notably heart failure.[16][17] PM2.5 is also linked to carotid artery thickening and increased risk of acute myocardial infarction.[16][17]

Pathophysiology [edit]

Population based studies show that atherosclerosis the major precursor of cardiovascular disease begins in childhood. The Pathobiological Determinants of Atherosclerosis in Youth Study demonstrated that intimal lesions appear in all the aortas and more than half of the right coronary arteries of youths aged 7–9 years.[18]

This is extremely important considering that 1 in 3 people will die from complications attributable to atherosclerosis. In order to stem the tide education and awareness that cardiovascular disease poses the greatest threat and measures to prevent or reverse this disease must be taken.

Obesity and diabetes mellitus are often linked to cardiovascular disease,[19] as are a history of chronic kidney disease and hypercholesterolaemia.[20] In fact, cardiovascular disease is the most life threatening of the diabetic complications and diabetics are two- to four-fold more likely to die of cardiovascular-related causes than nondiabetics.[21][22][23]

Screening [edit]

Screening ECGs (either at rest or with exercise) are not recommended in those without symptoms who are at low risk.[24] In those at higher risk the evidence for screening with ECGs is inconclusive.[24]

Some biomarkers may add to conventional cardiovascular risk factors in predicting the risk of future cardiovascular disease; however, the clinical value of some biomarkers is still questionable.[25][26] Currently, biomarkers which may reflect a higher risk of cardiovascular disease include:
Coronary artery calcification
Carotid intima-media thickness
Carotid total plaque area [27]
Higher fibrinogen and PAI-1 blood concentrations
Elevated homocysteine
Elevated blood levels of asymmetric dimethylarginine
Inflammation as measured by C-reactive protein
Elevated blood levels of brain natriuretic peptide (also known as B-type) (BNP)[28]

Prevention [edit]

Currently practiced measures to prevent cardiovascular disease include:
A low-fat, high-fiber diet including whole grains and plenty of fresh fruit and vegetables (at least five portions a day)[29][30]
Tobacco cessation and avoidance of second-hand smoke;[29]
Limit alcohol consumption to the recommended daily limits;[29] consumption of 1-2 standard alcoholic drinks per day may reduce risk by 30%[31][32] However excessive alcohol intake increases the risk of cardiovascular disease.[33]
Lower blood pressures, if elevated, through the use of antihypertensive medications[citation needed];
Decrease body fat (BMI) if overweight or obese;[34]
Increase daily activity to 30 minutes of vigorous exercise per day at least five times per week;[29]
Decrease psychosocial stress.[35] Stress however plays a relatively minor role in hypertension.[36] Specific relaxation therapies are not supported by the evidence.[37]

Routine counselling of adults to advise them to improve their diet and increase their physical activity has not been found to significantly alter behaviour, and thus is not recommended.[38]

Diet [edit]

Evidence suggests that the Mediterranean diet improves cardiovascular outcomes.[39] This may be by “about 30 percent” in those at high risk.[40] In clinical trials the DASH diet (high in nuts, fish, fruits and vegetables, and low in sweets, red meat and fat) has been shown to reduce blood pressure,[41] lower total and low density lipoprotein cholesterol [42] and improve metabolic syndrome;[43] but the long term benefits outside the context of a clinical trial have been questioned.[44]

Total fat intake does not appear to be an important risk factor.[45] A diet high in trans fatty acids however does appear to increase rates of cardiovascular disease.[46][45]

Worldwide, dietary guidelines recommend a reduction in saturated fat.[47] There however is some questions around the effect of saturated fat on cardiovascular disease in the medical literature.[48][49] A 2012 Cochrane review found suggestive evidence of a small benefit from replacing dietary saturated fat by unsaturated fat.[50] A 2013 meta analysis concludes that substitution with omega 6 linoleic acid (a type of unsaturated fat) may increase cardiovascular risk.[47] Replacement of saturated fats with carbohydrates does not change or may increase risk.[51][52] Benefits from replacement with polyunsaturated fat appears greatest[45][53] however supplementation with omega-3 fatty acids (a type of polysaturated fat) does not appear have an effect.[54]

The effect of a low salt diet is unclear with any benefit in either hypertensive or normal tensive people being small if present.[55] A low salt diet may be harmful in those with congestive heart failure.[55]

Supplements [edit]

While a healthy diet is beneficial, the effect of antioxidant supplementation (vitamin E, vitamin C, etc.) or vitamins generally has not been shown to improve protection against cardiovascular disease and in some cases may possibly result in harm.[56][57] Niacin, a type of vitamin B3, may be an exception with a modest decrease in the risk of cardiovascular events in those at high risk.[58][59] Magnesium supplementation lowers high blood pressure in a dose dependent manner.[60] Magnesium therapy is recommended for patients with ventricular arrhythmia associated with torsade de pointes who present with long QT syndrome as well as for the treatment of patients with digoxin intoxication-induced arrhythmias.[61] Results from an observational study conducted in the general Japanese population demonstrated that lower serum magnesium levels were associated with a greater average intima-media thickness and the risk of at least two carotid plaques.[62] Evidence to support omega-3 fatty acid supplementation is lacking.[63]

Medication [edit]

Aspirin has not been found to be of benefit overall in those at low risk of heart disease as the risk of serious bleeding is equal to the benefit with respect to cardiovascular problems.[64] Statins are effective in preventing further cardiovascular disease in those with a history of cardiovascular disease.[65] A decreased risk of death and strokes however seems to only occur in men.[65] In those without cardiovascular disease but risk factors statins appear to also be beneficial with a decrease in mortality and further heart disease.[66]

Management [edit]

Cardiovascular disease is treatable with initial treatment primarily focused on diet and lifestyle interventions.[67][68][69]

Epidemiology [edit]

Disability-adjusted life year for cardiovascular diseases per 100,000 inhabitants in 2004.[70]

no data

7900

Cardiovascular diseases are the leading cause of death. In 2008, 30% of all global death is attributed to cardiovascular diseases. Death caused by cardiovascular diseases are also higher in low and middle-income countries as over 80% of all global death caused by cardiovascular diseases occurred in those countries. It is also estimated that by 2030, over 23 million people will die from cardiovascular diseases annually.

Research [edit]

The first studies on cardiovascular health were performed in 1949 by Jerry Morris using occupational health data and were published in 1958.[71] The causes, prevention, and/or treatment of all forms of cardiovascular disease remain active fields of biomedical research, with hundreds of scientific studies being published on a weekly basis. A trend has emerged, particularly in the early 2000s, in which numerous studies have revealed a link between fast food and an increase in heart disease. These studies include those conducted by the Ryan Mackey Memorial Research Institute, Harvard University and the Sydney Center for Cardiovascular Health. Many major fast food chains, particularly McDonald’s, have protested the methods used in these studies and have responded with healthier menu options.

A fairly recent emphasis is on the link between low-grade inflammation that hallmarks atherosclerosis and its possible interventions. C-reactive protein (CRP) is a common inflammatory marker that has been found to be present in increased levels in patients at risk for cardiovascular disease.[72] Also osteoprotegerin which involved with regulation of a key inflammatory transcription factor called NF-κB has been found to be a risk factor of cardiovascular disease and mortality.[73][74]

Some areas currently being researched include possible links between infection with Chlamydophila pneumoniae (a major cause of pneumonia) and coronary artery disease. The Chlamydia link has become less plausible with the absence of improvement after antibiotic use.[75]

Several research also investigated the benefits of melatonin on cardiovascular diseases prevention and cure. Melatonin is a pineal gland secretion and it is shown to be able to lower total cholesterol, very low density and low density lipoprotein cholesterol levels in the blood plasma of rats. Reduction of blood pressure is also observed when pharmacological doses are applied. Thus, it is deemed to be a plausible treatment for hypertension. However, further research needs to be conducted to investigate the side effects, optimal dosage and etc. before it can be licensed for use.[76]

References [edit]

1.^ Maton, Anthea; Jean Hopkins, Charles William McLaughlin, Susan Johnson, Maryanna Quon Warner, David LaHart, Jill D. Wright (1993). Human Biology and Health. Englewood Cliffs, New Jersey: Prentice Hall. ISBN 0-13-981176-1.
2.^ a b Bridget B. Kelly; Institute of Medicine; Fuster, Valentin (2010). Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Washington, D.C: National Academies Press. ISBN 0-309-14774-3.
3.^ Dantas AP, Jimenez-Altayo F, Vila E (August 2012). “Vascular aging: facts and factors”. Frontiers in Vascular Physiology 3 (325): 1–2. doi:10.3389/fphys.2012.00325. PMID 22934073.
4.^ Countries, Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing; Fuster, Board on Global Health ; Valentin; Academies, Bridget B. Kelly, editors ; Institute of Medicine of the National (2010). Promoting cardiovascular health in the developing world : a critical challenge to achieve global health. Washington, D.C.: National Academies Press. pp. Chapter 2. ISBN 978-0-309-14774-3.
5.^ Mendis, S.; Puska, P.; Norrving, B.(editors) (2011), Global Atlas on cardiovascular disease prevention and control, ISBN 978-92-4-156437-3
6.^ McGill HC, McMahan CA, Gidding SS (March 2008). “Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study”. Circulation 117 (9): 1216–27. doi:10.1161/CIRCULATIONAHA.107.717033. PMID 18316498.
7.^ “WHO Disease and injury country estimates”. World Health Organization. 2009. Retrieved Nov. 11, 2009.
8.^ Yusuf S, Hawken S, Ounpuu S, et al. (2004). “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study”. Lancet 364 (9438): 937–52. doi:10.1016/S0140-6736(04)17018-9. PMID 15364185.
9.^ “Understand Your Risk of Heart Attack”. American Heart Association.http://www.heart.org/HEARTORG/Conditions/HeartAttack/UnderstandYourRiskofHeartAttack/Understand-Your-Risk-of-Heart-Attack_UCM_002040_Article.jsp#
10.^ Mackay, Mensah, Mendis, et al. The Atlas of Heart Disease and Stroke. World Health Organization. January 2004.
11.^ a b c d e f g Jousilahti Vartiainen, Tuomilehto Puska (1999). “Sex, Age,Cardiovascular Risk Factors, and coronary heart disease”. Circulation 99: 1165–1172.
12.^ a b c d Jani B, Rajkumar C (2006). “Ageing and vascular ageing”. Postgrad Med J 82: 357–362.
13.^ a b http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors
14.^ Jackson R, Chambles L, Higgins M, Kuulasmaa K, Wijnberg L, Williams D (WHO MONICA Project, and ARIC Study.) Sex difference in ischaemic heart disease mortality and risk factors in 46 communities: an ecologic analysis. Cardiovasc Risk Factors. 1999; 7:43-54.
15.^ a b Khallaf, Mohamed (2011). The Impact of Air Pollution on Health, Economy, Environment and Agricultural Sources. InTech. pp. 69–92. ISBN 978-953-307-528-0.
16.^ a b c d Franchini M, Mannucci PM (2012). “Air pollution and cardiovascular disease”. Thrombosis Research 129 (3): 230–4. doi:10.1016/j.thromres.2011.10.030. PMID 22113148.
17.^ a b “Cardiovascular Effects of Ambient Particulate Air Pollution Exposure”. Circulation 121 (25): 2755–65. 2010. doi:10.1161/CIRCULATIONAHA.109.893461. PMC 2924678. PMID 20585020.
18.^ Vanhecke TE, Miller WM, Franklin BA, Weber JE, McCullough PA (Oct 2006). “Awareness, knowledge, and perception of heart disease among adolescents”. Eur J Cardiovasc Prev Rehabil. 13 (5): 718–23. doi:10.1097/01.hjr.0000214611.91490.5e. PMID 17001210.
19.^ Highlander P, Shaw GP (2010). “Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics”. Ther Adv Cardiovasc Dis. 4: 43–54.
20.^ NPS Medicinewise (1 March 2011). “NPS Prescribing Practice Review 53: Managing lipids”. Retrieved 1 August 2011.
21.^ Kvan E., Pettersen K.I., Sandvik L., Reikvam A. (2007). “High mortality in diabetic patient with acute myocardial infarction: cardiovascular co-morbidities contribute most to the high risk”. Int J Cardiol 121: 184–188.
22.^ Norhammar A., Malmberg K., Diderhol E., Lagerqvist B., Lindahl B., Ryde et al. (2004). “Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J”. Am Coll Cardiol 43: 585–591.
23.^ DECODE , European Diabetes Epidemiology Group (1999). “Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria”. Lancet 354: 617–621. doi:10.1016/S0140-6736(98)12131-1. PMID 10466661.
24.^ a b Moyer, VA; U.S. Preventive Services Task, Force (2012 Oct 2). “Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement.”. Annals of internal medicine 157 (7): 512–8. doi:10.7326/0003-4819-157-7-201210020-00514. PMID 22847227.
25.^ Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS (2006). “Multiple biomarkers for the prediction of first major cardiovascular events and death”. N. Engl. J. Med. 355 (25): 2631–billy bob joe9. doi:10.1056/NEJMoa055373. PMID 17182988.
26.^ Spence JD (2006). “Technology Insight: ultrasound measurement of carotid plaque–patient management, genetic research, and therapy evaluation”. Nat Clin Pract Neurol 2 (11): 611–9. doi:10.1038/ncpneuro0324. PMID 17057748.
27.^ Inaba, Y; Chen, JA; Bergmann, SR (2012 Jan). “Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis.”. Atherosclerosis 220 (1): 128–33. doi:10.1016/j.atherosclerosis.2011.06.044. PMID 21764060.
28.^ Wang TJ, Larson MG, Levy D, et al. (Feb 2004). “Plasma natriuretic peptide levels and the risk of cardiovascular events and death”. N Engl J Med. 350 (7): 655–63. doi:10.1056/NEJMoa031994. PMID 14960742.
29.^ a b c d NHS Direct
30.^ Ignarro, LJ; Balestrieri, ML, Napoli, C (2007 Jan 15). “Nutrition, physical activity, and cardiovascular disease: an update.”. Cardiovascular research 73 (2): 326–40. doi:10.1016/j.cardiores.2006.06.030. PMID 16945357.
31.^ World Heart Federation (5 October 2011). “World Heart Federation: Cardiovascular disease risk factors”. Retrieved 5 October 2011.
32.^ The National Heart, Lung, and Blood Institute (NHLBI) (5 October 2011). “How To Prevent and Control Coronary Heart Disease Risk Factors – NHLBI, NIH”. Retrieved 5 October 2011.
33.^ Klatsky AL (May 2009). “Alcohol and cardiovascular diseases”. Expert Rev Cardiovasc Ther 7 (5): 499–506. doi:10.1586/erc.09.22. PMID 19419257.
34.^ McTigue KM, Hess R, Ziouras J (September 2006). “Obesity in older adults: a systematic review of the evidence for diagnosis and treatment”. Obesity (Silver Spring) 14 (9): 1485–97. doi:10.1038/oby.2006.171. PMID 17030958.
35.^ Linden W, Stossel C, Maurice J (April 1996). “Psychosocial interventions for patients with coronary artery disease: a meta-analysis”. Arch. Intern. Med. 156 (7): 745–52. PMID 8615707.
36.^ Marshall, IJ; Wolfe, CD; McKevitt, C (2012 Jul 9). “Lay perspectives on hypertension and drug adherence: systematic review of qualitative research.”. BMJ (Clinical research ed.) 345: e3953. PMC 3392078. PMID 22777025.
37.^ Dickinson, HO; Mason, JM; Nicolson, DJ; Campbell, F; Beyer, FR; Cook, JV; Williams, B; Ford, GA (2006 Feb). “Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials.”. Journal of hypertension 24 (2): 215–33. doi:10.1097/01.hjh.0000199800.72563.26. PMID 16508562.
38.^ Moyer, VA; U.S. Preventive Services Task, Force (2012 Sep 4). “Behavioral counseling interventions to promote a healthful diet and physical activity for cardiovascular disease prevention in adults: U.S. Preventive Services Task Force recommendation statement.”. Annals of internal medicine 157 (5): 367–71. doi:10.7326/0003-4819-157-5-201209040-00486. PMID 22733153.
39.^ Walker C, Reamy BV (April 2009). “Diets for cardiovascular disease prevention: what is the evidence?”. Am Fam Physician 79 (7): 571–8. PMID 19378874.
40.^ Estruch, Ramón et al (February 25, 2013). “Primary Prevention of Cardiovascular Disease with a Mediterranean Diet”. New England Journal of Medicine. doi:10.1056/NEJMoa1200303. Retrieved February 25, 2013.
41.^ Sacks FM, Svetkey LP, Vollmer WM, et al. (January 2001). “Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group”. N. Engl. J. Med. 344 (1): 3–10. doi:10.1056/NEJM200101043440101. PMID 11136953.
42.^ Obarzanek E, Sacks FM, Vollmer WM, et al. (July 2001). “Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial”. Am. J. Clin. Nutr. 74 (1): 80–9. PMID 11451721.
43.^ Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F (December 2005). “Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome”. Diabetes Care 28 (12): 2823–31. PMID 16306540.
44.^ Logan AG (March 2007). “DASH Diet: time for a critical appraisal?”. Am. J. Hypertens. 20 (3): 223–4. doi:10.1016/j.amjhyper.2006.10.006. PMID 17324730.
45.^ a b c Willett, WC (2012 Jul). “Dietary fats and coronary heart disease.”. Journal of internal medicine 272 (1): 13–24. PMID 22583051.
46.^ Mozaffarian, D; Aro, A; Willett, WC (2009 May). “Health effects of trans-fatty acids: experimental and observational evidence.”. European journal of clinical nutrition. 63 Suppl 2: S5–21. doi:10.1038/sj.ejcn.1602973. PMID 19424218.
47.^ a b Ramsden, CE; Zamora, D; Leelarthaepin, B; Majchrzak-Hong, SF; Faurot, KR; Suchindran, CM; Ringel, A; Davis, JM; Hibbeln, JR (2013 Feb 4). “Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis.”. BMJ (Clinical research ed.) 346: e8707. PMID 23386268.
48.^ Stamler J (March 2010). “Diet-heart: a problematic revisit”. Am. J. Clin. Nutr. 91 (3): 497–9. doi:10.3945/ajcn.2010.29216. PMID 20130097.
49.^ Siri-Tarino, PW; Sun Q, Hu FB, Krauss RM (March 2010). “Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease.”. The American Journal of Clinical Nutrition 91 (3): 535–46. doi:10.3945/ajcn.2009.27725. PMC 2824152. PMID 20071648.
50.^ Hooper, L; Summerbell, CD; Thompson, R; Sills, D; Roberts, FG; Moore, HJ; Davey Smith, G (2012 May 16). “Reduced or modified dietary fat for preventing cardiovascular disease.”. Cochrane database of systematic reviews (Online) 5: CD002137. PMID 22592684.
51.^ Siri-Tarino Patty W, Sun Qi, Hu Frank B, Krauss Ronald M (2010). “Saturated fat, carbohydrate, and cardiovascular disease”. American Journal of Clinical Nutrition 91 (3): 502–509. doi:10.3945/ajcn.2008.26285. PMC 2824150. PMID 20089734.
52.^ Micha, R; Mozaffarian, D (2010 Oct). “Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence.”. Lipids 45 (10): 893–905. doi:10.1007/s11745-010-3393-4. PMC 2950931. PMID 20354806.
53.^ Astrup, A; Dyerberg, J; Elwood, P; Hermansen, K; Hu, FB; Jakobsen, MU; Kok, FJ; Krauss, RM; Lecerf, JM; LeGrand, P; Nestel, P; Risérus, U; Sanders, T; Sinclair, A; Stender, S; Tholstrup, T; Willett, WC (2011 Apr). “The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010?”. The American journal of clinical nutrition 93 (4): 684–8. PMID 21270379.
54.^ Rizos, EC; Ntzani, EE; Bika, E; Kostapanos, MS; Elisaf, MS (2012 Sep 12). “Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.”. JAMA : the journal of the American Medical Association 308 (10): 1024–33. PMID 22968891.
55.^ a b Taylor, RS; Ashton, KE; Moxham, T; Hooper, L; Ebrahim, S (2011 Jul 6). “Reduced dietary salt for the prevention of cardiovascular disease.”. Cochrane database of systematic reviews (Online) (7): CD009217. doi:10.1002/14651858.CD009217. PMID 21735439.
56.^ Bhupathiraju, SN; Tucker, KL (2011 Aug 17). “Coronary heart disease prevention: nutrients, foods, and dietary patterns.”. Clinica chimica acta; international journal of clinical chemistry 412 (17-18): 1493–514. PMID 21575619.
57.^ Myung, SK; Ju, W; Cho, B; Oh, SW; Park, SM; Koo, BK; Park, BJ; for the Korean Meta-Analysis (KORMA) Study, Group (2013 Jan 18). “Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials.”. BMJ (Clinical research ed.) 346: f10. PMC 3548618. PMID 23335472.
58.^ Bruckert, E; Labreuche, J; Amarenco, P (2010 Jun). “Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis”. Atherosclerosis 210 (2): 353–61. doi:10.1016/j.atherosclerosis.2009.12.023. PMID 20079494.
59.^ Lavigne, PM; Karas, RH (2013 Jan 29). “The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.”. Journal of the American College of Cardiology 61 (4): 440–6. PMID 23265337.
60.^ Jee SH, Miller ER III, Guallar E et al. (2002). “The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials”. Am J Hypertens 15 (8): 691–696. doi:10.1016/S0895-7061(02)02964-3. PMID 12160191.
61.^ Zipes DP, Camm AJ, Borggrefe M et al. (2012). “ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society”. Circulation 114 (10): e385–e484. doi:10.1161/CIRCULATIONAHA.106.178233. PMID 16935995.
62.^ Massy ZA, Drüeke TB (2012). “Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis, and survival”. Clin Kidney J 5 (Suppl 1): i52–i61. doi:10.1093/ndtplus/sfr167.
63.^ Kwak, SM; Myung, SK; Lee, YJ; Seo, HG; for the Korean Meta-analysis Study, Group (2012 Apr 9). “Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized, Double-blind, Placebo-Controlled Trials.”. Archives of Internal Medicine. doi:10.1001/archinternmed.2012.262. PMID 22493407.
64.^ Berger, JS; Lala, A, Krantz, MJ, Baker, GS, Hiatt, WR (2011 Jul). “Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.”. American heart journal 162 (1): 115–24.e2. doi:10.1016/j.ahj.2011.04.006. PMID 21742097.
65.^ a b Gutierrez, J; Ramirez, G; Rundek, T; Sacco, RL (2012 Jun 25). “Statin Therapy in the Prevention of Recurrent Cardiovascular Events: A Sex-Based Meta-analysisStatin Therapy to Prevent Recurrent CV Events.”. Archives of Internal Medicine 172 (12): 909–19. doi:10.1001/archinternmed.2012.2145. PMID 22732744.
66.^ Taylor, F; Huffman, MD; Macedo, AF; Moore, TH; Burke, M; Davey Smith, G; Ward, K; Ebrahim, S (2013 Jan 31). “Statins for the primary prevention of cardiovascular disease.”. Cochrane database of systematic reviews (Online) 1: CD004816. PMID 23440795.
67.^ Ornish, Dean, “et al.” (Jul 1990). “‘Can lifestyle changes reverse coronary heart disease?’ The Lifestyle Heart Trial.”. Lancet 336 (8708): 129–33. doi:10.1016/0140-6736(90)91656-U. PMID 1973470.
68.^ Ornish, D., Scherwitz, L. W., Doody, R. S., Kesten, D., McLanahan, S. M., Brown, S. E. “et al.” (1983). “Effects of stress management training and dietary changes in treating ischemic heart disease”. JAMA 249 (54): 54. doi:10.1001/jama.249.1.54. PMID 6336794.
69.^ Ornish, D., Scherwitz, L. W., Billings, J. H., Brown, S. E., Gould, K. L., Merritt, T. A. “et al.” (1998). “Intensive lifestyle changes for reversal of coronary heart disease”. JAMA 280 (23): 2001–7. doi:10.1001/jama.280.23.2001. PMID 9863851.
70.^ “WHO Disease and injury country estimates”. World Health Organization. 2009. Retrieved Nov. 11, 2009.
71.^ Morris J. N., Crawford Margaret D. (1958). “Coronary Heart Disease and Physical Activity of Work”. British Medical Journal 2 (5111): 1485–1496. PMC 2027542. PMID 13608027.
72.^ Karakas M, Koenig W (December 2009). “CRP in cardiovascular disease”. Herz 34 (8): 607–13. doi:10.1007/s00059-009-3305-7. PMID 20024640.
73.^ 20448212
74.^ Venuraju SM, Yerramasu A, Corder R, Lahiri A (May 2010). “Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity”. J. Am. Coll. Cardiol. 55 (19): 2049–61. doi:10.1016/j.jacc.2010.03.013. PMID 20447527.
75.^ Andraws R, Berger JS, Brown DL (Jun 2005). “Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials”. JAMA 293 (21): 2641–7. doi:10.1001/jama.293.21.2641. PMID 15928286.
76.^ Dominguez-Rodriguez, Alberto (January 2012). “Melatonin and Cardiovascular Disease: Myth or Reality?”. Rev Esp Cardiol 65: 215–218.

External links [edit]
Cardiovascular disease at the Open Directory Project
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)

[show]
v ·
t ·
e

Pathology: Medical conditions and ICD code

[show]
v ·
t ·
e

Cardiovascular disease: heart disease ·Circulatory system pathology (I00–I52, 390–429)

[show]
v ·
t ·
e

Cardiovascular disease: vascular disease ·Circulatory system pathology (I70–I99, 440–456)

[show]
v ·
t ·
e

Certain conditions originating in the perinatal period / fetal disease (P, 760–779)

Categories: Heart diseases

Navigation menu

Create account
Log in

Article
Talk

Read
Edit
View history

Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikimedia Shop

Interaction

Help
About Wikipedia
Community portal
Recent changes
Contact Wikipedia

Toolbox

Print/export

Languages

العربية
Български
Català
Deutsch
Español
فارسی
Français
हिन्दी
Latviešu
Nederlands
नेपाली
नेपाल भाषा
日本語
Norsk bokmål
Polski
Português
Română
Slovenščina
Српски / srpski
Svenska
தமிழ்
తెలుగు
Türkçe
中文
Edit links

This page was last modified on 17 May 2013 at 07:22.

Assessing the Global Burden of Ischemic Heart Disease: Part 1: Methods for a Systematic Review of the Global Epidemiology of Ischemic Heart Disease in 1990 and 2010.

Moran AE, Oliver JT, Mirzaie M, Forouzanfar MH, Chilov M, Anderson L, Morrison JL, Khan A, Zhang N, Haynes N, Tran J, Murphy A, Degennaro V, Roth G, Zhao D, Peer N, Pichon-Riviere A, Rubinstein A, Pogosova N, Prabhakaran D, Naghavi M, Ezzati M, Mensah GA.

Source

Division of General Medicine, Department of Medicine, Columbia University Medical Center, New York, NY, USA.

Abstract

BACKGROUND:

Ischemic heart disease (IHD) is the leading cause of death worldwide. The GBD (Global Burden of Disease, Injuries, and Risk Factors) study (GBD 2010 Study) conducted a systematic review of IHD epidemiology literature from 1980 to 2008 to inform estimates of the burden on IHD in 21 world regions in 1990 and 2010.

METHODS:

The disease model of IHD for the GBD 2010 Study included IHD death and 3 sequelae: myocardial infarction, heart failure, and angina pectoris. Medline, EMBASE, and LILACS were searched for IHD epidemiology studies in GBD high-income and low- and middle-income regions published between 1980 and 2008 using a systematic protocol validated by regional IHD experts. Data from included studies were supplemented with unpublished data from selected high-quality surveillance and survey studies. The epidemiologic parameters of interest were incidence, prevalence, case fatality, and mortality.

RESULTS:

Literature searches yielded 40,205 unique papers, of which 1,801 met initial screening criteria. Upon detailed review of full text papers, 137 published studies were included. Unpublished data were obtained from 24 additional studies. Data were sufficient for high-income regions, but missing or sparse in many low- and middle-income regions, particularly Sub-Saharan Africa.

CONCLUSIONS:

A systematic review for the GBD 2010 Study provided IHD epidemiology estimates for most world regions, but highlighted the lack of information about IHD in Sub-Saharan Africa and other low-income regions. More complete knowledge of the global burden of IHD will require improved IHD surveillance programs in all world regions.

PMID: 23682350 [PubMed]
Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.

Yan Q, Zhang ZF, Chen XP, Gutmann DH, Xiong M, Xiao ZY, Huang ZY.

Source

Research Laboratory and Hepatic Surgical Center, Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong Universty of Science and Technology, Wuhan 430030, P.R. China.

Abstract

Loss of T-cadherin expression has been reported in a number of human cancers. We previously reported that T-cadherin re-expression suppressed cell growth and motility in glioma. Here, we report that the T-cadherin expression was significantly decreased in human hepatocellular carcinoma (HCC) compared to adjacent normal liver. In addition, T-cadherin expression in HCC with metastasis was significantly lower than in HCC without metastasis. To determine the mechanism underlying the reduced T-cadherin expression in HCC, we examined T-cadherin promoter methylation. We found that methylation of the T-cadherin promoter was present in 40% of HCC, but absent in all adjacent liver tissues. In the HCC with T-cadherin promoter methylation, the T-cadherin expression was significantly decreased compared to HCC without methylation. To provide a functional link between T-cadherin promoter methylation and T-cadherin growth regulation, we used the HepG2 hepatoma cell line that exhibits T-cadherin promoter methylation. Treatment of HepG2 cells with the demethylating agent 5-aza-2-deoxycytidine resulted in increased T-cadherin expression and reduced cell proliferation. These results demonstrate that the T-cadherin down-regulation by promoter methylation is associated with the development and progression of HCC, and suggest that T-cadherin is an important tumor suppressor in liver cancer.

Select a City:

Alabama (AL)
•Birmingham, AL
•Mobile, AL

Alaska (AK)

Arizona (AZ)
•Mesa, AZ
•Phoenix, AZ
•Tucson, AZ

Arkansas (AR)
•Hot Springs, AR
•Little Rock, AR

California (CA)
•Anaheim, CA
•Bakersfield, CA
•Fresno, CA
•Long Beach, CA
•Los Angeles, CA
•Sacramento, CA
•San Diego, CA
•San Francisco, CA
•San Jose, CA

Colorado (CO)
•Denver, CO

Connecticut (CT)

Delaware (DE)

District of Columbia (DC)
•Washington, DC

Florida (FL)
•Jacksonville, FL
•Miami, FL
•Orlando, FL
•Saint Petersburg, FL
•Tampa, FL

Georgia (GA)
•Atlanta, GA
•Augusta, GA
•Columbus, GA

Hawaii (HI)
•Honolulu, HI

Idaho (ID)

Illinois (IL)
•Chicago, IL

Indiana (IN)
•Fort Wayne, IN
•Indianapolis, IN

Iowa (IA)
•Des Moines, IA

Kansas (KS)
•Overland Park, KS
•Wichita, KS

Kentucky (KY)
•Lexington, KY
•Louisville, KY

Louisiana (LA)
•Alexandria, LA
•Baton Rouge, LA
•Lafayette, LA
•Lake Charles, LA
•Monroe, LA
•New Orleans, LA
•Shreveport, LA

Maine (ME)

Maryland (MD)
•Baltimore, MD

Massachusetts (MA)
•Boston, MA
•Worcester, MA

Michigan (MI)
•Detroit, MI
•Grand Rapids, MI

Minnesota (MN)

Mississippi (MS)
•Jackson, MS
•Meridian, MS

Missouri (MO)
•Columbia, MO
•Kansas City, MO
•Saint Louis, MO

Montana (MT)

Nebraska (NE)
•Lincoln, NE
•Omaha, NE

Nevada (NV)
•Las Vegas, NV

New Hampshire (NH)

New Jersey (NJ)

New Mexico (NM)
•Albuquerque, NM

New York (NY)
•Albany, NY
•Bronx, NY
•Brooklyn, NY
•Buffalo, NY
•New York, NY

North Carolina (NC)
•Charlotte, NC

North Dakota (ND)

Ohio (OH)
•Akron, OH
•Cincinnati, OH
•Cleveland, OH
•Columbus, OH
•Dayton, OH
•Toledo, OH

Oklahoma (OK)
•Lawton, OK
•Oklahoma City, OK
•Tulsa, OK

Oregon (OR)
•Portland, OR

Pennsylvania (PA)
•Allentown, PA
•Philadelphia, PA
•Pittsburgh, PA

Rhode Island (RI)

South Carolina (SC)
•Charleston, SC
•Greenville, SC

South Dakota (SD)

Tennessee (TN)
•Chattanooga, TN
•Knoxville, TN
•Memphis, TN
•Nashville, TN

Texas (TX)
•Amarillo, TX
•Arlington, TX
•Austin, TX
•Corpus Christi, TX
•Dallas, TX
•El Paso, TX
•Fort Worth, TX
•Houston, TX
•Lubbock, TX
•Plano, TX
•San Antonio, TX
•Sugar Land, TX
•Tyler, TX

Utah (UT)
•Salt Lake City, UT

Vermont (VT)

Virginia (VA)
•Richmond, VA

Washington (WA)
•Seattle, WA

West Virginia (WV)

Wisconsin (WI)
•Green Bay, WI
•Madison, WI
•Milwaukee, WI

Wyoming (W

Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease.

(PMID:23636477)
Abstract
Citations
BioEntities
Related Articles

De Caterina R,

Husted S,

Wallentin L,

Andreotti F,

Arnesen H,

Bachmann F,

Baigent C,

Huber K,

Jespersen J,

Kristensen SD,

Lip GY,

Morais J,

Rasmussen LH,

Siegbahn A,

Verheugt FW,

Weitz JI
Raffaele De Caterina, MD, PhD, Institute of Cardiology, “G. d’Annunzio” University – Chieti, Ospedale SS. Annunziata, Via dei Vestini, 66013 Chieti, Italy, E-mail: rdecater@unich.it.

Thrombosis and Haemostasis [2013, 109(5):769-786]

Type: Journal Article
DOI: 10.1160/TH12-06-0403

Abstract

Highlight Terms
Gene Ontology(1) Diseases(3) Genes/Proteins(1) Chemicals(3)

Anticoagulants are a mainstay of cardiovascular therapy, and parenteral anticoagulants have widespread use in cardiology, especially in acute situations. Parenteral anticoagulants include unfractionated heparin, low-molecular-weight heparins, the synthetic pentasaccharides fondaparinux, idraparinux and idrabiotaparinux, and parenteral direct thrombin inhibitors. The several shortcomings of unfractionated heparin and of low-molecular-weight heparins have prompted the development of the other newer agents. Here we review the mechanisms of action, pharmacological properties and side effects of parenteral anticoagulants used in the management of coronary heart disease treated with or without percutaneous coronary interventions, cardioversion for atrial fibrillation, and prosthetic heart valves and valve repair. Using an evidence-based approach, we describe the results of completed clinical trials, highlight ongoing research with currently available agents, and recommend therapeutic options for specific heart diseases.

Read Article at DOI (Subscription required)

Back to Results

Formats

Abstract

Full Text

PDF

Export citation (RIS)

Email citation

Terms of Use | Copyright | Accessibility | Cookies

Europe PubMed Central is a service of the Europe PMC Funders’ Group working in partnership with the European Bioinformatics Institute, University of Manchester and the British Library in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine (NCBI/NLM). It includes
Content referenced by

http://en.wikipedia.org/wiki/Cardiovascular_disease

http://www.ncbi.nlm.nih.gov/pubmed?term=heart%20disease

http://www.ihop-net.org/UniPub/iHOP/index.html?search=heart+&field=all&ncbi_tax_id=0&organism_syn=

http://www.healthgrades.com/hospital-directory

http://europepmc.org/abstract/MED/23636477

Posted in Uncategorized | Leave a comment

Hepatitis


Hepatitis

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Hepatitis

Classification and external resources

Alcoholic hepatitis evident by fatty change, cell necrosis, Mallory bodies

ICD-10

K75.9

ICD-9

573.3

DiseasesDB

20061

MedlinePlus

001154

MeSH

D006505

Hepatitis (plural hepatitides) is a medical condition defined by the inflammation of the liver and characterized by the presence of inflammatory cells in the tissue of the organ. The name is from the Greek hepar (ἧπαρ), the root being hepat- (ἡπατ-), meaning liver, and suffix -itis, meaning “inflammation” (c. 1727).[1] The condition can be self-limiting (healing on its own) or can progress to fibrosis (scarring) and cirrhosis.

Hepatitis may occur with limited or no symptoms, but often leads to jaundice, anorexia (poor appetite) and malaise. Hepatitis is acute when it lasts less than six months and chronic when it persists longer. A group of viruses known as the hepatitis viruses cause most cases of hepatitis worldwide, but hepatitis can also be caused by toxic substances (notably alcohol, certain medications, some industrial organic solvents and plants), other infections and autoimmune diseases.

Contents
[hide] 1 Signs and symptoms 1.1 Acute
1.2 Chronic

2 Diagnosis 2.1 Hepatitis A
2.2 Hepatitis C

3 Pathology 3.1 Acute
3.2 Chronic
3.3 Specific cases

4 Causes 4.1 Acute
4.2 Chronic
4.3 Notes

5 Discussion 5.1 Alcoholic hepatitis
5.2 Drug-induced
5.3 Other toxic substances
5.4 Metabolic disorders
5.5 Obstructive
5.6 Autoimmune
5.7 Alpha 1-antitrypsin deficiency
5.8 Non-alcoholic fatty liver disease
5.9 Ischemic hepatitis
5.10 Giant cell hepatitis

6 See also
7 References
8 External links

Signs and symptoms [edit]

Acute [edit]

Initial features are of nonspecific flu-like symptoms, common to almost all acute viral infections and may include malaise, muscle and joint aches, fever, nausea or vomiting, diarrhea, and headache. More specific symptoms, which can be present in acute hepatitis from any cause, are: profound loss of appetite, aversion to smoking among smokers, dark urine, yellowing of the eyes and skin (i.e., jaundice) and abdominal discomfort. Physical findings are usually minimal, apart from jaundice in a third and tender hepatomegaly (swelling of the liver) in about 10%. Some exhibit lymphadenopathy (enlarged lymph nodes, in 5%) or splenomegaly (enlargement of the spleen, in 5%).[2]

Acute viral hepatitis is more likely to be asymptomatic in younger people. Symptomatic individuals may present after convalescent stage of 7 to 10 days, with the total illness lasting 2 to 6 weeks.[3]

A small proportion of people with acute hepatitis progress to acute liver failure, in which the liver is unable to clear harmful substances from the circulation (leading to confusion and coma due to hepatic encephalopathy) and produce blood proteins (leading to peripheral oedema and bleeding). This may become life-threatening and occasionally requires a liver transplant.

Chronic [edit]

Chronic hepatitis often leads to nonspecific symptoms such as malaise, tiredness and weakness, and often leads to no symptoms at all. It is commonly identified on blood tests performed either for screening or to evaluate nonspecific symptoms. The occurrence of jaundice indicates advanced liver damage. On physical examination there may be enlargement of the liver.[4]

Extensive damage to and scarring of liver (i.e. cirrhosis) leads to weight loss, easy bruising and bleeding tendencies, peripheral edema (swelling of the legs) and accumulation of ascites (fluid in the peritoneal cavity). Eventually, cirrhosis may lead to various complications: esophageal varices (enlarged veins in the wall of the esophagus that can cause life-threatening bleeding) hepatic encephalopathy (confusion and coma) and hepatorenal syndrome (kidney dysfunction).

Acne, abnormal menstruation, lung scarring, inflammation of the thyroid gland and kidneys may be present in women with autoimmune hepatitis.[4]

Diagnosis [edit]

Diagnosis can be made using various biochemical markers of hepatitis in conjunction with an assessment of the patient’s medical history and a physical examination.

The following are biochemical markers used in the diagnosis of hepatitis:

Hepatitis A [edit]

Data taken from Harrison’s Principle of Internal Medicine, 17 Edition [5]

Marker

Detection Time

Description

Significance

Faecal HAV

2-4 weeks

-

Early detection

Ig M anti HAV

4-12 weeks

Enzyme immunoassay for antibodies

During Acute Illness

Ig G anti HAV

5 weeks – persistent

Enzyme immunoassay for antobodies

Old infection or Reinfection

Hepatitis C [edit]

Marker

Detection Time

Description

Significance

Note

HCV-RNA

1–3 weeks

PCR

Demonstrates presence or absence of virus

Results may be intermittent during course of infection. Negative result is not indicative of absence.

anti-HCV

5–6 weeks

Enzyme Immunoassay for antibodies

Demonstrates past or present infection

High false positive in those with autoimmune disorders and populations with low virus prevalence.

ALT

5–6 weeks

-

Peak in ALT coincides with peak in anti-HCV

Fluctuating ALT levels is an indication of active liver disease.

Data taken from the WHO website on Hepatitis C.[6]

Pathology [edit]

The liver, like all organs, responds to injury in a limited number of ways and a number of patterns have been identified. Liver biopsies are rarely performed for acute hepatitis and because of this the histology of chronic hepatitis is better known than that of acute hepatitis.

Acute [edit]

In acute hepatitis the lesions (areas of abnormal tissue) predominantly contain diffuse sinusoidal and portal mononuclear infiltrates (lymphocytes, plasma cells, Kupffer cells) and swollen hepatocytes. Acidophilic cells (Councilman bodies) are common. Hepatocyte regeneration and cholestasis (canalicular bile plugs) typically are present. Bridging hepatic necrosis (areas of necrosis connecting two or more portal tracts) may also occur. There may be some lobular disarray. Although aggregates of lymphocytes in portal zones may occur these are usually neither common nor prominent. The normal architecture is preserved. There is no evidence of fibrosis or cirrhosis (fibrosis plus regenerative nodules). In severe cases prominent hepatocellular necrosis around the central vein (zone 3) may be seen.

In submassive necrosis – a rare presentation of acute hepatitis – there is widespread hepatocellular necrosis beginning in the centrizonal distribution and progressing towards portal tracts. The degree of parenchymal inflammation is variable and is proportional to duration of disease.[7][8] Two distinct patterns of necrosis have been recognised: (1) zonal coagulative necrosis or (2) panlobular (nonzonal) necrosis.[9] Numerous macrophages and lymphocytes are present. Necrosis and inflammation of the biliary tree occurs.[10] Hyperplasia of the surviving biliary tract cells may be present. Stromal haemorrhage is common.

The histology may show some correlation with the cause:
Zone 1 (periportal) occurs in phosphorus poisoning or eclampsia.
Zone 2 (midzonal) – rare – is seen in yellow fever.
Zone 3 (centrilobular) occurs with ischemic injury, toxic effects, carbon tetrachloride exposure or chloroform ingestion. Drugs such as acetaminophen may be metabolized in zone 1 to toxic compounds that cause necrosis in zone 3.

Where patients have recovered from this condition, biopsies commonly show multiacinar regenerative nodules (previously known as adenomatous hyperplasia).[11]

Massive hepatic necrosis is also known and is usually rapidly fatal. The pathology resembles that of submassive necrosis but is more markered in both degree and extent.

Chronic [edit]

Chronic hepatitis has been better studied and several conditions have been described.

Chronic hepatitis with piecemeal (periportal) necrosis (or interface hepatitis) with or without fibrosis.[12] (formerly chronic active hepatitis) is any case of hepatitis occurring for more than 6 months with portal based inflammation, fibrosis, disruption of the terminal plate, and piecemeal necrosis. This term has now been replaced by the diagnosis of ‘chronic hepatitis

Chronic hepatitis without piecemeal necrosis (or interface hepatitis)[12] (formerly called chronic persistent hepatitis) is chronic hepatitis with no significant periportal necrosis or regeneration with a fairly dense mononuclear portal infiltrate. Councilman bodies are frequently seen within the lobule.

Chronic hepatitis without piecemeal necrosis (or interface hepatitis)[12] (formerly called chronic lobular hepatitis) is chronic hepatitis with persistent parenchymal focal hepatocyte necrosis (apoptosis) with mononuclear sinusoidal infiltrates.

The older terms have been deprecated because the conditions are now understood as being able to alter over time so that what might have been regarded as a relatively benign lesion could still progress to cirrhosis. The simpler term chronic hepatitis is now preferred in association with the causative agent (when known) and a grade based on the degree of inflammation, piecemeal or bridging necrosis (interface hepatitis) and the stage of fibrosis. Several grading systems have been proposed but none have been adopted universally.

Cirrhosis is a diffuse process characterized by regenerative nodules that are separated from one another by bands of fibrosis. It is the end stage for many chronic liver diseases. The pathophysiological process that results in cirrhosis is as follows: hepatocytes are lost through a gradual process of hepatocellular injury and inflammation. This injury stimulates a regenerative response in the remaining hepatocytes. The fibrotic scars limit the extent to which the normal architecture can be reestablished as the scars isolate groups of hepatocytes. This results in nodules formation. Angiogenisis (new vessel formation) accompanies scar production which results in the formation of abnormal channels between the central hepatic veins and the portal vessels. This in turn causes shunting of blood around the regenerating parenchyma. Normal vascular structures including the sinusoidal channels may be obliterated by fibrotic tissue leading to portal hypertension. The overall reduction in hepatocyte mass, in conjunction with the portal blood shunting, prevents the liver from accomplishing its usual functions – the filtering of blood from the gastrointestinal tract and serum protein production. These changes give rise to the clinical manifestations of cirrhosis.

Specific cases [edit]

Most of the causes of hepatitis cannot be distinguished on the basis of the pathology but some do have particular features that are suggestive of a particular diagnosis.

The presence of micronodular cirrhosis, Mallory bodies and fatty change within a single biopsy are highly suggestive of alcoholic injury.[13] Perivenular, pericellular fibrosis (known as ‘chicken wire fibrosis’ because of its appearance on trichrome or van Gieson stains) with partial or complete obliteration of the central vein is also very suggestive of alcohol abuse.

Cardiac, ischemic and venous outflow obstruction all cause similar patterns.[14] The sinusoids are often dilated and filled with erythrocytes. The liver cell plates may be compressed. Coagulative necrosis of the hepatocytes can occur around the central vein. Hemosiderin and lipochrome laden macrophages and inflammatory cells may be found. At the edge of the fibrotic zone cholestasis may be present. The portal tracts are rarely significantly involved until late in the course.

Biliary tract disease including primary biliary cirrhosis, sclerosing cholangitis, inflammatory changes associated with idiopathic inflammatory bowel disease and duct obstruction have similar histology in their early stages. Although these diseases tend to primarily involve the biliary tract they may also be associated with chronic inflammation within the liver and difficult to distinguish on histological grounds alone. The fibrotic changes associated with these disease principally involve the portal tracts with cholangiole proliferation, portal tract inflammation with neutrophils surrounding the cholangioles, disruption of the terminal plate by mononuclear inflammatory cells and occasional hepatocyte necrosis. The central veins are either not involved in the fibrotic process or become involved only late in the course of the disease. Consequently the central–portal relationships are minimally distorted. Where cirrhosis is present it tends to be in the form of a portal–portal bridging fibrosis.

Hepatitis E causes different histological patterns that depend on the host’s background.[15] In immunocompetent patients the typical pattern is of severe intralobular necrosis and acute cholangitis in the portal tract with numerous neutrophils. This normally resolves without sequelae. Disease is more severe in those with preexisting liver disease such as cirrhosis. In the immunocompromised patients chronic infection may result with rapid progression to cirrhosis. The histology is similar to that found in hepatitis C virus with dense lymphocytic portal infiltrate, constant piecemeal necrosis and fibrosis.

Causes [edit]

Acute
Viral hepatitis (15 families) Adenoviridae: Adenoviruses
Arenaviruses: Guanarito virus,[16] Junín virus,[16] Lassa fever virus,[16] Lujo virus,[17] Machupo virus[16] and Sabiá virus[16]
Bunyaviruses: Crimean-Congo hemorrhagic fever virus,[18] Dobrava virus,[19] Hantaan virus,[20] Puumala virus,[21] Rift Valley fever virus,[22] Seoul virus[23] and SFTS virus[24]
Coronaviridae: Severe acute respiratory syndrome virus[25]
Erythrovirus: Parvovirus B19[26]
Flaviviruses: Akhurma virus,[27] Dengue,[28] Hepatitis C, Kyasanur Forest disease virus,[29] Omsk hemorrhagic fever virus,[29] Yellow fever
Filoviruses: Ebola virus and Marburg virus[30]
Hepadnaviridae: Hepatitis B
Hepeviridae: Hepatitis E
Herpesviruses: Cytomegalovirus,[31] Epstein Barr virus,[32] Varicella zoster virus, Human herpesvirus 6, Human herpesvirus 7 and Human herpesvirus 8[33]
Orthomyxoviruses: Influenza[34]
Parvoviridae: Parvovirus B19[26]
Picornaviruses: Echovirus,[35] Hepatitis A
Reovirus: Colorado tick fever virus,[36] Reovirus 3[37]
Unassigned family: Hepatitis D

Bacterial Anaplasma[38]
Babesia[39]
Bartonella[40]
Chlamydia trachomatis[41]
Coxiella burnetii[42]
Ehrlichia[43]
Leptospira
Listeria[44]
Mycobacterium tuberculosis[45]
Nocardia[46]
Novosphingobium aromaticivorans[47][48][49][50]
Orientia tsutsugamushi[51][52][53]
Rickettsia[53]
Rhodococcus[54]
Salmonella[55]
Streptococcus pyogenes[56]
Treponema pallidum[57]
Yersinia[58]

Protozoal Entamoeba histolytica[59]
Cryptosporidium[60]
Isospora[61][62]
Leishmania[59]
Plasmodium[63]
Toxoplasma

Parasitic Ascaris lumbricoides[59]
Ancylostoma[64]
Baylisascaris[65]
Capillaria hepatica[66]
Clonorchis sinensis[59]
Dicrocoelium dendriticum[67]
Echinococcus[59]
Fasciola hepatica[59]
Fasciolopsis buski[68]
Metorchis[69]
Necator[64]
Opisthorchis[59]
Paragonimus[70]
Strongyloides stercoralis[71]
Schistosoma[72]
Toxocara[73]

Fungal Aspergillus[74]
Candida[75]
Cryptococcus[66]
Histoplasma[76]
Microsporidium[77][78][79]

Algal Prototheca[80][81]

This section does not cite any references or sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2011)

Non infectious Alcohol[82]
Auto immune conditions: systemic lupus erythematosus[83]
Drugs: Paracetamol, amoxycillin, antituberculosis medicines, minocycline and many others (see longer list below).
Ischemic hepatitis (circulatory insufficiency)
Metabolic diseases: Wilson’s disease[84]
Pregnancy
Toxins: Amanita toxin in mushrooms, carbon tetrachloride, asafetida

Chronic
Alcohol[82]
Autoimmune Autoimmune hepatitis

Drugs Isoniazid
Ketoconazole
Methyldopa
Nitrofurantoin

Inherited Wilson’s disease[84]
Alpha 1-antitrypsin deficiency

Non-alcoholic steatohepatitis
Viral hepatitis: (Hepatitis A does not cause chronic hepatitis) Hepatitis B with or without hepatitis D
Hepatitis C
Hepatitis E[85]

Notes [edit]
Primary biliary cirrhosis and primary sclerosing cholangitis occasionally mimic chronic hepatitis[3]

Discussion [edit]

Alcoholic hepatitis [edit]

Main article: Alcoholic hepatitis

Ethanol, mostly in alcoholic beverages, is a significant cause of hepatitis. Usually alcoholic hepatitis comes after a period of increased alcohol consumption. Alcoholic hepatitis is characterized by a variable constellation of symptoms, which may include feeling unwell, enlargement of the liver, development of fluid in the abdomen ascites, and modest elevation of liver blood tests. Alcoholic hepatitis can vary from mild with only liver test elevation to severe liver inflammation with development of jaundice, prolonged prothrombin time, and liver failure. Severe cases are characterized by either obtundation (dulled consciousness) or the combination of elevated bilirubin levels and prolonged prothrombin time; the mortality rate in both categories is 50% within 30 days of onset.

Alcoholic hepatitis is distinct from cirrhosis caused by long-term alcohol consumption. Alcoholic hepatitis can occur in patients with chronic alcoholic liver disease and alcoholic cirrhosis. Alcoholic hepatitis by itself does not lead to cirrhosis, but cirrhosis is more common in patients with long-term alcohol consumption. Patients who drink alcohol to excess are also more often than others found to have hepatitis C.[citation needed] The combination of hepatitis C and alcohol consumption accelerates the development of cirrhosis.

Drug-induced [edit]

Main article: Hepatotoxicity

A large number of drugs can cause hepatitis:[86]
Agomelatine (antidepressant)
Allopurinol
Amitriptyline (antidepressant)
Amiodarone (antiarrhythmic)
Atomoxetine [87]
Azathioprine[88]
Halothane (a specific type of anesthetic gas)
Hormonal contraceptives
Ibuprofen and indomethacin (NSAIDs)
Isoniazid (INH), rifampicin, and pyrazinamide (tuberculosis-specific antibiotics)
Ketoconazole (antifungal)
Loratadine (antihistamine)
Methotrexate (immune suppressant)
Methyldopa (antihypertensive)
Minocycline (tetracycline antibiotic)
Nifedipine (antihypertensive)
Nitrofurantoin (antibiotic)
Paracetamol (acetaminophen in the United States) can cause hepatitis when taken in an overdose. The severity of liver damage may be limited by prompt administration of acetylcysteine.
Phenytoin and valproic acid (antiepileptics)
Troglitazone (antidiabetic, withdrawn in 2000 for causing hepatitis)
Zidovudine (antiretroviral i.e., against HIV)
Some herbs and nutritional supplements[89]

The clinical course of drug-induced hepatitis is quite variable, depending on the drug and the patient’s tendency to react to the drug. For example, halothane hepatitis can range from mild to fatal as can INH-induced hepatitis. Hormonal contraception can cause structural changes in the liver. Amiodarone hepatitis can be untreatable since the long half life of the drug (up to 60 days) means that there is no effective way to stop exposure to the drug. Statins can cause elevations of liver function blood tests normally without indicating an underlying hepatitis. Lastly, human variability is such that any drug can be a cause of hepatitis.

Other toxic substances [edit]

Other toxic substances can cause hepatitis. Examples include:
Amatoxin-containing mushrooms, including the Death Cap (Amanita phalloides), the Destroying Angel (Amanita ocreata), and some species of Galerina. A portion of a single mushroom can be enough to be lethal (10 mg or less of α-amanitin).
White phosphorus, an industrial toxin and war chemical.
All chlorinated hydrocarbons (i.e. Carbon tetrachloride, chloroform, and trichloroethylene) can cause steatohepatitis (hepatitis with fatty liver).
Cylindrospermopsin, a toxin from the cyanobacterium Cylindrospermopsis raciborskii and other cyanobacteria.

Metabolic disorders [edit]

Some metabolic disorders cause different forms of hepatitis. Hemochromatosis (due to iron accumulation) and Wilson’s disease (copper accumulation) can cause liver inflammation and necrosis.

Non-alcoholic steatohepatitis (NASH) is effectively a consequence of metabolic syndrome.

Obstructive [edit]

Obstructive jaundice is jaundice occurring due to obstruction of the bile duct (by gallstones or external obstruction by cancer). If longstanding, it leads to destruction and inflammation of liver tissue.

Autoimmune [edit]

Anomalous presentation of human leukocyte antigen (HLA) class II on the surface of hepatocytes, possibly due to genetic predisposition or acute liver infection; causes a cell-mediated immune response against the body’s own liver, resulting in autoimmune hepatitis.

Alpha 1-antitrypsin deficiency [edit]

In severe cases of alpha 1-antitrypsin deficiency (A1AD), the accumulated protein in the endoplasmic reticulum causes liver cell damage and inflammation.

Non-alcoholic fatty liver disease [edit]

Non-alcoholic fatty liver disease (NAFLD) is the occurrence of fatty liver in people who have no history of alcohol use. It is most commonly associated with obesity (80% of all obese people have fatty liver). It is more common in women. Severe NAFLD leads to inflammation, a state referred to as non-alcoholic steatohepatitis (NASH), which on biopsy of the liver resembles alcoholic hepatitis (with fat droplets and inflammatory cells, but usually no Mallory bodies).

The diagnosis depends on medical history, physical exam, blood tests, radiological imaging and sometimes a liver biopsy. The initial evaluation to identify the presence of fatty infiltration of the liver is medical imaging, including such ultrasound, computed tomography (CT), or magnetic resonance (MRI). However, imaging cannot readily identify inflammation in the liver. Therefore, the differentiation between steatosis and NASH often requires a liver biopsy. It can also be difficult to distinguish NASH from alcoholic hepatitis when the patient has a history of alcohol consumption. Sometimes in such cases a trial of abstinence from alcohol along with follow-up blood tests and a repeated liver biopsy are required.

NASH is becoming recognized as the most important cause of liver disease second only to hepatitis C in numbers of patients going on to cirrhosis.[citation needed]

Ischemic hepatitis [edit]

Main article: Ischemic hepatitis

Ischemic hepatitis is caused by decreased circulation to the liver cells. Usually this is due to decreased blood pressure (or shock), leading to the equivalent term “shock liver.” Patients with ischemic hepatitis are usually very ill due to the underlying cause of shock. Rarely, ischemic hepatitis can be caused by local problems with the blood vessels that supply oxygen to the liver (such as thrombosis, or clotting of the hepatic artery which partially supplies blood to liver cells). Blood testing of a person with ischemic hepatitis will show very high levels of transaminase enzymes (AST and ALT), which may exceed 1000 U/L. The elevation in these blood tests is usually transient (lasting 7 to 10 days). It is rare that liver function will be affected by ischemic hepatitis.

Giant cell hepatitis [edit]

Giant cell hepatitis is a rare form of hepatitis (~100 cases reported) that predominantly occurs in children. Diagnosis is made on the basis of the presence of hepatocellular multinucleate giant cells.[9][90][91] Cases presenting in adults are rare and tend to be rapidly progressive.[92][93][94][95][96] The cause is currently unknown but an infectious cause is suspected.[97][98] The condition tends to improve with the use of ribivirin suggesting a viral origin.[99][100] Hepatitis E,[101] hepatitis C,[102] paramyxovirus,[103][104][105][106] papillomavirus[107][108] and Human herpes virus 6[109][110] have been suggested as causes. A similar condition has been reported in cats but it is not known if there is any connection between these conditions.[111]

See also [edit]
Hepatocellular carcinoma
World Hepatitis Day

References [edit]

1.^ “Online Etymology Dictionary”. Etymonline.com. Retrieved 2012-08-26.
2.^ Ryder S, Beckingham I (2001). “Acute hepatitis”. BMJ 322 (7279): 151–153. doi:10.1136/bmj.322.7279.151. PMC 1119417. PMID 11159575.
3.^ a b Bain VG, Ma M. “Ch. 14: Acute Viral Hepatitis”. First principle of gastroenterology. (an online text book)
4.^ a b Chronic hepatitis at Merck Manual of Diagnosis and Therapy Home Edition
5.^ “Acute Viral Hepatitis : Introduction”.
6.^ “WHO | Hepatitis C”. Who.int. 2010-12-08. Retrieved 2012-08-26.
7.^ Boyer JL, Klatskin G (1970). “Pattern of necrosis in acute viral hepatitis. Prognostic value of bridging (subacute hepatic necrosis)”. N. Engl. J. Med. 283 (20): 1063–71. doi:10.1056/NEJM197011122832001. PMID 4319402.
8.^ Gimson AE (July 1996). “Fulminant and late onset hepatic failure”. Br J Anaesth 77 (1): 90–8. doi:10.1093/bja/77.1.90. PMID 8703634.
9.^ a b Kirsch R, Yap J, Roberts EA, Cutz E (April 2009). “Clinicopathologic spectrum of massive and submassive hepatic necrosis in infants and children”. Hum. Pathol. 40 (4): 516–26. doi:10.1016/j.humpath.2008.07.018. PMID 19121848.
10.^ Nakanuma Y, Sasaki M, Terada T, Harada K (1994). “Intrahepatic peribiliary glands of humans. II. Pathological spectrum”. J. Gastroenterol. Hepatol. 9 (1): 80–6. doi:10.1111/j.1440-1746.1994.tb01221.x. PMID 8155873.
11.^ Wanless IR (September 1995). “Terminology of nodular hepatocellular lesions”. Hepatology 22 (3): 983–993. doi:10.1002/hep.1840220341. PMID 7657307.
12.^ a b c Gastroenterology IWPotWCo (August 1994). “Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver: summary of recommendations developed by an international working party, supported by the World Congresses of Gastroenterology, Los Angeles, 1994″. Am. J. Gastroenterol. 89 (8 Suppl): S177–81. PMID 8048409.
13.^ “Alcoholic liver disease: morphological manifestations. Review by an international group”. Lancet 1 (8222): 707–11. March 1981. PMID 6110925.
14.^ Arcidi JM, Moore GW, Hutchins GM (August 1981). “Hepatic morphology in cardiac dysfunction: a clinicopathologic study of 1000 subjects at autopsy”. Am. J. Pathol. 104 (2): 159–66. PMC 1903755. PMID 6455066.
15.^ Selves J, Kamar N, Mansuy JM, Péron JM (December 2010). “[Hepatitis E virus: A new entity]“. Ann Pathol (in French) 30 (6): 432–8. doi:10.1016/j.annpat.2010.10.003. PMID 21167429.
16.^ a b c d e Miguet JP, Coaquette A, Bresson-Hadni S, Lab M (June 1990). “[The other types of viral hepatitis]“. Rev Prat (in French) 40 (18): 1656–9. PMID 2164704.
17.^ Briese T, Paweska JT, McMullan LK, et al. (May 2009). “Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa”. In Buchmeier, Michael J. PLoS Pathog. 5 (5): e1000455. doi:10.1371/journal.ppat.1000455. PMC 2680969. PMID 19478873.
18.^ Appannanavar SB, Mishra B (July 2011). “An update on crimean congo hemorrhagic Fever”. J Glob Infect Dis 3 (3): 285–92. doi:10.4103/0974-777X.83537. PMC 3162818. PMID 21887063.
19.^ Peters W (June 2002). “Novel and challenging infections of man. A brief overview”. Parassitologia 44 (1–2): 33–42. PMID 12404808.
20.^ Glass GE, Watson AJ, LeDuc JW, Childs JE (1994). “Domestic cases of hemorrhagic fever with renal syndrome in the United States”. Nephron 68 (1): 48–51. doi:10.1159/000188086. PMID 7991040.
21.^ Olsson GE, Leirs H, Henttonen H (August 2010). “Hantaviruses and their hosts in Europe: reservoirs here and there, but not everywhere?”. Vector Borne Zoonotic Dis. 10 (6): 549–61. doi:10.1089/vbz.2009.0138. PMID 20795916.
22.^ Ikegami T, Makino S (May 2011). “The pathogenesis of Rift Valley fever”. Viruses 3 (5): 493–519. doi:10.3390/v3050493. PMC 3111045. PMID 21666766.
23.^ Burke RL, Kronmann KC, Daniels CC, et al. (November 2011). “A Review of Zoonotic Disease Surveillance Supported by the Armed Forces Health Surveillance Center”. Zoonoses Public Health 59 (3): 164–75. doi:10.1111/j.1863-2378.2011.01440.x. PMID 22128834.
24.^ Fever with thrombocytopenia associated with a novel Bunyavirus in China. N Engl J Med. 2011 Mar 16. Full text
25.^ Weiss SR, Leibowitz JL (2011). “Coronavirus pathogenesis”. Adv. Virus Res. Advances in Virus Research 81: 85–164. doi:10.1016/B978-0-12-385885-6.00009-2. ISBN 9780123858856. PMID 22094080.
26.^ a b Naides SJ (May 1998). “Rheumatic manifestations of parvovirus B19 infection”. Rheum. Dis. Clin. North Am. 24 (2): 375–401. doi:10.1016/S0889-857X(05)70014-4. PMID 9606764.
27.^ Charrel RN, de Lamballerie X (2003). “[The Alkhurma virus (family Flaviviridae, genus Flavivirus): an emerging pathogen responsible for hemorrhage fever in the Middle East]“. Med Trop (Mars) (in French) 63 (3): 296–9. PMID 14579470.
28.^ Ramos-De La Medina A, Remes-Troche JM, González-Medina MF, et al. (April 2011). “[Abdominal and gastrointestinal symptoms of Dengue fever. Analysis of a cohort of 8559 patients]“. Gastroenterol Hepatol (in Spanish; Castilian) 34 (4): 243–7. doi:10.1016/j.gastrohep.2011.01.012. PMID 21474206.
29.^ a b Gritsun TS, Nuttall PA, Gould EA (2003). “Tick-borne flaviviruses”. Adv. Virus Res. Advances in Virus Research 61: 317–71. doi:10.1016/S0065-3527(03)61008-0. ISBN 0120398613. PMID 14714436.
30.^ Tandon BN, Acharya SK (April 1987). “Viral diseases involving the liver”. Baillieres Clin. Gastroenterol. 1 (2): 211–30. doi:10.1016/0950-3528(87)90002-9. PMID 2822180.
31.^ Xiong W (November 2010). “[Clinical efficacy of treating infant cytomegalovirus hepatitis with ganciclovir and impact on cytokines]“. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (in Chinese) 26 (11): 1130–2. PMID 21322282.
32.^ Okano M, Gross TG (November 2011). “Acute or Chronic Life-Threatening Diseases Associated With Epstein-Barr Virus Infection”. Am. J. Med. Sci. 343 (6): 483–9. doi:10.1097/MAJ.0b013e318236e02d. PMID 22104426.
33.^ Gallegos-Orozco JF, Rakela-Brödner J (October 2010). “Hepatitis viruses: not always what it seems to be”. Rev Med Chil 138 (10): 1302–11. doi:10.4067/S0034-98872010001100016. PMID 21279280.
34.^ Papic N, Pangercic A, Vargovic M, Barsic B, Vince A, Kuzman I (September 2011). “Liver involvement during influenza infection: perspective on the 2009 influenza pandemic”. Influenza Other Respi Viruses 6 (3): e2–5. doi:10.1111/j.1750-2659.2011.00287.x. PMID 21951624.
35.^ Bondarenko VI, Zadorozhnaia VI (March 1992). “[The role of enteroviruses in the etiology of diseases of the pancreas, kidneys and liver]“. Lik. Sprava (in Russian) (3): 58–62. PMID 1329355.
36.^ Zaidi SA, Singer C (May 2002). “Gastrointestinal and hepatic manifestations of tickborne diseases in the United States”. Clin. Infect. Dis. 34 (9): 1206–12. doi:10.1086/339871. PMID 11941547.
37.^ Organ EL, Rubin DH (1998). “Pathogenesis of reovirus gastrointestinal and hepatobiliary disease”. Curr. Top. Microbiol. Immunol. Current Topics in Microbiology and Immunology 233 (Pt 2): 67–83. doi:10.1007/978-3-642-72095-6_4. ISBN 978-3-642-72097-0. PMID 9599932.
38.^ Heyman P, Cochez C, Hofhuis A, et al. (January 2010). “A clear and present danger: tick-borne diseases in Europe”. Expert Rev Anti Infect Ther 8 (1): 33–50. doi:10.1586/eri.09.118. PMID 20014900.
39.^ Siński E, Welc-Faleciak R, Pogłód R (2011). “Babesia spp. infections transmitted through blood transfusion”. Wiad Parazytol 57 (2): 77–81. PMID 21682090.
40.^ Massei F, Gori L, Macchia P, Maggiore G (September 2005). “The expanded spectrum of bartonellosis in children”. Infect. Dis. Clin. North Am. 19 (3): 691–711. doi:10.1016/j.idc.2005.06.001. PMID 16102656.
41.^ Yang HW, Jung SH, Han HY, et al. (June 2008). “[Clinical feature of Fitz-Hugh-Curtis syndrome: analysis of 25 cases]“. Korean J Hepatol (in Korean) 14 (2): 178–84. doi:10.3350/kjhep.2008.14.2.178. PMID 18617765.
42.^ Parveen, M.D. Kumar, Michael, M.D. Clark, ed. (2005). “Figure 7.12 (Some causes of acute parenchymal damage)”. Clinical Medicine. Philadelphia, PA: W.B. Saunders. ISBN 0-7020-2763-4.
43.^ Blanco JR, Oteo JA (December 2002). “Human granulocytic ehrlichiosis in Europe”. Clin. Microbiol. Infect. 8 (12): 763–72. doi:10.1046/j.1469-0691.2002.00557.x. PMID 12519349.
44.^ Scholing M, Schneeberger PM, van den Dries P, Drenth JP (June 2007). “Clinical features of liver involvement in adult patients with listeriosis. Review of the literature”. Infection 35 (4): 212–8. doi:10.1007/s15010-007-6006-2. PMID 17646920.
45.^ Drebber U, Kasper HU, Ratering J, et al. (July 2008). “Hepatic granulomas: histological and molecular pathological approach to differential diagnosis–a study of 442 cases”. Liver Int. 28 (6): 828–34. doi:10.1111/j.1478-3231.2008.01695.x. PMID 18312287.
46.^ Raby N, Forbes G, Williams R (March 1990). “Nocardia infection in patients with liver transplants or chronic liver disease: radiologic findings”. Radiology 174 (3 Pt 1): 713–6. PMID 2406779.
47.^ Mohammed JP, Mattner J (July 2009). “Autoimmune disease triggered by infection with alphaproteobacteria”. Expert Rev Clin Immunol 5 (4): 369–379. doi:10.1586/ECI.09.23. PMC 2742979. PMID 20161124.
48.^ Kaplan MM (November 2004). “Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis”. Am. J. Gastroenterol. 99 (11): 2147–9. doi:10.1111/j.1572-0241.2004.41121.x. PMID 15554995.
49.^ Selmi C, Gershwin ME (July 2004). “Bacteria and human autoimmunity: the case of primary biliary cirrhosis”. Curr Opin Rheumatol 16 (4): 406–10. doi:10.1097/01.bor.0000130538.76808.c2. PMID 15201604.
50.^ Selmi C, Balkwill DL, Invernizzi P, et al. (November 2003). “Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium”. Hepatology 38 (5): 1250–7. doi:10.1053/jhep.2003.50446. PMID 14578864.
51.^ Yen TH, Chang CT, Lin JL, Jiang JR, Lee KF (May 2003). “Scrub typhus: a frequently overlooked cause of acute renal failure”. Ren Fail 25 (3): 397–410. doi:10.1081/JDI-120021152. PMID 12803503.
52.^ Park JI, Han SH, Cho SC, et al. (September 2003). “[Outbreak of hepatitis by Orientia tsutsugamushi in the early years of the new millenium]“. Taehan Kan Hakhoe Chi (in Korean) 9 (3): 198–204. PMID 14515037.
53.^ a b Bernabeu-Wittel M, Segura-Porta F (March 2005). “[Rickettsioses]“. Enferm. Infecc. Microbiol. Clin. (in Spanish; Castilian) 23 (3): 163–72. doi:10.1157/13072167. PMID 15757589.
54.^ Brown JM, McNeil MM (2003). “Nocardia, Rhodococcus, Gordonia, Actinomadura, Streptomyces, and other aerobic actinomycetes”. In Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH. Manual of clinical microbiology (8th ed.). Washington DC: American Society for Microbiology. pp. 502–531.
55.^ Connor BA, Schwartz E (October 2005). “Typhoid and paratyphoid fever in travellers”. Lancet Infect Dis 5 (10): 623–8. doi:10.1016/S1473-3099(05)70239-5. PMID 16183516.
56.^ Elishkewitz K, Shapiro R, Amir J, Nussinovitch M. “Hepatitis in scarlet fever”. Isr Med Assoc J 6 (9): 569–570.
57.^ Cook GC (December 1997). “Liver involvement in systemic infection”. Eur J Gastroenterol Hepatol 9 (12): 1239–47. PMID 9471032.
58.^ Bottone EJ (April 1997). “Yersinia enterocolitica: the charisma continues”. Clin. Microbiol. Rev. 10 (2): 257–76. PMC 172919. PMID 9105754.
59.^ a b c d e f g Seitz HM (1995). “[Parasitic diseases of the liver]“. Verh Dtsch Ges Pathol (in German) 79: 241–8. PMID 8600687.
60.^ Chen XM, LaRusso NF (August 2002). “Cryptosporidiosis and the pathogenesis of AIDS-cholangiopathy”. Semin. Liver Dis. 22 (3): 277–89. doi:10.1055/s-2002-34505. PMID 12360421.
61.^ Michiels JF, Hofman P, Bernard E, et al. (November 1994). “Intestinal and extraintestinal Isospora belli infection in an AIDS patient. A second case report”. Pathol. Res. Pract. 190 (11): 1089–93; discussion 1094. doi:10.1016/S0344-0338(11)80908-8. PMID 7746744.
62.^ Walther Z, Topazian MD (September 2009). “Isospora cholangiopathy: case study with histologic characterization and molecular confirmation”. Hum. Pathol. 40 (9): 1342–6. doi:10.1016/j.humpath.2009.01.020. PMID 19447468.
63.^ Anand AC, Puri P (September 2005). “Jaundice in malaria”. J. Gastroenterol. Hepatol. 20 (9): 1322–32. doi:10.1111/j.1440-1746.2005.03884.x. PMID 16105116.
64.^ a b Miller TA (1979). “Hookworm infection in man”. Adv. Parasitol. Advances in Parasitology 17: 315–84. doi:10.1016/S0065-308X(08)60552-7. ISBN 9780120317172. PMID 395835.
65.^ Gavin PJ, Kazacos KR, Shulman ST (October 2005). “Baylisascariasis”. Clin. Microbiol. Rev. 18 (4): 703–18. doi:10.1128/CMR.18.4.703-718.2005. PMC 1265913. PMID 16223954.
66.^ a b Li CD, Yang HL, Wang Y (February 2010). “Capillaria hepatica in China”. World J. Gastroenterol. 16 (6): 698–702. doi:10.3748/wjg.v16.i6.698. PMC 2817057. PMID 20135717.
67.^ Pokora Z (2001). “[Role of gastropods in epidemiology of human parasitic diseases]“. Wiad Parazytol (in Polish) 47 (1): 3–24. PMID 16888946.
68.^ Garcia HH, Moro PL, Schantz PM (October 2007). “Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis”. Curr. Opin. Infect. Dis. 20 (5): 489–94. doi:10.1097/QCO.0b013e3282a95e39. PMID 17762782.
69.^ Mordvinov VA, Yurlova NI, Ogorodova LM, Katokhin AV (March 2012). “Opisthorchis felineus and Metorchis bilis are the main agents of liver fluke infection of humans in Russia”. Parasitol. Int. 61 (1): 25–31. doi:10.1016/j.parint.2011.07.021. PMID 21840415.
70.^ Singcharoen T, Rawd-Aree P, Baddeley H (January 1988). “Computed tomography findings in disseminated paragonimiasis”. Br J Radiol 61 (721): 83–6. doi:10.1259/0007-1285-61-721-83. PMID 3349245.
71.^ Soroczan W (1996). “[Strongyloidosis. II. Clinical manifestations]“. Wiad Parazytol (in Polish) 42 (3): 291–312. PMID 9012132.
72.^ Fried B, Reddy A, Mayer D (June 2011). “Helminths in human carcinogenesis”. Cancer Lett. 305 (2): 239–49. doi:10.1016/j.canlet.2010.07.008. PMID 20667649.
73.^ Ishibashi H, Tsuchiya Y (1995). “[Hepatic toxocariasis]“. Ryoikibetsu Shokogun Shirizu (in Japanese) (7): 48–50. PMID 8749411.
74.^ Nikeghbalian S, Salahi R, Salahi H, et al. (December 2009). “Hepatic abscesses after liver transplant: 1997-2008″. Exp Clin Transplant 7 (4): 256–60. PMID 20353378.
75.^ Romero FA, Razonable RR (April 2011). “Infections in liver transplant recipients”. World J Hepatol 3 (4): 83–92. doi:10.4254/wjh.v3.i4.83. PMC 3098392. PMID 21603030.
76.^ Aidé MA (November 2009). “Chapter 4—histoplasmosis”. J Bras Pneumol 35 (11): 1145–51. doi:10.1590/S1806-37132009001100013. PMID 20011851.
77.^ Chukwuma C (January 1996). “Microsporidium in AIDS patients: a perspective”. East Afr Med J 73 (1): 72–5. PMID 8625869.
78.^ Arcay L (May 2001). “[Human microsporidiosis]“. Invest Clin (in Spanish; Castilian) 42 (Suppl 1): 3–42. PMID 11416983.
79.^ Atías A (June 1995). “[Update on microsporidiosis in humans]“. Rev Med Chil (in Spanish; Castilian) 123 (6): 762–72. PMID 8525232.
80.^ Chan JC, Jeffers LJ, Gould EW, et al. (1990). “Visceral protothecosis mimicking sclerosing cholangitis in an immunocompetent host: successful antifungal therapy”. Rev. Infect. Dis. 12 (5): 802–7. doi:10.1093/clinids/12.5.802. PMID 2237120.
81.^ Narita M, Muder RR, Cacciarelli TV, Singh N (August 2008). “Protothecosis after liver transplantation”. Liver Transpl. 14 (8): 1211–5. doi:10.1002/lt.21565. PMID 18668655.
82.^ a b “Alcoholic hepatitis”. Mayo Clinic.
83.^ Barosa, R.; Ramos, L. R.; Fonseca, C.; Freitas, J. (2013). “Acute hepatitis in a young woman with systemic lupus erythematosus: A diagnostic challenge”. Case Reports 2013: bcr2013008591. doi:10.1136/bcr-2013-008591.
84.^ a b “About Wilson Disease”. Wilson Disease Association.
85.^ de Niet A, Zaaijer HL, Ten Berge I, Weegink CJ, Reesink HW, Beuers U (2012). “Chronic hepatitis E after solid organ transplantation”. Neth J Med 70 (6): 261–266.
86.^ “Hepatitis as a result of chemicals and drugs”. HealthAtoZ. Archived from the original on 2006-06-23. Retrieved 2006-07-01.
87.^ Lim JR, Faught PR, Chalasani NP, Molleston JP (2006). “Severe liver injury after initiating therapy with atomoxetine in two children”. J. Pediatr. 148 (6): 831–4. doi:10.1016/j.jpeds.2006.01.035. PMID 16769398.
88.^ Bastida G, Nos P, Aguas M, Beltrán B, Rubín A, Dasí F, Ponce J (2005). “Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease”. Aliment Pharmacol Ther 22 (9): 775–82. doi:10.1111/j.1365-2036.2005.02636.x. PMID 16225485.
89.^ Nadir A, Reddy D, Van Thiel DH (2000). “Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity”. Am. J. Gastroenterol. 95 (12): 3634–7. doi:10.1111/j.1572-0241.2000.03386.x. PMID 11151906.
90.^ Torbenson M, Hart J, Westerhoff M, et al. (October 2010). “Neonatal giant cell hepatitis: histological and etiological findings”. Am. J. Surg. Pathol. 34 (10): 1498–503. doi:10.1097/PAS.0b013e3181f069ab. PMID 20871223.
91.^ Krokhina NB, Ushakova RA, Kobeleva IaM (2010). “[Significance of hepatic biopsy specimens in the diagnosis of liver disease in babies of the first year of life]“. Arkh. Patol. (in Russian) 72 (1): 19–23. PMID 20369579.
92.^ Hayashi H, Narita R, Hiura M, et al. (2011). “A case of adult autoimmune hepatitis with histological features of giant cell hepatitis”. Intern. Med. 50 (4): 315–9. doi:10.2169/internalmedicine.50.4063. PMID 21325763.
93.^ Hartl J, Buettner R, Rockmann F, et al. (November 2010). “Giant cell hepatitis: an unusual cause of fulminant liver failure”. Z Gastroenterol 48 (11): 1293–6. doi:10.1055/s-0029-1245476. PMID 21043007.
94.^ Gábor L, Pál K, Zsuzsa S (September 1997). “Giant cell hepatitis in adults”. Pathol. Oncol. Res. 3 (3): 215–8. doi:10.1007/BF02899924. PMID 18470733.
95.^ Alexopoulou A, Deutsch M, Ageletopoulou J, et al. (May 2003). “A fatal case of postinfantile giant cell hepatitis in a patient with chronic lymphocytic leukaemia”. Eur J Gastroenterol Hepatol 15 (5): 551–5. doi:10.1097/01.meg.0000050026.34359.7c. PMID 12702915.
96.^ Bianchi L, Terracciano LM (November 1994). “[Giant cell hepatitis in adults]“. Praxis (Bern 1994) (in German) 83 (44): 1237–41. PMID 7973279.
97.^ Duhaut P, Bosshard S, Ducroix JP (November 2004). “Is giant cell arteritis an infectious disease? Biological and epidemiological evidence”. Presse Médicale (Paris, France : 1983) 33 (19 Pt 2): 1403–8. doi:10.1016/S0755-4982(04)98939-7. PMID 15615251.
98.^ Shet TM, Kandalkar BM, Vora IM (January 1998). “Neonatal hepatitis–an autopsy study of 14 cases”. Indian J Pathol Microbiol 41 (1): 77–84. PMID 9581081.
99.^ Hassoun Z, N’Guyen B, Cote J, et al. (September 2000). “A case of giant cell hepatitis recurring after liver transplantation and treated with ribavirin”. Can. J. Gastroenterol. 14 (8): 729–31. PMID 11185540.
100.^ Durand F, Degott C, Sauvanet A, et al. (March 1997). “Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin”. J. Hepatol. 26 (3): 722–6. doi:10.1016/S0168-8278(97)80440-0. PMID 9075682.
101.^ Harmanci O, Onal IK, Ersoy O, Gürel B, Sökmensüer C, Bayraktar Y (December 2007). “Postinfantile giant cell hepatitis due to hepatitis E virus along with the presence of autoantibodies”. Digestive Diseases and Sciences 52 (12): 3521–3. doi:10.1007/s10620-006-9698-8. PMID 17410455.
102.^ Moreno A, Moreno A, Pérez-Elías MJ, Quereda C, Fernández-Muñoz R, Antela A, Moreno L, Bárcena R, López-San Román A, Celma ML, García-Martos M, Moreno S (October 2006). “Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature”. Human Pathology 37 (10): 1344–9. doi:10.1016/j.humpath.2006.05.003. PMID 16949926.
103.^ Fimmel CJ, Guo L, Compans RW, et al. (October 1998). “A case of syncytial giant cell hepatitis with features of a paramyxoviral infection”. Am. J. Gastroenterol. 93 (10): 1931–7. doi:10.1111/j.1572-0241.1998.00548.x. PMID 9772058.
104.^ Krech RH, Geenen V, Maschek H, Högemann B (May 1998). “[Adult giant cell hepatitis with fatal outcome. Clinicopathologic case report and reflections on pathogenesis]“. Pathologe (in German) 19 (3): 221–5. doi:10.1007/s002920050277. PMID 9648148.
105.^ Koff RS (September 1991). “Acute and chronic giant cell hepatitis: a paramyxovirus infection?”. Gastroenterology 101 (3): 863–4. PMID 1860651.
106.^ Phillips MJ, Blendis LM, Poucell S, et al. (February 1991). “Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features”. N. Engl. J. Med. 324 (7): 455–60. doi:10.1056/NEJM199102143240705. PMID 1988831.
107.^ Drut R, Gómez MA, Drut RM, Cueto RE, Lojo M (1998). “[Human papillomavirus, neonatal giant cell hepatitis and biliary duct atresia]“. Acta Gastroenterol. Latinoam. (in Spanish; Castilian) 28 (1): 27–31. PMID 9607071.
108.^ Drut R, Gómez MA, Drut RM, Lojo MM (1996). “Human papillomavirus (HPV)-associated neonatal giant cell hepatitis (NGCH)”. Pediatr Pathol Lab Med 16 (3): 403–12. PMID 9025842.
109.^ Potenza L, Luppi M, Barozzi P, et al. (August 2008). “HHV-6A in syncytial giant-cell hepatitis”. N. Engl. J. Med. 359 (6): 593–602. doi:10.1056/NEJMoa074479. PMID 18687640.
110.^ Kuntzen T, Friedrichs N, Fischer HP, Eis-Hübinger AM, Sauerbruch T, Spengler U (October 2005). “Postinfantile giant cell hepatitis with autoimmune features following a human herpesvirus 6-induced adverse drug reaction”. Eur J Gastroenterol Hepatol 17 (10): 1131–4. doi:10.1097/00042737-200510000-00020. PMID 16148562.
111.^ Suzuki K, Nakayama H, Doi K (February 2001). “Giant cell hepatitis in two young cats”. J. Vet. Med. Sci. 63 (2): 199–201. doi:10.1292/jvms.63.199. PMID 11258461.

External links [edit]
WHO fact sheet of hepatitis
Viral Hepatitis at the Centers for Disease Control

[show]
v ·
t ·
e

Digestive system, Digestive disease, Gastroenterology (primarily K20–K93, 530–579)

( ·
)
·
( ·
)
·
()
·
()
·
( ·
·
·
)
·
·
·

( ·
·
)
·
( ·
)
·
·
·
·
·
·
·
·
·

( ·
·
)
·
()
·
·
·
·
·
·
·
·
·

·
( ·
·
·
·
·
)
·
( ·
)
·
·

()
·
()
·
·
·
·
·
·
·
·
·
()
·

()
·
·
·

·
·
·

( ·
)
·
()

( ·
·
)
·
()
·
()
·
( ·
·
·
)
·
·
( ·
)
·
( ·
)
·
·

·
·
·
·
·

( ·
·
)
·
·
·
·

( ·
)
·

( ·
·
·
)
·
·
·

()
·

( ·
)
·
·
·
·

( ·
)

( ·
)

()
·
·

[show]
v ·
t ·
e

Inflammation

Categories: Hepatitis
Inflammations
Healthcare-associated infections

Navigation menu

Create account
Log in

Article
Talk

Read
Edit
View history

Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikimedia Shop

Interaction

Help
About Wikipedia
Community portal
Recent changes
Contact Wikipedia

Toolbox

Print/export

Languages

العربية
Azərbaycanca
বাংলা
Беларуская
Беларуская (тарашкевіца)‎
Български
Bosanski
Català
Česky
Dansk
Deutsch
Eesti
Ελληνικά
Español
Esperanto
Euskara
فارسی
Français
Gaeilge
Galego
한국어
Հայերեն
Hrvatski
Bahasa Indonesia
Íslenska
Italiano
עברית
Basa Jawa
Қазақша
Kiswahili
Latina
Magyar
Македонски
മലയാളം
मराठी
Bahasa Melayu
Nederlands
日本語
Norsk bokmål
پنجابی
Polski
Português
Русский
Shqip
Simple English
Slovenščina
Suomi
Svenska
Tagalog
தமிழ்
తెలుగు
ไทย
Türkçe
Українська
اردو
中文
Edit links

CROI 2013: complications of HIV disease, viral hepatitis, and antiretroviral therapy.

Luetkemeyer AF, Havlir DV, Currier JS.

Source

University of California San Francisco and San Francisco General Hospital, San Francisco, CA, USA.

Abstract

Studies with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) monoinfection and HIV coinfection were highlighted at the 2013 Conference on Retroviruses and Opportunistic Infections (CROI). In HCV monoinfected patients, several interferon alfa-sparing, all-oral regimens demonstrated cure rates of greater than 90% with 12 weeks of treatment, including for hard-to-treat patients. Cure rates of 75% were attained in HIV/HCV coinfected patients with the addition of the investigational HCV protease inhibitor (PI) simeprevir to peginterferon alfa and ribavirin. Drug-drug interaction data to inform safe coadminstration of antiretroviral therapy with DAA-based HCV treatment were presented. There was continued emphasis on pathogenesis, management, and prevention of the long-term complications of HIV disease and its therapies, including cardiovascular disease, renal disease, alterations in bone metabolism, and vitamin D deficiency, along with a growing focus on biomarkers to predict development of end-organ disease. Understanding the elevated risk for non-AIDS-defining malignancies in the HIV-infected population and optimal management was a focal point of this year’s data. Finally, the conference provided important information on tuberculosis coinfection and cryptococcal meningitis.
Fetal versus adult PreB or B cells [?]: the human VH repertoire.

Tonnelle C, Cuisinier AM, Gauthier L, Guelpa-Fonlupt V, Milili M, Schiff C, Fougereau M
Centre d’Immunologie Marseille Luminy, France.

At the preB stage, when only the IGH locus has rearranged, mu chains become expressed in association with the psi L chains, lambda-like and VpreB, thus forming the preB receptor. By the use of a monoclonal anti VpreB antibody, preB cells were isolated from two adult bone marrow samples, and the VH repertoire was analyzed and compared to fetal, XLA (X-linked agammaglobulinemia), and adult B repertoires. Most VH genes identified were also expressed in fetal liver, XLA bone marrow, and adult PBLs, with similar predominant usage of certain germline genes. Multiple D [?]/D [?] fusions, limited N diversity, and preferential use of JH4 with a low level of DQ52 usage were also identified. Few mutations could be observed, not specifically localized in CDR [?] regions, that could be interpreted as not positively selected. Conversely, a shorter length of CDR3 appeared to be the hallmark of the preB step. Thus, the association of psi L chains with mu does not bring about a bias in the VH gene usage, but a first selection on the CDR3 region could be the result of recognition by given autoantigens or ligands different for preB cells and B cells [?].

Ann. N. Y. Acad. Sci. (1995)
Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery.

Han WK, Wagener G, Zhu Y, Wang S, Lee HT
Thomas Jefferson University Hospital, Department of Medicine, Jefferson Medical School, Philadelphia, Pennsylvania 19107, USA. won.han@jefferson.edu

BACKGROUND AND OBJECTIVES: Serum creatinine (Scr) does not allow for early diagnosis of acute kidney injury (AKI). The diagnostic utility of urinary kidney injury molecule-1 (KIM-1), N-acetyl-beta-D-glucosaminidase (NAG), and neutrophil gelatinase associated lipocalin (NGAL) was evaluated for the early detection of postoperative AKI in a prospective study of 90 adults undergoing cardiac surgery. Designs, setting, participants, & measurements: Urinary KIM-1, NAG, and NGAL were measured at 5 time points for the first 24 h after operation and normalized to the urinary creatinine concentration after cardiac surgery. Receiver-operating characteristic curves were generated and the areas under the curve (AUCs) compared for performance of biomarkers in detection of postoperative AKI. RESULTS: Thirty-six patients developed AKI, defined as an increase in Scr of > or =0.3 mg/dl within 72 h after surgery. The AUCs for KIM-1 to predict AKI immediately and 3 h after operation were 0.68 and 0.65; 0.61 and 0.63 for NAG; and 0.59 and 0.65 for NGAL, respectively. Combining the three biomarkers enhanced the sensitivity of early detection of postoperative AKI compared with individual biomarkers: the AUCs for the three biomarkers combined were 0.75 and 0.78. The performance of combining biomarkers was even better among 16 early postoperative AKI patients with AUCs of 0.80 and 0.84, respectively. CONCLUSIONS: The results of this study support that a combination of urinary biomarkers may allow for early detection of postoperative AKI after cardiac surgery before a rise in Scr.

Clin J Am Soc Nephrol (2009)
PMID: 19406962 Fulltext – Related articles – Download

Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma.

Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH, Hsu HC
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.

PURPOSE: KIAA0101 is a proliferating cell nuclear antigen-associated factor and involved in cell proliferation. This study is to elucidate its role in the progression, early tumor recurrence (ETR), and prognosis of hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN: KIAA0101 mRNA was measured by reverse transcription-PCR in 216 resected, unifocal, primary HCCs and its protein in 164 cases by immunohistochemistry. RESULTS: KIAA0101 mRNA was overexpressed in 131 (61%) HCCs, and protein was detected in 105 (64%). KIAA0101 mRNA overexpression correlated with higher tumor grade (P = 0.0001), higher tumor stage with vascular invasion and various extents of intrahepatic spread (P = 1 x 10(-8)), ETR (P = 1.8 x 10(-6)), and lower 5-year survival (P = 0.0026). Multivariate analysis confirmed that KIAA0101 overexpression was an independent risk factor associated with high-grade tumor (P = 0.0001), high-stage tumor (P < 0.0001), and ETR (P = 0.0052) and thus contributed to poor prognosis. KIAA0101 protein-positive tumor cells accumulated at the borders of tumor macro-trabeculae and were more abundant in tumor thrombi than in the main tumors. Hence, KIAA0101 may contribute to growth advantage and resistance to hypoxic insult. In this series, p53 mutation was detected in 93 of 184 (51%) HCCs. In both p53-mutated and non-p53-mutated HCCs, KIAA0101 overexpression correlated with higher vascular invasion (stages IIIA to IV; all Ps < 0.0001) and, accordingly, led to lower 5-year survival rates (P = 0.011 and 0.029, respectively). CONCLUSION: KIAA0101 correlates with enhanced metastatic potential and is a significant prognostic factor of HCC.

Clin. Cancer Res. (2007)
PMID: 17875765

DIPA [?], which can localize to the centrosome, associates with p78/MCRS1/MSP58 and acts as a repressor of gene transcription.

Du X, Wang Q, Hirohashi Y, Greene MI
Department of Pathology and Laboratory Medicine, 252 John Morgan Building, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

DIPA [?] (delta-interacting protein A) was initially identified as a protein that associates with the hepatitis delta antigen. In this study, we found that DIPA [?] can associate with p78/MCRS/MSP58, a Forkhead-associated domain containing protein implicated in malignant transformation as well as in regulation of gene transcription and translation. We analyzed the interaction between DIPA [?] and p78 by co-immunoprecipitation and identified the structural regions involved in the interaction. Consistent with the physical interaction, we found that DIPA [?] is predominant co-localized with p78 to the nucleus. In addition, a fraction of DIPA [?] can be detected on the centrosome. Furthermore, we demonstrate that DIPA [?] can act as a repressor of gene transcription, an activity that appears to be enhanced by p78. Taken together, our results revealed a novel protein complex that plays a role in regulation of gene expression and cell proliferation. We propose that dysfunction of DIPA [?] may contribute to malignant transformation by affecting the functions of p78.

Exp. Mol. Pathol. (2006)
PMID: 17014843 Fulltext – Related articles – Download citation

. Johns Hopkins Hospital, Baltimore
2. Mayo Clinic, Rochester, Minn.
3. Massachusetts General Hospital, Boston
4. Cleveland Clinic
5. Ronald Reagan UCLA Medical Center, Los Angeles
6. New York-Presbyterian University Hospital of Columbia and Cornell
7. University of California, San Francisco Medical Center
8. Barnes-Jewish Hospital/Washington University, St. Louis
9. Hospital of the University of Pennsylvania, Philadelphia
10. Duke University Medical Center, Durham, N.C.
11. Brigham and Women’s Hospital, Boston
12. University of Washington Medical Center, Seattle
13. UPMC-University of Pittsburgh Medical Center
14. University of Michigan Hospitals and Health Centers, Ann Arbor

And here are the No. 1 hospitals in each specialty category:

• Cancer: University of Texas M.D. Anderson Cancer Center, Houston
• Diabetes & Endocrinology: Mayo Clinic, Rochester
• Ear, Nose & Throat: Johns Hopkins Hospital, Baltimore
• Gastroenterology: Mayo Clinic, Rochester
• Geriatrics: Mount Sinai Medical Center, New York
• Gynecology: Johns Hopkins Hospital, Baltimore
• Heart & Heart Surgery: Cleveland Clinic
• Kidney Disorders: Mayo Clinic, Rochester
• Neurology & Neurosurgery: Johns Hopkins Hospital, Baltimore
• Ophthalmology: Bascom Palmer Eye Institute at the University of Miami
• Orthopedics: Hospital for Special Surgery, New York
• Psychiatry: Massachusetts General Hospital, Boston
• Pulmonology: National Jewish Health, Denver
• Rehabilitation: Rehabilitation Institute of Chicago
• Rheumatology: Johns Hopkins Hospital, Baltimore
• Urology: Johns Hopkins Hospital, Baltimore

To see the entire list and a detailed description of the analysis in the specialties, visit the U.S. News website.

HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS

R.Palmer Beasley a b, Chia-Chin Lin a b, Lu-Yu Hwang a b, Chia-Siang Chien a b

Abstract

A prospective general population study of 22 707 Chinese men in Taiwan has shown that the incidence of primary hepatocellular carcinoma (PHC) among carriers of hepatitis B surface antigen (HBsAg) is much higher than among non-carriers (1158/100 000 vs 5/100 000 during 75 000 man-years of follow-up). The relative risk is 223. PHC and cirrhosis accounted for 54·3% of the 105 deaths among HBsAg carriers but accounted for only 1·5% of the 202 deaths among non-carriers. These findings support the hypothesis that hepatitis B virus has a primary role in the aetiology of PHC.

a University of Washington Medical Research Unit, Taipei;, Taiwan

b Institute of Public Health, College of Medicine, National Taiwan University; and Government Employees' Clinic Centre, Taipei, Taiwan

Copyright © 2013 Elsevier Limited. All rights reserved. The Lancet® is a registered trademark of Reed Elsevier Properties S.A., used under licence
The Lancet.com website is operated by Elsevier Inc. The content on this site is intended for health professionals.
Cookies are set by this site. To decline them or learn more, visit our Cookies page.

Content referenced by

http://en.wikipedia.org/wiki/Hepatitis

http://www.ncbi.nlm.nih.gov/pubmed?term=hepatitis

http://www.ihop-net.org/UniPub/iHOP/index.html?search=hepatitis+E&field=all&ncbi_tax_id=0&organism_syn=

http://hepatitiscresearchandnewsupdates.blogspot.ca/2010/07/best-hospitals-in-us.html

http://scholar.google.ca/scholar?hl=en&q=hepatitis&btnG=&as_sdt=1%2C5&as_sdtp=

PMID: 23681961 [PubMed - in process]

Posted in Uncategorized | Leave a comment

Uterine Endometrial Cancer


Endometrial cancer

From Wikipedia, the free encyclopedia

Jump to: navigation, search

This article may require cleanup to meet Wikipedia’s quality standards. No cleanup reason has been specified. Please help improve this article if you can. (February 2010)

Endometrial

Classification and external resources

Micrograph of endometrioid endometrial adenocarcinoma, the most common form of endometrial cancer. H&E stain.

ICD-10

C54.1

ICD-9

182.0

OMIM

608089

DiseasesDB

4252

MedlinePlus

000910

eMedicine

med/674 radio/253

MeSH

D016889

Endometrial cancer refers to several types of malignancies that arise from the endometrium, or lining, of the uterus. Endometrial cancers are the most common gynecologic cancers in the United States, with over 35,000 women diagnosed each year. The incidence is on a slow rise secondary to the obesity epidemic. The most common subtype, endometrioid adenocarcinoma, typically occurs within a few decades of menopause, is associated with obesity, excessive estrogen exposure, often develops in the setting of endometrial hyperplasia, and presents most often with vaginal bleeding. Endometrial carcinoma is the third most common cause of gynecologic cancer death (behind ovarian and cervical cancer). A total abdominal hysterectomy (surgical removal of the uterus) with bilateral salpingo-oophorectomy is the most common therapeutic approach.

Endometrial cancer may sometimes be referred to as uterine cancer. However, different cancers may develop not only from the endometrium itself but also from other tissues of the uterus, including cervical cancer, sarcoma of the myometrium, and trophoblastic disease.

Contents
[hide] 1 Classification 1.1 Carcinoma
1.2 Sarcoma

2 Signs and symptoms
3 Risk factors
4 Diagnosis 4.1 Clinical evaluation
4.2 Pathology
4.3 Further evaluation
4.4 Staging

5 Treatment 5.1 Complications of treatment

6 Prognosis 6.1 Survival rates

7 Epidemiology
8 See also
9 Additional images
10 References
11 External links

Classification [edit]

Carcinoma [edit]

Most endometrial cancers are carcinomas (usually adenocarcinomas), meaning that they originate from the single layer of epithelial cells that line the endometrium and form the endometrial glands. There are many microscopic subtypes of endometrial carcinoma, including the common endometrioid type, in which the cancer cells grow in patterns reminiscent of normal endometrium, and the far more aggressive papillary serous carcinoma and clear cell endometrial carcinomas. Some authorities have proposed that endometrial carcinomas be classified into two pathogenetic groups:[1]
Type I: These cancers occur most commonly in pre- and peri-menopausal women, often with a history of unopposed estrogen exposure and/or endometrial hyperplasia. They are often minimally invasive into the underlying uterine wall, are of the low-grade endometrioid type, and carry a good prognosis.
Type II: These cancers occur in older, post-menopausal women, are more common in African-Americans, are not associated with increased exposure to estrogen, and carry a poorer prognosis. They include:
the high-grade endometrioid cancer,
the uterine papillary serous carcinoma,
the uterine clear cell carcinoma.

FIGO grading of Endometrial Carcinoma

G1: Highly differentiated (composed of glands and 5% of lesion is of solid growth pattern). G2: Moderately differentiated ( 6%-50% of lesion composed of solid sheets of cells). G3: Undifferentiated ( > 50% of lesion composed of solid sheets of cells).

Sarcoma [edit]

Main article: Uterine sarcoma

In contrast to endometrial carcinomas, the uncommon endometrial stromal sarcomas are cancers that originate in the non-glandular connective tissue of the endometrium. Uterine carcinosarcoma, formerly called Malignant mixed müllerian tumor, is a rare uterine cancer that contains cancerous cells of both glandular and sarcomatous appearance – in this case, the cell of origin is unknown.[2]

Endometrial stromal sarcoma.

Uterine carcinosarcoma.

An endometrial adenocarcinoma invading the uterine muscle.

Signs and symptoms [edit]
Vaginal bleeding and/or spotting in postmenopausal women.
Abnormal uterine bleeding, abnormal menstrual periods.
Bleeding between normal periods in premenopausal women in women older than 40: extremely long, heavy, or frequent episodes of bleeding (may indicate premalignant changes).
Anemia, caused by chronic loss of blood. (This may occur if the woman has ignored symptoms of prolonged or frequent abnormal menstrual bleeding.)
Lower abdominal pain or pelvic cramping.
Thin white or clear vaginal discharge in postmenopausal women.

Risk factors [edit]
obesity -
high levels of estrogen
endometrial hyperplasia
hypertension
polycystic ovary syndrome[3]
nulliparity (never having carried a pregnancy)
infertility (inability to become pregnant)
early menarche (onset of menstruation)
late menopause (cessation of menstruation)
endometrial polyps or other benign growths of the uterine lining
diabetes
Tamoxifen
high intake of animal fat[4]
pelvic radiation therapy
breast cancer
ovarian cancer
anovulatory cycles
age over 35
lack of exercise[5]
heavy daily alcohol consumption (possibly a risk factor) [6]

Diagnosis [edit]

Clinical evaluation [edit]

Routine screening of asymptomatic women is not indicated, since the disease is highly curable in its early stages. Results from a pelvic examination are frequently normal, especially in the early stages of disease. Changes in the size, shape or consistency of the uterus and/or its surrounding, supporting structures may exist when the disease is more advanced.
A Pap smear may be either normal or show abnormal cellular changes. A Pap smear is used to screen for cervical cancer not endometrial cancer.
Office endometrial biopsy is the traditional diagnostic method. Both endometrial and endocervical material should be sampled.
If endometrial biopsy does not yield sufficient diagnostic material, a dilation and curettage (D&C) is necessary for diagnosing the cancer.
Hysteroscopy allows the direct visualization of the uterine cavity and can be used to detect the presence of lesions or tumours. It also permits the doctor to obtain cell samples with minimal damage to the endometrial lining (unlike blind D&C).
Endometrial biopsy or aspiration may assist the diagnosis.
Transvaginal ultrasound to evaluate the endometrial thickness in women with postmenopausal bleeding is increasingly being used to evaluate for endometrial cancer.
Ongoing research suggests that serum p53 antibody may hold value in identifying high-risk endometrial cancer.[7]

Diagnostic test study of S-p53 Ab and agreement study for high-risk endometrial cancer Kappa: 0.70 Sensitivity (%): 64 Specificity(%): 96 PPV: 78 NPV: 92

Pathology [edit]

Endometrial adenocarcinoma
The histopathology of endometrial cancers is highly diverse. The most common finding is a well-differentiated endometrioid adenocarcinoma, which is composed of numerous, small, crowded glands with varying degrees of nuclear atypia, mitotic activity, and stratification. This often appears on a background of endometrial hyperplasia. Frank adenocarcinoma may be distinguished from atypical hyperplasia by the finding of clear stromal invasion, or “back-to-back” glands which represent nondestructive replacement of the endometrial stroma by the cancer. With progression of the disease, the myometrium is infiltrated.[2] However, other subtypes of endometrial cancer exist and carry a less favorable diagnosis such as the uterine papillary serous carcinoma and the clear cell carcinoma.

Further evaluation [edit]

Patients with newly-diagnosed endometrial cancer do not routinely undergo imaging studies, such as CT scans, to evaluate for extent of disease, since this is of low yield. Preoperative evaluation should include a complete medical history and physical examination, pelvic examination and rectal examination with stool guaiac test, chest X-ray, complete blood count, and blood chemistry tests, including liver function tests. Colonoscopy is recommended if the stool is guaiac positive or the woman has symptoms, due to the etiologic factors common to both endometrial cancer and colon cancer. The tumor marker CA-125 is sometimes checked, since this can predict advanced stage disease.[8] In addition to this, both D&C and Pipelle biopsy curettage give 65-70% positive predictive value. But most important of these is hysteroscopy which gives 90-95% positive predictive value.

Staging [edit]

Endometrial carcinoma is surgically staged using the FIGO cancer staging system.

The 2010 FIGO staging system is as follows: Carcinoma of the Endometrium
IA Tumor confined to the uterus, no or ½ myometrial invasion
II Tumor involves the uterus and the cervical stroma
IIIA Tumor invades serosa or adnexa
IIIB Vaginal and/or parametrial involvement
IIIC1 Pelvic lymph node involvement
IIIC2 Para-aortic lymph node involvement, with or without pelvic node involvement
IVA Tumor invasion bladder mucosa and/or bowel mucosa
IVB Distant metastases including abdominal metastases and/or inguinal lymph nodes

Treatment [edit]

The primary treatment is surgical. Surgical treatment should consist of, at least, cytologic sampling of the peritoneal fluid, abdominal exploration, palpation and biopsy of suspicious lymph nodes, abdominal hysterectomy, and removal of both ovaries (bilateral salpingo-oophorectomy). Lymphadenectomy, or removal of pelvic and para-aortic lymph nodes, is sometimes performed for tumors that have high risk features, such as pathologic grade 3 serous or clear-cell tumors, invasion of more than 1/2 the myometrium, or extension to the cervix or adnexa. Sometimes, removal of the omentum is also performed.

Abdominal hysterectomy is recommended over vaginal hysterectomy because it affords the opportunity to examine and obtain washings of the abdominal cavity to detect any further evidence of cancer.

Women with stage 1 disease who are at increased risk for recurrence and those with stage 2 disease are often offered surgery in combination with radiation therapy.[9] Chemotherapy may be considered in some cases, especially for those with stage 3 and 4 disease. Hormonal therapy with progestins and antiestrogens has been used for the treatment of endometrial stromal sarcomas.[10]

The antibody Herceptin, which is used to treat breast cancers that overexpress the HER2/neu protein, has been tried with some success in a phase II trial in women with uterine papillary serous carcinomas that overexpress HER2/neu.[11]

Complications of treatment [edit]
Uterine perforation may occur during a dilatation and curettage (D&C) or an endometrial biopsy.

Prognosis [edit]

While endometrial cancers are 40% more common in Caucasian women, an African American woman who is diagnosed with uterine cancer is twice as likely to die (possibly due to the higher frequency of aggressive subtypes in that population, but more probably due to delay in the diagnosis).

Survival rates [edit]

The 5-year survival rates for endometrial adenocarcinoma following appropriate treatment are:[12]

Stage

5 year survival rate

I-A

90%

I-B

88%

I-C

75%

II

69%

III-A

58%

III-B

50%

III-C

47%

IV-A

17%

IV-B

15%

Epidemiology [edit]

It’s the most frequent cancer occurring in the female genital tract in the United States and many other Western countries. It appears most frequently between ages of 55 and 65, and uncommon below 40. There are two pictures of this disease, perimenopausal women with estrogen excess and in older women with endometrial atrophy.[13]

See also [edit]
Arias-Stella reaction

Additional images [edit]

Endometrioid endometrial adenocarcinoma – intermediate magnification. H&E stain.

Endometrioid endometrial adenocarcinoma – high magnification. H&E stain.

Endometrioid endometrial adenocarcinoma – very high magnification. H&E stain.

Uterine papillary serous carcinoma. H&E stain.

References [edit]

1.^ Bokhman JV (1983). “Two pathogenetic types of endometrial carcinoma”. Gynecol. Oncol. 15 (1): 10–7. doi:10.1016/0090-8258(83)90111-7. PMID 6822361.
2.^ a b Richard Cote, Saul Suster, Lawrence Weiss, Noel Weidner (Editor) (2002). Modern Surgical Pathology (2 Volume Set). London: W B Saunders. ISBN 0-7216-7253-1.
3.^ J.C.E. Underwood and S.S. Cross (2009). General and Systemic pathology. London: Elsevier (Churchill Livingstone). ISBN 978-0-443-06889-8.
4.^ Goodman, ET; et al (1997). “Diet, body size, physical activity, and the risk of endometrial cancer.”. Cancer Res 57: 5077.
5.^ Friedenreich, CM; Neilson, HK, Lynch, BM (2010 Sep). “State of the epidemiological evidence on physical activity and cancer prevention.”. European journal of cancer (Oxford, England : 1990) 46 (14): 2593–604. doi:10.1016/j.ejca.2010.07.028. PMID 20843488.
6.^ “Thirteen studies to date have reported on the relationship between endometrial cancer and alcohol consumption. Only two of these studies have reported that endometrial cancer incidence is associated with consumption of alcohol; all the others have reported either no definite association, or an inverse association.” (Six studies showed an inverse association; that is, drinking was associated with a lower risk of endometrial cancer) “…if such an inverse association exists, it appears to be more pronounced in younger, or premenopausal, women.”[3] “Our results suggest that only alcohol consumption equivalent to 2 or more drinks per day increases risk of endometrial cancer in postmenopausal women.”
7.^ Yamazawa, K; Shimada, H; Hirai, M; Hirashiki, K; Ochiai, T; Ishikura, H; Shozu, M; Isaka, K (2007). “Serum p53 antibody as a diagnostic marker of high-risk endometrial cancer.”. American journal of obstetrics and gynecology 197 (5): 505.e1–7. doi:10.1016/j.ajog.2007.04.033. PMID 17980190.
8.^ Dotters, DJ (2000). “Preoperative CA 125 in endometrial cancer: is it useful?”. American journal of obstetrics and gynecology 182 (6): 1328–34. doi:10.1067/mob.2000.106251. PMID 10871446.
9.^ Chong, I; Hoskin, PJ (2008). “Vaginal vault brachytherapy as sole postoperative treatment for low-risk endometrial cancer.”. Brachytherapy 7 (2): 195–9. doi:10.1016/j.brachy.2008.01.001. PMID 18358790.
10.^ [1] American Cancer Society – Uterine Sarcomas – Hormonal Therapy (accessed 5-25-07)
11.^ Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. (2008). “Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu”. Int J Gynaecol Obstet 102 (2): 128–31. doi:10.1016/j.ijgo.2008.04.008. PMID 18555254.
12.^ American Cancer Society (2009-10-22). “How Is Endometrial Cancer Staged?”. Retrieved 2010-03-09 [Note Stage I definitions in ref differed from those used on Wiki page, so adjusted table labels from 0, IA, IB, to IA, IB, IC matching definitions used here].
13.^ DiCristofano A, Ellenson LH: Endometrial carcinoma. Annual Review of Pathology: Mechanisms of Disease, Vol. 2:57 , 2007. [A comprehensive discussion of pathogenesis.]

External links [edit]
American Cancer Society’s Detailed Guide: Endometrial Cancer
U.S. National Cancer Institute: Endometrial cancer
NIH Endometrial cancer fact page
Anatomical pathology images
MedPix endometrial cancer images

[hide]
v ·
t ·
e

Tumors: female urogenital neoplasia (C51–C58/D25–D28, 179–184/218–221)

Adnexa

Ovaries

Glandular and epithelial/
surface epithelial-
stromal tumor

CMS: Ovarian serous cystadenoma ·Mucinous cystadenoma ·Cystadenocarcinoma (Papillary serous cystadenocarcinoma) ·Krukenberg tumor

Endometrioid tumor ·Clear-cell ovarian carcinoma ·Brenner tumour

Sex cord-gonadal stromal

Leydig cell tumour ·Sertoli cell tumour ·Sertoli-Leydig cell tumour ·Thecoma ·Granulosa cell tumour ·Luteoma ·Sex cord tumour with annular tubules

Germ cell

Dysgerminoma ·Nongerminomatous (Embryonal carcinoma, Endodermal sinus tumor, Gonadoblastoma, Teratoma/Struma ovarii, Choriocarcinoma)

Fibroma

Meigs syndrome

Fallopian tube

Adenomatoid tumor

Uterus

Myometrium

Uterine fibroids/leiomyoma ·Leiomyosarcoma ·Adenomyoma

Endometrium

Endometrioid tumor ·Uterine papillary serous carcinoma ·Clear cell carcinoma ·Endometrial intraepithelial neoplasia

Cervix

Cervical intraepithelial neoplasia ·SCC ·Glassy cell carcinoma ·Villoglandular adenocarcinoma

Placenta

Choriocarcinoma ·Gestational trophoblastic disease

General

Uterine sarcoma ·Mixed Müllerian tumor

Vagina

SCC ·Botryoid rhabdomyosarcoma ·Clear cell adenocarcinoma of the vagina ·Vaginal intraepithelial neoplasia

Vulva

SCC ·Melanoma ·Papillary hidradenoma ·Extramammary Paget’s disease ·Vulvar intraepithelial neoplasia

M: ♀ FRS

anat/phys/devp

noco/cong/npls, sysi/epon

proc/asst, drug (G1/G2B/G3CD)

Categories: Gynaecological cancer

Navigation menu

Create account
Log in

Article
Talk

Read
Edit
View history

Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikimedia Shop

Interaction

Help
About Wikipedia
Community portal
Recent changes
Contact Wikipedia

Toolbox

Print/export

Languages

العربية
Bosanski
Česky
Deutsch
Español
Français
Bahasa Indonesia
Italiano
עברית
Kinyarwanda
Latina
Nederlands
日本語
Norsk bokmål
Polski
Português
Simple English
Slovenčina
Türkçe
Edit links

Anthropometric Measures and the Risk of Endometrial Cancer, Overall and by Tumor Microsatellite Status and Histological Subtype.

Amankwah EK, Friedenreich CM, Magliocco AM, Brant R, Courneya KS, Speidel T, Rahman W, Langley AR, Cook LS.

Abstract

Obesity is an established risk factor for endometrial cancer, but this association is not well understood for subtypes of endometrial cancer. We evaluated the association of recent and adult-life obesity with subtypes of endometrial cancer based on microsatellite status (microsatellite-stable (MSS) vs. microsatellite-instable (MSI)) and histology (type I vs. type II). Analyses were based on a population-based case-control study (524 cases and 1,032 controls) conducted in Alberta, Canada (2002-2006) and included the following groupings of subtypes: MSS = 337 and MSI = 130; type I = 458 and type II = 66. Logistic and polytomous logistic regression were used to estimate odds ratios and 95% confidence intervals for overall endometrial cancer and subtypes of endometrial cancer, respectively. The risks of all subtypes of endometrial cancer, except type II, increased with an increase in all of the anthropometric characteristics examined. The risks for MSI tumors were suggestively stronger than those for MSS tumors; the risk with high (≥30) body mass index (weight (kg)/height (m)2) was significantly stronger for MSI tumors (odds ratio = 4.96, 95% confidence interval: 2.76, 8.91) than for MSS tumors (odds ratio = 2.33, 95% confidence interval: 1.66, 3.28) (P-heterogeneity = 0.02). Obesity is associated with most subtypes of endometrial cancer, and further studies are warranted to elucidate the biological mechanisms underlying the stronger risk for the MSI subtype with a high body mass index.

KEYWORDS:

DNA mismatch repair, endometrial neoplasms, microsatellite instability, risk factors

PMID: 23673247 [PubMed - as supplied by publisher]

LinkOut – more resources

Supplemental Content

Save items

Add to FavoritesView more options

Related citations in PubMed

Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.[Digestion. 2004]

Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer.[Gynecol Oncol. 2007]

The association of tumor microsatellite instability phenotype with family history of colorectal cancer.[Cancer Epidemiol Biomarkers Pr...]

Review Chemotherapeutic implications in microsatellite unstable colorectal cancer.[Cancer Biomark. 2006]

Review A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.[Cancer Res. 1998]

See reviews…See all…

Recent activity

Clear Turn Off
Anthropometric Measures and the

Characterization and mutation analysis of human LEFTY [?] A and LEFTY [?] B, homologues of murine genes implicated in left-right axis development.

Kosaki K, Bassi MT, Kosaki R, Lewin M, Belmont J, Schauer G, Casey B
Department of Pathology S230, Baylor College of Medicine, Houston, TX 77030, USA.

Members of the transforming growth factor (TGF)-beta family of cell-signaling molecules have been implicated recently in mammalian left-right (LR) axis development, the process by which vertebrates lateralize unpaired organs (e.g., heart, stomach, and spleen). Two family members, Lefty1 [?] and Lefty2, are expressed exclusively on the left side of the mouse embryo by 8.0 days post coitum. This asymmetry is lost or reversed in two murine models of abnormal LR-axis specification, inversus viscerum (iv) and inversion of embryonic turning (inv). Furthermore, mice homozygous for a Lefty1 [?] null allele manifest LR malformations and misexpress Lefty2. We hypothesized that Lefty [?] mutations may be associated with human LR-axis malformations. We now report characterization of two Lefty [?] homologues, LEFTY [?] A and LEFTY [?] B, separated by approximately 50 kb on chromosome 1q42. Each comprises four exons spliced at identical positions. LEFTY [?] A is identical to ebaf, a cDNA previously identified in a search for genes expressed in human endometrium. The deduced amino acid sequences of LEFTY [?] A and LEFTY [?] B are more similar to each other than to Lefty1 [?] or Lefty2. Analysis of 126 human cases of LR-axis malformations showed one nonsense and one missense mutation in LEFTY [?] A. Both mutations lie in the cysteine [?]-knot region of the protein LEFTY A, and the phenotype of affected individuals is very similar to that typically seen in Lefty1 [?]-/- mice with LR-axis malformations.

Matrix-metalloproteinases in Hodgkin lymphoma.

Thorns C, Bernd HW, Hatton D, Merz H, Feller AC, Lange K.

Source

Institute of Pathology, University of Luebeck, German Consultation and Reference Centre for Lymphomas, Germany. thorns@patho.mu-luebeck.de

Abstract

BACKGROUND:

Classical Hodgkin lymphomas are characterized by relatively few tumour cells and prominent proliferation of plasma cells, histiocytes, lymphocytes and eosinophils. In addition there is a varying degree of sclerosis, which is especially prominent in nodular sclerosis. These morphological peculiarities led to the idea that the interaction between tumour cells and bystander cells as well as the extracellular matrix may be important in Hodgkin lymphomas.

MATERIALS AND METHODS:

Thirty-four classical Hodgkin lymphomas (CHL) were analysed regarding the expression of EMMPRIN, MMP-2, -7, -9, -10 and-11 using immunohistochemistry.

RESULTS:

The tumour cells were positive for EMMPRIN in 100% of the cases. In 82% of CHL the Hodgkin and Reed-Sternberg cells (HRS) were negative for MMP-2. In contrast the surrounding non-neoplastic cells were MMP-2-positive in 71% of the cases. The HRS cells stained positive for MMP-7 in 68% of CHL, whereas only a few surrounding cells were positive for this marker. In all but one case (97%) the HRS cells were negative for MMP-9. However, the surrounding cells stained positive in 32%, thus resembling the staining pattern for MMP-2. Only scattered cells of both populations, HRS cells as well as bystander cells, stained for MMP-10 and -11, and no specific staining pattern was observed.

CONCLUSION:

Our data indicate a complex interaction between tumour cells and bystander cells with regard to metalloproteinases. The expression of EMMPRIN in the tumour cells may induce the expression of MMP-2 in the surrounding non-neoplastic cells. MMP-2 can be activated by MMP-7, which is expressed in the tumour cells. It is tempting to speculate that an interruption of this cycle could be of therapeutic benefit.

PMID: 12820423 [PubMed - indexed for MEDLINE]

MeSH Terms, Substances
Alabama (AL)Birmingham, AL
Alaska (AK)Arizona (AZ)Phoenix, AZ
Scottsdale, AZ
Tucson, AZ
Arkansas (AR)Fayetteville, AR
Little Rock, AR
California (CA)Berkeley, CA
Danville, CA
Laguna Hills, CA
Long Beach, CA
Los Angeles, CA
Los Gatos, CA
Mountain View, CA
Newport Beach, CA
Orange, CA
Palo Alto, CA
Pasadena, CA
Sacramento, CA
San Diego, CA
San Francisco, CA
San Jose, CA
San Mateo, CA
Torrance, CA
West Hollywood, CA
Colorado (CO)Colorado Springs, CO
Denver, CO
Englewood, CO
Connecticut (CT)Danbury, CT
Hartford, CT
New Haven, CT
Stamford, CT
Delaware (DE)Newark, DE
Washington, D.C. (DC)Washington, DC
Florida (FL)Aventura, FL
Boca Raton, FL
Bonita Springs, FL
Boynton Beach, FL
Clearwater, FL
Daytona Beach, FL
Fort Lauderdale, FL
Fort Myers, FL
Hollywood, FL
Jacksonville, FL
Margate, FL
Miami, FL
Miami Beach, FL
New Port Richey, FL
Orlando, FL
Ormond Beach, FL
Pembroke Pines, FL
Sarasota, FL
South Miami, FL
Tampa, FL
West Palm Beach, FL
Georgia (GA)Atlanta, GA
Decatur, GA
Marietta, GA
Savannah, GA
Hawaii (HI)Idaho (ID)Illinois (IL)Chicago, IL
Evanston, IL
Lake Forest, IL
Park Ridge, IL
Peoria, IL
Indiana (IN)South Bend, IN
Iowa (IA)Clive, IA
Des Moines, IA
Iowa City, IA
Kansas (KS)Kansas City, KS
Overland Park, KS
Shawnee, KS
Kentucky (KY)Louisiana (LA)Baton Rouge, LA
New Orleans, LA
Shreveport, LA
Maine (ME)Portland, ME
Maryland (MD)Annapolis, MD
Baltimore, MD
Rockville, MD
Upper Marlboro, MD
Massachusetts (MA)Boston, MA
Michigan (MI)Ann Arbor, MI
Dearborn, MI
Detroit, MI
Grand Blanc, MI
Grand Rapids, MI
Grosse Pointe, MI
Pontiac, MI
Rochester, MI
Royal Oak, MI
Saginaw, MI
Southfield, MI
Minnesota (MN)Edina, MN
Minneapolis, MN
Rochester, MN
Mississippi (MS)Jackson, MS
Missouri (MO)Kansas City, MO
Montana (MT)Nebraska (NE)Omaha, NE
Nevada (NV)Las Vegas, NV
New Hampshire (NH)New Jersey (NJ)Hackensack, NJ
Hoboken, NJ
Morristown, NJ
New Brunswick, NJ
Newark, NJ
Summit, NJ
New Mexico (NM)Albuquerque, NM
New York (NY)Albany, NY
Buffalo, NY
New York, NY
Rochester, NY
Syracuse, NY
White Plains, NY
North Carolina (NC)Charlotte, NC
Clinton, NC
Durham, NC
North Dakota (ND)Ohio (OH)Akron, OH
Canton, OH
Centerville, OH
Cincinnati, OH
Cleveland, OH
Columbus, OH
Kettering, OH
Toledo, OH
Oklahoma (OK)Oklahoma City, OK
Tulsa, OK
Oregon (OR)Portland, OR
Pennsylvania (PA)Chester, PA
Philadelphia, PA
Pittsburgh, PA
Rhode Island (RI)Providence, RI
South Carolina (SC)Charleston, SC
South Dakota (SD)Tennessee (TN)Chattanooga, TN
Cleveland, TN
Texas (TX)Austin, TX
Bedford, TX
Dallas, TX
Fort Worth, TX
Houston, TX
Plano, TX
San Antonio, TX
Weatherford, TX
Utah (UT)Salt Lake City, UT
Vermont (VT)Virginia (VA)Charlottesville, VA
Norfolk, VA
Richmond, VA
Virginia Beach, VA
Washington (WA)Seattle, WA
West Virginia (WV)Charleston, WV
Wisconsin (WI)Madison, WI
Milwaukee, WI
Waukesha, WI
Wauwatosa, WI
Wyoming (WY)
Medical Tools & Articles:

Tools & Services:

Bookmark this page
Symptom Search
Symptom Checker
Medical Dictionary
Medical Articles:

Disease & Treatments Search
Misdiagnosis Center
Full list of interesting articles
Forums

Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast Cancer

J. Julie Kim,
Takeshi Kurita and
Serdar E. Bulun

- Author Affiliations

Division of Reproductive Biology Research, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611

Address all correspondence and requests for reprints to: Serdar Bulun, M.D., Department of Obstetrics and Gynecology, 250 East Superior Street, Suite 03-2306, Chicago, Illinois 60611. E-mail: s-bulun@northwestern.edu.

Abstract

Progesterone receptor (PR) mediates the actions of the ovarian steroid progesterone, which together with estradiol regulates gonadotropin secretion, prepares the endometrium for implantation, maintains pregnancy, and differentiates breast tissue. Separation of estrogen and progesterone actions in hormone-responsive tissues remains a challenge. Pathologies of the uterus and breast, including endometrial cancer, endometriosis, uterine fibroids, and breast cancer, are highly associated with estrogen, considered to be the mitogenic factor. Emerging evidence supports distinct roles of progesterone and its influence on the pathogenesis of these diseases. Progesterone antagonizes estrogen-driven growth in the endometrium, and insufficient progesterone action strikingly increases the risk of endometrial cancer. In endometriosis, eutopic and ectopic tissues do not respond sufficiently to progesterone and are considered to be progesterone-resistant, which contributes to proliferation and survival. In uterine fibroids, progesterone promotes growth by increasing proliferation, cellular hypertrophy, and deposition of extracellular matrix. In normal mammary tissue and breast cancer, progesterone is pro-proliferative and carcinogenic. A key difference between these tissues that could explain the diverse effects of progesterone is the paracrine interactions of PR-expressing stroma and epithelium. Normal endometrium is a mucosa containing large quantities of distinct stromal cells with abundant PR, which influences epithelial cell proliferation and differentiation and protects against carcinogenic transformation. In contrast, the primary target cells of progesterone in the breast and fibroids are the mammary epithelial cells and the leiomyoma cells, which lack specifically organized stromal components with significant PR expression. This review provides a unifying perspective for the diverse effects of progesterone across human tissues and diseases.

Footnotes

Abbreviations:
APCAdenomatous polyposis coliatRAall trans-RAChIPchromatin immunoprecipitationECMextracellular matrixERestrogen receptorHand2heart and neural crest derivatives expressed 2HRThormone replacement therapyHSD17B217β-hydroxysteroid dehydrogenase type 2LMSPleiomyoma-derived side populationMECmammary epithelial cellMPAmedroxyprogesterone acetatePPARperoxisome proliferator-activated receptorPRprogesterone receptorPREprogesterone response elementPRKOPR knockoutRAretinoic acidRANKreceptor activator of nuclear factor κBRANKLRANK ligandRARRA receptorRBPretinol binding proteinSF1steroidogenic factor-1.

Received July 5, 2012.
Accepted September 17, 2012.
Copyright © 2013 by The Endocrine Society

Previous | Next ArticleTable of Contents

This Article

Published online before print January 9, 2013, doi: 10.1210/er.2012-1043 Endocrine Reviews February 1, 2013 vol. 34 no. 1 130-162

Abstract
Full Text
Full Text (PDF)

All Versions of this Article:er.2012-1043v1
34/1/130 most recent

- Services
Email this article to a colleague
Alert me when this article is cited
Alert me if a correction is posted
Similar articles in this journal
Similar articles in PubMed
Download to citation manager
Reprints, Permissions and Rights

+ Google Scholar

+ PubMed

This Article

Published online before print January 9, 2013, doi: 10.1210/er.2012-1043 Endocrine Reviews February 1, 2013 vol. 34 no. 1 130-162

Abstract
Full Text
Full Text (PDF)

All Versions of this Article:er.2012-1043v1
34/1/130 most recent

Other Endocrine Society Journals
EndocrinologyEndocrine ReviewsJCEMMolecular EndocrinologyTREM CollectionTEAM MonographsEndocrine NewsHormones and Cancer
Shop Our Store

Sign Up for eToc-Alerts

Copyright © 2013 The Endocrine Society
Privacy
Site Map
For Patients
Advertising Disclaimer

The Endocrine Society publishes Endocrine Reviews. Stanford University Libraries’ HighWire Press assists in the publication of Endocrine Reviews Online
Content referenced by

http://en.wikipedia.org/wiki/Endometrial_cancer

http://www.ncbi.nlm.nih.gov/pubmed?term=uterine%20endometrial%20cancer

http://www.ihop-net.org/UniPub/iHOP/index.html?field=all&search=uterine&organism_id=0

http://www.ihop-net.org/UniPub/iHOP/pm/1796083.html?nr=9&pmid=10053005

http://www.rightdiagnosis.com/specialists/gynecological-oncology.htm

http://scholar.google.ca/scholar?as_ylo=2013&q=uterine+endometrial+cancer&hl=en&as_sdt=0,5

Posted in Uncategorized | Leave a comment

Colorectal Cancer


Colorectal cancer

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Colorectal cancer

Classification and external resources

Diagram of the lower gastrointestinal tract

ICD-10

C18-C20/C21

ICD-9

153.0-154.1

ICD-O:

M8140/3 (95% of cases)

OMIM

114500

DiseasesDB

2975

MedlinePlus

000262

eMedicine

med/413 med/1994 ped/3037

Colorectal cancer, commonly known as colon cancer or bowel cancer, is a cancer from uncontrolled cell growth in the colon or rectum (parts of the large intestine), or in the appendix. Genetic analysis shows that essentially colon and rectal tumours are genetically the same cancer.[1] Symptoms of colorectal cancer typically include rectal bleeding and anemia which are sometimes associated with weight loss and changes in bowel habits.

Most colorectal cancer occurs due to lifestyle and increasing age with only a minority of cases associated with underlying genetic disorders. It typically starts in the lining of the bowel and if left untreated, can grow into the muscle layers underneath, and then through the bowel wall. Screening is effective at decreasing the chance of dying from colorectal cancer and is recommended starting at the age of 50 and continuing until a person is 75 years old. Localized bowel cancer is usually diagnosed through sigmoidoscopy or colonoscopy.

Cancers that are confined within the wall of the colon are often curable with surgery while cancer that has spread widely around the body is usually not curable and management then focuses on extending the person’s life via chemotherapy and improving quality of life. Colorectal cancer is the third most commonly diagnosed cancer in the world, but it is more common in developed countries. Around 60% of cases were diagnosed in the developed world. It is estimated that worldwide, in 2008, 1.23 million new cases of colorectal cancer were clinically diagnosed, and that it killed 608,000 people.[2]

Contents
[hide] 1 Signs and symptoms
2 Cause 2.1 Inflammatory bowel disease
2.2 Genetics

3 Pathogenesis
4 Diagnosis 4.1 Pathology

5 Prevention 5.1 Lifestyle
5.2 Medication
5.3 Screening

6 Management 6.1 Surgery
6.2 Chemotherapy
6.3 Radiation
6.4 Palliative care

7 Prognosis 7.1 Follow-up

8 Epidemiology
9 Society and culture 9.1 Notable cases

10 Research
11 References
12 External links

Signs and symptoms [edit]

The symptoms and signs of colorectal cancer depend on the location of tumor in the bowel, and whether it has spread elsewhere in the body (metastasis). The classic warning signs include: worsening constipation, blood in the stool, weight loss, fever, loss of appetite, and nausea or vomiting in someone over 50 years old.[3] While rectal bleeding or anemia are high-risk features in those over the age of 50,[4] other commonly described symptoms including weight loss and change in bowel habit are typically only concerning if associated with bleeding.[4][5]

Cause [edit]

Greater than 75-95% of colon cancer occurs in people with little or no genetic risk.[6][7] Other risk factors include older age, male gender,[7] high intake of fat, alcohol or red meat, obesity, smoking and a lack of physical exercise.[6] Approximately 10% of cases are linked to insufficient activity.[8] The risk for alcohol appears to increase at greater than one drink per day.[9]

Inflammatory bowel disease [edit]

People with inflammatory bowel disease (ulcerative colitis and Crohn’s disease) are at increased risk of colon cancer.[10] The risk is greater the longer a person has had the disease,[11] and the worse the severity of inflammation.[12] In these high risk groups both prevention with aspirin and regular colonoscopies are recommended.[11] People with inflammatory bowel disease account for less than 2% of colon cancer cases yearly.[12] In those with Crohn’s disease 2% get colorectal cancer after 10 years, 8% after 20 years, and 18% after 30 years.[12] In those with ulcerative colitis approximately 16% develop either a cancer precursor or cancer of the colon over 30 years.[12]

Genetics [edit]

Those with a family history in two or more first-degree relatives have a two to threefold greater risk of disease and this group accounts for about 20% of all cases. A number of genetic syndromes are also associated with higher rates of colorectal cancer. The most common of these is hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome) which is present in about 3% of people with colorectal cancer.[7] Other syndromes that are strongly associated include: Gardner syndrome,[13] and familial adenomatous polyposis (FAP) in which cancer nearly always occurs and is the cause of 1% of cases.[14]

Pathogenesis [edit]

Colorectal cancer is a disease originating from the epithelial cells lining the colon or rectum of the gastrointestinal tract, most frequently as a result of mutations in the Wnt signaling pathway that artificially increase signaling activity. The mutations can be inherited or are acquired, and most probably occur in the intestinal crypt stem cell.[15][16][not in citation given] The most commonly mutated gene in all colorectal cancer is the APC gene, which produces the APC protein. The APC protein is a “brake” on the accumulation of β-catenin protein; without APC, β-catenin accumulates to high levels and translocates (moves) into the nucleus, binds to DNA, and activates the transcription of genes that are normally important for stem cell renewal and differentiation but when inappropriately expressed at high levels can cause cancer. While APC is mutated in most colon cancers, some cancers have increased β-catenin because of mutations in β-catenin (CTNNB1) that block its degradation, or they have mutation(s) in other genes with function analogous to APC such as AXIN1, AXIN2, TCF7L2, or NKD1.[17]

Beyond the defects in the Wnt-APC-beta-catenin signaling pathway, other mutations must occur for the cell to become cancerous. The p53 protein, produced by the TP53 gene, normally monitors cell division and kills cells if they have Wnt pathway defects. Eventually, a cell line acquires a mutation in the TP53 gene and transforms the tissue from an adenoma into an invasive carcinoma. (Sometimes the gene encoding p53 is not mutated, but another protective protein named BAX is.)[17]

Other apoptotic proteins commonly deactivated in colorectal cancers are TGF-β and DCC (Deleted in Colorectal Cancer). TGF-β has a deactivating mutation in at least half of colorectal cancers. Sometimes TGF-β is not deactivated, but a downstream protein named SMAD is.[17] DCC commonly has deletion of its chromosome segment in colorectal cancer.[18]

Some genes are oncogenes – they are overexpressed in colorectal cancer. For example, genes encoding the proteins KRAS, RAF, and PI3K, which normally stimulate the cell to divide in response to growth factors, can acquire mutations that result in over-activation of cell proliferation. The chronological order of mutations is sometimes important, with a primary KRAS mutation generally leading to a self-limiting hyperplastic or borderline lesion, but if occurring after a previous APC mutation it often progresses to cancer.[19] PTEN, a tumor suppressor, normally inhibits PI3K, but can sometimes become mutated and deactivated.[17]

Comprehensive, genome-scale analysis has revealed that colorectal carcinomas are clearly separable into hypermutated and non-hypermutated tumor types.[20] In addition to the oncogenic and inactivating mutations described for the genes above, non-hypermutated samples also contain mutated CTNNB1, FAM123B, SOX9, ATM, and ARID1A. Progressing through a distinct set of genetic events, hypermutated tumors display mutated forms of ACVR2A, TGFBR2, MSH3, MSH6, SLC9A9, TCF7L2, and BRAF. The common theme among these genes, across both tumor types, is their involvement in WNT and TGF-β signaling pathways, which in turn results in increased activity of MYC, a central player in colorectal cancer.[20]

Diagnosis [edit]

Diagnosis of colorectal cancer is via tumor biopsy typically done during sigmoidoscopy or colonoscopy. The extent of the disease is then usually determined by a CT scan of the chest, abdomen and pelvis. There are other potential imaging test such as PET and MRI which may be used in certain cases. Colon cancer staging is done next and based on the TNM system which is determined by how much the initial tumor has spread, if and where lymph nodes are involved, and if and how many metastases there are.[7]

Pathology [edit]

The pathology of the tumor is usually reported from the analysis of tissue taken from a biopsy or surgery. A pathology report will usually contain a description of cell type and grade. The most common colon cancer cell type is adenocarcinoma which accounts for 95% of cases. Other, rarer types include lymphoma and squamous cell carcinoma.

Cancers on the right side (ascending colon and cecum) tend to be exophytic, that is, the tumour grows outwards from one location in the bowel wall. This very rarely causes obstruction of feces, and presents with symptoms such as anemia. Left-sided tumours tend to be circumferential, and can obstruct the bowel much like a napkin ring which can present with thinner calibre stools.

Adenocarcinoma is a malignant epithelial tumor, originating from glandular epithelium of the colorectal mucosa. It invades the wall, infiltrating the muscularis mucosae, the submucosa and thence the muscularis propria. Tumor cells describe irregular tubular structures, harboring pluristratification, multiple lumens, reduced stroma (“back to back” aspect). Sometimes, tumor cells are discohesive and secrete mucus, which invades the interstitium producing large pools of mucus/colloid (optically “empty” spaces) – mucinous (colloid) adenocarcinoma, poorly differentiated. If the mucus remains inside the tumor cell, it pushes the nucleus at the periphery – “signet-ring cell.” Depending on glandular architecture, cellular pleomorphism, and mucosecretion of the predominant pattern, adenocarcinoma may present three degrees of differentiation: well, moderately, and poorly differentiated.[21]

Most colorectal cancer tumors are thought to be cyclooxygenase-2 (COX-2) positive.[citation needed] This enzyme is generally not found in healthy colon tissue, but is thought to fuel abnormal cell growth.

Colorectal lesions

Appearance of the inside of the colon showing one invasive colorectal carcinoma (the crater-like, reddish, irregularly shaped tumor).

Gross appearance of a colectomy specimen containing two adenomatous polyps (the brownish oval tumors above the labels, attached to the normal beige lining by a stalk) and one invasive colorectal carcinoma (the crater-like, reddish, irregularly shaped tumor located above the label).

Endoscopic image of colon cancer identified in sigmoid colon on screening colonoscopy in the setting of Crohn’s disease.

PET/CT of a staging exam of colon carcinoma. Besides the primary tumor a lot of lesions can be seen. On cursor position: lung nodule.

Micrographs (H&E stain)

Cancer — Invasive adenocarcinoma (the most common type of colorectal cancer). The cancerous cells are seen in the center and at the bottom right of the image (blue). Near normal colon-lining cells are seen at the top right of the image.

Cancer — Histopathologic image of colonic carcinoid.

Precancer — Tubular adenoma (left of image), a type of colonic polyp and a precursor of colorectal cancer. Normal colorectal mucosa is seen on the right.

Precancer — Colorectal villous adenoma.

Prevention [edit]

Most colorectal cancers should be preventable, through increased surveillance, improved lifestyle, and, probably, the use of dietary chemopreventative agents[citation needed].

Lifestyle [edit]

Current dietary recommendations to prevent colorectal cancer include increasing the consumption of whole grains, fruits and vegetables, and reducing the intake of red meat.[22][23] The evidence for fiber and fruits and vegetables however is poor.[23] Physical activity can moderately reduce the risk of colorectal cancer.[24]

Medication [edit]

Aspirin and celecoxib appear to decrease the risk of colorectal cancer in those at high risk.[25] However it is not recommended in those at average risk.[26] There is tentative evidence for calcium supplementation but it is not sufficient to make a recommendation.[27] Vitamin D intake and blood levels are associated with a lower risk of colon cancer.[28][29]

Screening [edit]

More than 80% of colorectal cancers arise from adenomatous polyps making this cancer amenable to screening. Diagnosis of cases of colorectal cancer through screening tends to occur 2–3 years before diagnosis of cases with symptoms.[7] Screening has the potential to reduce colorectal cancer deaths by 60%.[30]

The three main screening tests are fecal occult blood testing, flexible sigmoidoscopy and colonoscopy.[7] Of the three, only sigmoidoscopy cannot screen the right side of the colon where 42% of malignancies are found.[31] Virtual colonoscopy via a CT scan appears as good as standard colonoscopy for detecting cancers and large adenomas but is expensive, associated with radiation exposure, and cannot remove any detected abnormal growths like standard colonoscopy can.[7]

A new screening method is the M2-PK Test. The enzyme biomarker M2-PK has been identified as a key enzyme in colorectal cancers and polyps. M2-PK does not depend on blood in the stool and is specifically related to changes in the tumour metabolism. It does not require any special preparation prior to testing. Only a small stool sample is needed. M2-PK features a high sensitivity for colorectal cancer and polyps and is able to detect bleeding and non-bleeding colorectal cancer and polyps.[32] In the event of a positive result people would be asked to undergo further examination e.g. colonoscopy.

Fecal occult blood testing of the stool is typically recommended every two years and can be either guaiac based or immunochemical.[7] Medical societies recommend screening between the age of 50 and 75 years with sigmoidoscopy every 5 years and colonoscopy every 10 years. For those at high risk, screenings usually begin at around 40.[7][33] For people with average risk who have had a high-quality colonoscopy with normal results, the American Gastroenterological Association does not recommend any type of screening in the 10 years following the colonoscopy.[34][35] For people over 75 or those with a life expectancy of less than 10 years, screening is not recommended.[36]

Management [edit]

The treatment of colorectal cancer depends on how advanced it is.[37] When colorectal cancer is caught early surgery can be curative. However, when it is detected at later stages (metastases are present), this is less likely and treatment is often directed more at extending life and keeping people comfortable.[7]

Surgery [edit]

For people with localized cancer the preferred treatment is complete surgical removal with the attempt of achieving a cure. This can either be done by an open laparotomy or sometimes laparoscopically. If there are only a few metastases in the liver or lungs they may also be removed. Sometimes chemotherapy is used before surgery to shrink the cancer before attempting to remove it. The two most common sites of recurrence if it occurs is in the liver and lungs.[7]

Chemotherapy [edit]

Chemotherapy may be used in addition to surgery in certain cases[7] as adjuvant therapy. If cancer has entered the lymph nodes, adding the chemotherapy agents fluorouracil or capecitabine increases life expectancy. If the lymph nodes do not contain cancer, the benefits of chemotherapy are controversial. If the cancer is widely metastatic or unresectable, treatment is then palliative. Typically in this case, a couple of different chemotherapy medications are used.[7] Chemotherapy drugs may include combinations of agents including fluorouracil, capecitabine, UFT, leucovorin, irinotecan, or oxaliplatin.[38]

Radiation [edit]

While a combination of radiation and chemotherapy may be useful for rectal cancer,[7] its use in colon cancer is not routine due to the sensitivity of the bowels to radiation.[39]

Palliative care [edit]

In people with incurable colorectal cancer, palliative care can be considered for improving quality of life. Surgical options may include non-curative surgical removal of some of the cancer tissue, bypassing part of the intestines, or stent placement. These procedures can be considered to improve symptoms and reduce complications such as bleeding from the tumor, abdominal pain and intestinal obstruction.[40] Non-operative methods of symptomatic treatment include radiation therapy to decrease tumor size as well as pain medications.[41]

Prognosis [edit]

In Europe the five-year survival for colorectal cancer is less than 60%. In the developed world about a third of people who get the disease die from it.[7]

Survival is directly related to detection and the type of cancer involved, but overall is poor for symptomatic cancers, as they are typically quite advanced. Survival rates for early stage detection is about 5 times that of late stage cancers. For example, patients with a tumor that has not breached the muscularis mucosa (TNM stage Tis, N0, M0) have an average 5-year survival of 100%, while those with an invasive cancer, i.e. T1 (within the submucosal layer) or T2 (within the muscular layer) cancer have an average 5-year survival of approximately 90%. Those with a more invasive tumor, yet without node involvement (T3-4, N0, M0) have an average 5-year survival of approximately 70%. Patients with positive regional lymph nodes (any T, N1-3, M0) have an average 5-year survival of approximately 40%, while those with distant metastases (any T, any N, M1) have an average 5-year survival of approximately 5%.[42]

According to the American Cancer Society statistics in 2006,[43] over 20% of patients present with metastatic (stage IV) colorectal cancer at the time of diagnosis, and up to 25% of this group will have isolated liver metastasis that is potentially resectable. Lesions which undergo curative resection have demonstrated 5-year survival outcomes now exceeding 50%.[44]

Follow-up [edit]

The aims of follow-up are to diagnose, in the earliest possible stage, any metastasis or tumors that develop later, but did not originate from the original cancer (metachronous lesions).

The U.S. National Comprehensive Cancer Network and American Society of Clinical Oncology provide guidelines for the follow-up of colon cancer.[45][46] A medical history and physical examination are recommended every 3 to 6 months for 2 years, then every 6 months for 5 years. Carcinoembryonic antigen blood level measurements follow the same timing, but are only advised for patients with T2 or greater lesions who are candidates for intervention. A CT-scan of the chest, abdomen and pelvis can be considered annually for the first 3 years for patients who are at high risk of recurrence (for example, patients who had poorly differentiated tumors or venous or lymphatic invasion) and are candidates for curative surgery (with the aim to cure). A colonoscopy can be done after 1 year, except if it could not be done during the initial staging because of an obstructing mass, in which case it should be performed after 3 to 6 months. If a villous polyp, a polyp >1 centimeter or high grade dysplasia is found, it can be repeated after 3 years, then every 5 years. For other abnormalities, the colonoscopy can be repeated after 1 year.

Routine PET or ultrasound scanning, chest X-rays, complete blood count or liver function tests are not recommended.[45][46] These guidelines are based on recent meta-analyses showing intensive surveillance and close follow-up can reduce the 5-year mortality rate from 37% to 30%.[47][48][49]

Epidemiology [edit]

Age-standardized death from colorectal cancer per 100,000 inhabitants in 2004.[50]

no data

27.5

Globally greater than 1 million people get colorectal cancer yearly[7] resulting in about 0.5 million deaths.[51] As of 2008 it is the second most common cause of cancer in women and the third most common in men[52] with it being the fourth most common cause of cancer death after lung, stomach, and liver cancer.[53] It is more common in developed than developing countries.[51]
USA Based on rates from 2007-2009, 4.96% of US men and women born today will be diagnosed with colorectal cancer during their lifetime.[54] From 2005-2009, the median age at diagnosis for cancer of the colon and rectum in the US was 69 years of age. Approximately 0.1% were diagnosed under age 20; 1.1% between 20 and 34; 4.0% between 35 and 44; 13.4% between 45 and 54; 20.4% between 55 and 64; 24.0% between 65 and 74; 25.0% between 75 and 84; and 12.0% 85+ years of age. Rates are higher among males (54 per 100,000 c.f. 40 per 100,000 for females).
Globally incidences vary 10-fold with highest rates in the Australia, New Zealand, Europe and the US and lowest rates in Africa and South-Central Asia.[2]

Society and culture [edit]

In the United States, March is colorectal cancer awareness month.[30]

Notable cases [edit]

Main article: List of people diagnosed with colorectal cancer
Corazon Aquino, former president of the Philippines[55]
Pope John Paul II[56]
Ronald Reagan[57]
Harold Wilson, former Prime Minister of the United Kingdom[58]
Robin Gibb, musician and member of the Bee Gees[59]
Humayun Ahmed, Bengali writer and film maker[60]

Research [edit]
Bowel & Cancer Research
Mouse models of colorectal and intestinal cancer
The Cancer Genome Atlas[20]

References [edit]

1.^ Cancer Genome Atlas Network (19 July 2012). “Comprehensive molecular characterization of human colon and rectal cancer.”. Nature 487: 330–337.
2.^ a b Colorectal Cancer Incidence, Mortality and Prevalence Worldwide in 2008 — Summary. Available from: Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. (2010) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. Accessed on 11 Oct 2012.
3.^ al.], edited by Tadataka Yamada ; associate editors, David H. Alpers … [et (2008). Principles of clinical gastroenterology. Chichester, West Sussex: Wiley-Blackwell. p. 381. ISBN 978-1-4051-6910-3.
4.^ a b Astin M, Griffin, T, Neal, RD, Rose, P, Hamilton, W (May 2011). "The diagnostic value of symptoms for colorectal cancer in primary care: a systematic review". The British journal of general practice : the journal of the Royal College of General Practitioners 61 (586): 231–43. doi:10.3399/bjgp11X572427. PMC 3080228. PMID 21619747.
5.^ Adelstein BA, Macaskill, P, Chan, SF, Katelaris, PH, Irwig, L (2011). "Most bowel cancer symptoms do not indicate colorectal cancer and polyps: a systematic review.". BMC gastroenterology 11: 65. doi:10.1186/1471-230X-11-65. PMC 3120795. PMID 21624112.
6.^ a b Watson AJ, Collins, PD (2011). "Colon cancer: a civilization disorder.". Digestive diseases (Basel, Switzerland) 29 (2): 222–8. doi:10.1159/000323926. PMID 21734388.
7.^ a b c d e f g h i j k l m n o p Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N (2010). "Colorectal cancer.". Lancet 375 (9719): 1030–47. doi:10.1016/S0140-6736(10)60353-4. PMID 20304247.
8.^ Lee, I-Min; Shiroma, Eric J; Lobelo, Felipe; Puska, Pekka; Blair, Steven N; Katzmarzyk, Peter T (1 July 2012). "Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy". The Lancet 380 (9838): 219–29. doi:10.1016/S0140-6736(12)61031-9. PMID 22818936.
9.^ Fedirko V, Tramacere, I, Bagnardi, V, Rota, M, Scotti, L, Islami, F, Negri, E, Straif, K, Romieu, I, La Vecchia, C, Boffetta, P, Jenab, M (Sep 2011). "Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies.". Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 22 (9): 1958–72. doi:10.1093/annonc/mdq653. PMID 21307158.
10.^ Jawad N, Direkze, N, Leedham, SJ (2011). "Inflammatory bowel disease and colon cancer.". Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 185: 99–115. doi:10.1007/978-3-642-03503-6_6. PMID 21822822.
11.^ a b Xie J, Itzkowitz, SH (2008). "Cancer in inflammatory bowel disease.". World journal of gastroenterology : WJG 14 (3): 378–89. PMC 2679126. PMID 18200660.
12.^ a b c d Triantafillidis JK, Nasioulas, G, Kosmidis, PA (Jul 2009). "Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies.". Anticancer research 29 (7): 2727–37. PMID 19596953.
13.^ Juhn E, Khachemoune, A (2010). "Gardner syndrome: skin manifestations, differential diagnosis and management.". American journal of clinical dermatology 11 (2): 117–22. doi:10.2165/11311180-000000000-00000. PMID 20141232.
14.^ Half E, Bercovich, D, Rozen, P (2009). "Familial adenomatous polyposis.". Orphanet journal of rare diseases 4: 22. doi:10.1186/1750-1172-4-22. PMC 2772987. PMID 19822006.
15.^ Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993). "Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis". Nature 363 (6429): 558–61. doi:10.1038/363558a0. PMID 8505985.
16.^ Srikumar Chakravarthi, Baba Krishnan, Malathy Madhavan (1999). "Apoptosis and expression of p53 in colorectal neoplasms". Indian J Med Res 86 (7): 95–102.
17.^ a b c d Markowitz SD, Bertagnolli MM (December 2009). "Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer". N. Engl. J. Med. 361 (25): 2449–60. doi:10.1056/NEJMra0804588. PMC 2843693. PMID 20018966.
18.^ Mehlen P, Fearon ER (August 2004). "Role of the dependence receptor DCC in colorectal cancer pathogenesis". J. Clin. Oncol. 22 (16): 3420–8. doi:10.1200/JCO.2004.02.019. PMID 15310786.
19.^ Vogelstein, B.; Kinzler, K. W. (2004). "Cancer genes and the pathways they control". Nature Medicine 10 (8): 789–799. doi:10.1038/nm1087. PMID 15286780. edit
20.^ a b c Muzny, DM.; Bainbridge, MN.; Chang, K.; Dinh, HH.; Drummond, JA.; Fowler, G.; Kovar, CL.; Lewis, LR. et al. (Jul 2012). "Comprehensive molecular characterization of human colon and rectal cancer.". Nature 487 (7407): 330–7. doi:10.1038/nature11252. PMID 22810696.
21.^ Pathology atlas
22.^ Campos FG, Logullo Waitzberg, AG, Kiss, DR, Waitzberg, DL, Habr-Gama, A, Gama-Rodrigues, J (Jan 2005). "Diet and colorectal cancer: current evidence for etiology and prevention.". Nutricion hospitalaria : organo oficial de la Sociedad Espanola de Nutricion Parenteral y Enteral 20 (1): 18–25. PMID 15762416.
23.^ a b Doyle VC, Logullo Waitzberg, AG, Kiss, DR, Waitzberg, DL, Habr-Gama, A, Gama-Rodrigues, J (May 2007). "Nutrition and colorectal cancer risk: a literature review.". Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates 30 (3): 178–82; quiz 182–3. doi:10.1097/01.SGA.0000278165.05435.c0. PMID 17568255.
24.^ Harriss DJ, Atkinson, G, Batterham, A, George, K, Cable, NT, Reilly, T, Haboubi, N, Renehan, AG, Colorectal Cancer, Lifestyle, Exercise And Research, Group (Sep 2009). "Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity.". Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 11 (7): 689–701. doi:10.1111/j.1463-1318.2009.01767.x. PMID 19207713.
25.^ Cooper K, Squires, H, Carroll, C, Papaioannou, D, Booth, A, Logan, RF, Maguire, C, Hind, D, Tappenden, P (Jun 2010). "Chemoprevention of colorectal cancer: systematic review and economic evaluation.". Health technology assessment (Winchester, England) 14 (32): 1–206. doi:10.3310/hta14320. PMID 20594533.
26.^ Agency for Healthcare Research and Quality (2010/2011). "Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer". United States Department of Health & Human Services.
27.^ Weingarten MA, Zalmanovici, A, Yaphe, J (2008). "Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps.". Cochrane database of systematic reviews (Online) (1): CD003548. doi:10.1002/14651858.CD003548.pub4. PMID 18254022.
28.^ Ma Y, Zhang, P, Wang, F, Yang, J, Liu, Z, Qin, H (2011). "Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies.". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29 (28): 3775–82. doi:10.1200/JCO.2011.35.7566. PMID 21876081.
29.^ Yin L, Grandi, N, Raum, E, Haug, U, Arndt, V, Brenner, H (Jul 2011). "Meta-analysis: Serum vitamin D and colorectal adenoma risk.". Preventive medicine 53 (1-2): 10–6. doi:10.1016/j.ypmed.2011.05.013. PMID 21672549.
30.^ a b He J, Efron, JE (2011). "Screening for colorectal cancer.". Advances in surgery 45: 31–44. PMID 21954677.
31.^ Siegel RL, Ward EM, Jemal A (Mar 2012). "Trends in Colorectal Cancer Incidence Rates in the United States by Tumor Location and Stage, 1992–2008". Cancer Epidemiology, Biomarkers & Prevention 21 (3). 411–6 (See Introduction). doi:10.1158/1055-9965.EPI-11-1020. PMID 22219318. Retrieved 2012-09-16.
32.^ C. Tonus, M. Sellinger u. a.: Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: A meta-analysis. In: World journal of gastroenterology : WJG. Band 18, Nummer 30, August 2012, S. 4004–4011, ISSN 1007-9327. doi:10.3748/wjg.v18.i30.4004. PMID 22912551. PMC 3419997.
33.^ "Screening for Colorectal Cancer". U.S. Preventive Services Task Force. 2008.
34.^ American Gastroenterological Association, "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (American Gastroenterological Association), retrieved August 17, 2012
35.^ Winawer, S; Fletcher, R; Rex, D; Bond, J; Burt, R; Ferrucci, J; Ganiats, T; Levin, T; Woolf, S; Johnson, D; Kirk, L; Litin, S; Simmang, C; Gastrointestinal Consortium, Panel (2003 Feb). "Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.". Gastroenterology 124 (2): 544–60. doi:10.1053/gast.2003.50044. PMID 12557158.
36.^ Qaseem A, Denberg TD, Hopkins RH Jr, et al. (2012). "Screening for Colorectal Cancer: A Guidance Statement From the American College of Physicians". Annals of internal medicine 156 (5): 378–386. doi:10.1059/0003-4819-156-5-201203060-00010. PMID 22393133.
37.^ Stein A, Atanackovic, D, Bokemeyer, C (Sep 2011). "Current standards and new trends in the primary treatment of colorectal cancer.". European journal of cancer (Oxford, England : 1990). 47 Suppl 3: S312–4. doi:10.1016/S0959-8049(11)70183-6. PMID 21943995.
38.^ "Chemotherapy of metastatic colorectal cancer". Prescrire Int 19 (109): 219–24. October 2010. PMID 21180382.
39.^ authors, editors, Vincent T. DeVita, Jr., Theodore S. Lawrence, Steven A. Rosenberg ; associate scientific advisors, Robert A. Weinberg, Ronald A. DePinho ; with 421 contributing (2008). DeVita, Hellman, and Rosenberg's cancer : principles & practice of oncology (8th ed. ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 1258. ISBN 978-0-7817-7207-5.
40.^ Wasserberg N, Kaufman HS (December 2007). "Palliation of colorectal cancer". Surg Oncol 16 (4): 299–310. doi:10.1016/j.suronc.2007.08.008. PMID 17913495.
41.^ Amersi F, Stamos MJ, Ko CY (July 2004). "Palliative care for colorectal cancer". Surg. Oncol. Clin. N. Am. 13 (3): 467–77. doi:10.1016/j.soc.2004.03.002. PMID 15236729.
42.^ Box 3-1, Page 107 in: Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 0-7817-7153-6.
43.^ http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Statistics_2006_Presentation.asp
44.^ Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M (April 2006). "Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies". Br. J. Cancer 94 (7): 982–99. doi:10.1038/sj.bjc.6603033. PMC 2361241. PMID 16538219.
45.^ a b NCCN Clinical Practice Guidelines in Oncology - Colon Cancer (version 1, 2008: September 19, 2007).
46.^ a b Desch CE, Benson AB 3rd, Somerfield MR, et al.; American Society of Clinical Oncology (2005). "Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline". J Clin Oncol 23 (33): 8512–9. doi:10.1200/JCO.2005.04.0063. PMID 16260687.
47.^ Jeffery M, Hickey BE, Hider PN (2002). "Follow-up strategies for patients treated for non-metastatic colorectal cancer". Cochrane Database Syst Rev (1): CD002200. doi:10.1002/14651858.CD002200. PMID 11869629.
48.^ Renehan AG, Egger M, Saunders MP, O'Dwyer ST (2002). "Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials". BMJ 324 (7341): 831–8. doi:10.1136/bmj.324.7341.813. PMC 100789. PMID 11934773.
49.^ Figueredo A, Rumble RB, Maroun J, et al.; Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care (2003). "Follow-up of patients with curatively resected colorectal cancer: a practice guideline". BMC Cancer 3: 26. doi:10.1186/1471-2407-3-26. PMC 270033. PMID 14529575.
50.^ "WHO Disease and injury country estimates". World Health Organization. 2009. Retrieved Nov. 11, 2009.
51.^ a b Merika E, Saif, MW, Katz, A, Syrigos, K, Morse, M (Sep 2010). "Review. Colon cancer vaccines: an update.". In vivo (Athens, Greece) 24 (5): 607–28. PMID 20952724.
52.^ Jemal A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D (2011). "Global cancer statistics". CA: a cancer journal for clinicians 61 (2): 69–90. doi:10.3322/caac.20107. PMID 21296855.
53.^ WHO (February 2010). "Cancer". World Health Organization. Retrieved 2011-01-05.
54.^ Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). "SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations).". National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012.
55.^ http://www.abs-cbnnews.com/storypage.aspx?StoryID=112887
56.^ "Pope John Paul II". ABC News Online.
57.^ "Reagan turns 90". BBC News: Americas. 6 February 2001.
58.^ Daily Mail
59.^ Klein, Sarah (2012-04-23). "12 Famous Faces Touched By Colorectal Cancer". Huffington Post.
60.^ "Humayun Ahmed dies". Bdnews24.com. 2012-07-19. Retrieved 2012-07-19.

External links [edit]

Wikimedia Commons has media related to: Colorectal cancer

Colorectal cancer at the Open Directory Project

[show]

Identifying Molecular Targets of Lifestyle Modifications in Colon Cancer Prevention.

Derry MM, Raina K, Agarwal C, Agarwal R.

Source

Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus Aurora, CO, USA.

Abstract

One in four deaths in the United States is cancer-related, and colorectal cancer (CRC) is the second leading cause of cancer-associated deaths. Screening strategies are utilized but have not reduced disease incidence or mortality. In this regard, there is an interest in cancer preventive strategies focusing on lifestyle intervention, where specific etiologic factors involved in cancer initiation, promotion, and progression could be targeted. For example, exposure to dietary carcinogens, such as nitrosamines and polycyclic aromatic hydrocarbons influences colon carcinogenesis. Furthermore, dietary deficiencies could alter sensitivity to genetic damage and influence carcinogen metabolism contributing to CRC. High alcohol consumption increases the risk of mutations including the fact that acetaldehyde, an ethanol metabolite, is classified as a group 1 carcinogen. Tobacco smoke exposure is also a risk factor for cancer development; approximately 20% of CRCs are associated with smoking. Additionally, obese patients have a higher risk of cancer development, which is further supported by the fact that physical activity decreases CRC risk by 55%. Similarly, chronic inflammatory conditions also increase the risk of CRC development. Moreover, the circadian clock alters digestion and regulates other biochemical, physiological, and behavioral processes that could influence CRC. Taken together, colon carcinogenesis involves a number of etiological factors, and therefore, to create effective preventive strategies, molecular targets need to be identified and beleaguered prior to disease progression. With this in mind, the following is a comprehensive review identifying downstream target proteins of the above lifestyle risk factors, which are modulated during colon carcinogenesis and could be targeted for CRC prevention by novel agents including phytochemicals.

KEYWORDS:

colorectal cancer, grape seed extract, lifestyle modification, molecular targets, phytochemicals, prevention, silibinin

Expression and chromosomal mapping of mouse Gpx2 gene encoding the gastrointestinal form of glutathione peroxidase, GPX-GI.

Chu FF, Esworthy RS, Ho YS, Bermeister M, Swiderek K, Elliott RW
Department of Medical Oncology, City of Hope Medical Center, Duarte, CA 91010, USA.

GPX-GI is a cytosolic tetrameric Se-dependent glutathione peroxidase, similar in properties to GPX-1. Unlike the almost ubiquitous GPX-1, GPX-GI is mainly expressed in the epithelium of gastrointestinal tract. GPX-GI contributes to at least fifty percent of GPX activity in rodent small intestinal epithelium. The total GPX activity consists of at least 70% of selenium-dependent GPX activity in this compartment. By analyzing a panel of mouse interspecies DNA from the Jackson Laboratory’s backcross resource, we mapped Gpx2 gene to mouse chromosome 12 between D12Mit4 and D12Mit5, near the Ccs1 locus which contains a colon cancer susceptibility gene. A pseudogene, Gpx2-ps is mapped to mouse chromosome 7. Comparison of Gpx2 gene expression in three pairs of C57BL/6Ha and ICR/Ha mice which are respectively resistant and sensitive to dimethylhydrazine-induced colon cancer, we found a higher Gpx2 mRNA level in C57BL/6Ha colon than ICR/Ha colon. Interestingly, a lower level of GPX activity is found in the resistant strain of mice. Because GPX-1 has three times higher specific activity than GPX-GI, our data suggest that the decreased GPX activity may result from a higher level of Gpx2 gene expression in those cells co-express Gpx1 gene.

Biomed. Environ. Sci. (1997)
PMID: 9315306 Fulltext – Related articles – Download citation

University of Texas M.D. Anderson Cancer Center

Houston, TX

See Cancer scorecard

Ranked in Houston metro area and Texas

100.0/100

#2

Memorial Sloan-Kettering Cancer Center

New York, NY

See Cancer scorecard

Ranked in New York metro area and New York

93.8/100

#3

Johns Hopkins Hospital

Baltimore, MD

See Cancer scorecard

Ranked in Baltimore metro area and Maryland

85.2/100

#4

Mayo Clinic

Rochester, MN

See Cancer scorecard

Ranked in Minnesota

84.7/100

#5

Dana-Farber/Brigham and Women’s Cancer Center

Boston, MA

See Cancer scorecard

Ranked in Boston metro area and Massachusetts

81.2/100

#6

Cleveland Clinic

Cleveland, OH

See Cancer scorecard

Ranked in Cleveland metro area and Ohio

76.5/100

#7

Massachusetts General Hospital

Boston, MA

See Cancer scorecard

Ranked in Boston metro area and Massachusetts

74.9/100

#8

University of Washington Medical Center

Seattle, WA

See Cancer scorecard

Ranked in Seattle metro area and Washington

74.1/100

#9

Ronald Reagan UCLA Medical Center

Los Angeles, CA

See Cancer scorecard

Ranked in Los Angeles metro area and California

71.0/100

#10

Barnes-Jewish Hospital/Washington University

Saint Louis, MO

See Cancer scorecard

Ranked in St. Louis metro area and Missouri

68.2/100

1 2 3 .. 90>

Disclaimer and a note about your health

Top Doctors: Cancer
Gynecologic Oncologists

Hematologists

Medical Oncologists

Oncologists

Pediatric Hematologist-Oncologists

Radiation Oncologists

|
Healthcare Jobs

The Lancet, Volume 355, Issue 9209, Pages 1041 – 1047, 25 March 2000

doi:10.1016/S0140-6736(00)02034-1Cite or Link Using DOI

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

JY Douillard MD a , D Cunningham MD b, AD Roth MD c, M Navarro MD d, RD James MD e, P Karasek MD f, P Jandik MD g, T Iveson MD h, Prof J Carmichael MD i, M Alakl MD j, G Gruia MD j, L Awad MSc j, Prof P Rougier MD k

Summary

Background

Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer.

Methods

387 patients previously untreated with chemotherapy (other than adjuvant) for advanced colorectal cancer were randomly assigned open-label irinotecan plus fluorouracil and calcium folinate (irinotecan group, n=199) or fluorouracil and calcium folinate alone (no-irinotecan group, n=188). Infusion schedules were once weekly or every 2 weeks, and were chosen by each centre. We assessed response rates and time to progression, and also response duration, survival, and quality of life. Analyses were done on the intention-to-treat population and on evaluable patients.

Findings

The response rate was significantly higher in patients in the irinotecan group than in those in the no-irinotecan group (49 vs 31%, p<0·001 for evaluable patients, 35 vs 22%, p<0·005 by intention to treat). Time to progression was significantly longer in the irinotecan group than in the no-irinotecan group (median 6·7 vs 4·4 months, p<0·001), and overall survival was higher (median 17·4 vs 14·1 months, p=0·031). Some grade 3 and 4 toxic effects were significantly more frequent in the irinotecan group than in the no-irinotecan group, but effects were predictible, reversible, non-cumulative, and manageable.

Interpretation

Irinotecan combined with fluorouracil and calcium folinate was well-tolerated and increased response rate, time to progression, and survival, with a later deterioration in quality of life. This combination should be considered as a reference first-line treatment for metastatic colorectal cancer.

To read this article in full you will need to login or make a payment

Already Registered

Content referenced by

http://en.wikipedia.org/wiki/Colorectal_cancer

http://www.ncbi.nlm.nih.gov/pubmed?term=colorectal%20cancer

http://www.ihop-net.org/UniPub/iHOP/index.html?field=all&search=colon cancer&organism_id=0

http://health.usnews.com/best-hospitals/rankings/cancer

http://scholar.google.ca/scholar?hl=en&q=colorectal+cancer&btnG=&as_sdt=1%2C5&as_sdtp=

Posted in Uncategorized | Leave a comment

Stomach Cancer


Stomach cancer

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Stomach cancer

Classification and external resources

A suspicious stomach ulcer that was ultimately diagnosed as cancer on biopsy and resected. The surgical specimen was subsequently kept for educational purposes.

ICD-10

C16

ICD-9

151.9

OMIM

137215

DiseasesDB

12445

MedlinePlus

000223

eMedicine

med/845

MeSH

D013274

Stomach cancer, or gastric cancer, refers to cancer arising from any part of the stomach. Stomach cancer causes about 800,000 deaths worldwide per year.[1] Prognosis is poor (5-year survival <5 to 15%) because most patients present with advanced disease.[2]

Contents
[hide] 1 Signs and symptoms
2 Causes
3 Diagnosis 3.1 Histopathology
3.2 Staging

4 Management 4.1 Surgery
4.2 Chemotherapy
4.3 Radiation
4.4 Multimodality therapy

5 Epidemiology
6 Other animals
7 References
8 External links

Signs and symptoms [edit]

Endoscopic image of linitis plastica, a type of stomach cancer where the entire stomach is invaded, leading to a leather bottle-like appearance with blood coming out of it.

Endoscopic image of early stage of the stomach cancer. Its histology was poorly differentiated adenocarcinoma with signet ring cells.Left above=Normal, right above=FICE, left low=acetate stained, right low= AIM stained
Stomach cancer is often either asymptomatic (producing no noticeable symptoms) or it may cause only nonspecific symptoms (symptoms which are not specific to just stomach cancer, but also to other related or unrelated disorders) in its early stages. By the time symptoms occur, the cancer has often reached an advanced stage (see below) and may have also metastasized (spread to other, perhaps distant, parts of the body), which is one of the main reasons for its relatively poor prognosis.[citation needed] Stomach cancer can cause the following signs and symptoms:

Stage 1 (Early)
Indigestion or a burning sensation (heartburn)
Loss of appetite, especially for meat
Abdominal discomfort or irritation

Stage 2 (Middle)
Weakness and fatigue
Bloating of the stomach, usually after meals

Stage 3 (Late)
Abdominal pain in the upper abdomen
Nausea and occasional vomiting
Diarrhea or constipation
Weight loss
Bleeding (vomiting blood or having blood in the stool) which will appear as black. This can lead to anemia.
Dysphagia; this feature suggests a tumor in the cardia or extension of the gastric tumor into the esophagus.

Note that these can be symptoms of other problems such as a stomach virus, gastric ulcer or tropical sprue.

Causes [edit]

Most stomach cancer is caused by Helicobacter pylori infection. Dietary factors are not proven causes,[2] but some foods, such as smoked foods, salted fish and meat, and pickled vegetables are associated with a higher risk. Nitrates and nitrites in cured meats can be converted by certain bacteria, including H. pylori, into compounds that have been found to cause stomach cancer in animals. On the other hand, the American Cancer Society recommends eating fresh fruits and vegetables that contain antioxidant vitamins, such as A and C, and says that they lower the risk of stomach cancer,[3] and a Mediterranean diet is associated with lower rates of stomach cancer.[4]

Smoking increases the risk of developing gastric cancer significantly, from 40% increased risk for current smokers to 82% increase for heavy smokers. Gastric cancers due to smoking mostly occur in the upper part of the stomach near the esophagus[3][5][6] Some studies show increased risk with alcohol consumption as well.[7]

Other factors associated with increased risk are autoimmune atrophic gastritis, intestinal metaplasia, and genetic factors.

H. pylori is the main risk factor in 65–80% of gastric cancers, but in only 2% of such infections.[8] The mechanism by which H. pylori induces stomach cancer potentially involves chronic inflammation, or the action of H. pylori virulence factors such as CagA.[9] Approximately ten percent of cases show a genetic component.[10] Some studies indicate that bracken consumption and spores are correlated with incidence of stomach cancer, though causality has yet to be established.[11]

Gastric cancer shows a male predominance in its incidence as up to three males are affected for every female. Estrogen may protect women against the development of this cancer form.[12] A very small percentage of diffuse-type gastric cancers (see Histopathology below) are thought to be genetic. Hereditary Diffuse Gastric Cancer (HDGC) has recently been identified and research is ongoing. However, genetic testing and treatment options are already available for families at risk.[13]

The International Cancer Genome Consortium is leading efforts to map stomach cancer's complete genome.[citation needed]

Diagnosis [edit]

To find the cause of symptoms, the doctor asks about the patient's medical history, does a physical exam, and may order laboratory studies. The patient may also have one or all of the following exams:
Gastroscopic exam is the diagnostic method of choice. This involves insertion of a fiber optic camera into the stomach to visualize it.
Upper GI series (may be called barium roentgenogram)
Computed tomography or CT scanning of the abdomen may reveal gastric cancer, but is more useful to determine invasion into adjacent tissues, or the presence of spread to local lymph nodes.

Abnormal tissue seen in a gastroscope examination will be biopsied by the surgeon or gastroenterologist. This tissue is then sent to a pathologist for histological examination under a microscope to check for the presence of cancerous cells. A biopsy, with subsequent histological analysis, is the only sure way to confirm the presence of cancer cells.

Various gastroscopic modalities have been developed to increase yield of detected mucosa with a dye that accentuates the cell structure and can identify areas of dysplasia. Endocytoscopy involves ultra-high magnification to visualize cellular structure to better determine areas of dysplasia. Other gastroscopic modalities such as optical coherence tomography are also being tested investigationally for similar applications.[14]

A number of cutaneous conditions are associated with gastric cancer. A condition of darkened hyperplasia of the skin, frequently of the axilla and groin, known as acanthosis nigricans, is associated with intra-abdominal cancers such as gastric cancer. Other cutaneous manifestations of gastric cancer include tripe palms (a similar darkening hyperplasia of the skin of the palms) and the Leser-Trelat sign, which is the rapid development of skin lesions known as seborrheic keratoses.[15]

Various blood tests may be done, including: Complete Blood Count (CBC) to check for anemia. Also, a stool test may be performed to check for blood in the stool.

Histopathology [edit]

Poor to moderately differentiated adenocarcinoma of the stomach. H&E stain.

Gastric signet ring cell carcinoma. H&E stain.

Adenocarcinoma of the stomach and intestinal metaplasia. H&E stain. Gastric adenocarcinoma is a malignant epithelial tumor, originating from glandular epithelium of the gastric mucosa. Stomach cancers are overwhelmingly adenocarcinomas (90%).[16] Histologically, there are two major types of gastric adenocarcinoma (Lauren classification): intestinal type or diffuse type. Adenocarcinomas tend to aggressively invade the gastric wall, infiltrating the muscularis mucosae, the submucosa, and thence the muscularis propria. Intestinal type adenocarcinoma tumor cells describe irregular tubular structures, harboring pluristratification, multiple lumens, reduced stroma ("back to back" aspect). Often, it associates intestinal metaplasia in neighboring mucosa. Depending on glandular architecture, cellular pleomorphism and mucosecretion, adenocarcinoma may present 3 degrees of differentiation: well, moderate and poorly differentiated. Diffuse type adenocarcinoma (mucinous, colloid, linitis plastica, leather-bottle stomach) Tumor cells are discohesive and secrete mucus which is delivered in the interstitium, producing large pools of mucus/colloid (optically "empty" spaces). It is poorly differentiated. If the mucus remains inside the tumor cell, it pushes the nucleus to the periphery: "signet-ring cell".
Around 5% of gastric malignancies are lymphomas (MALTomas, or MALT lymphoma).[17]
Carcinoid and stromal tumors may also occur.

Staging [edit]

If cancer cells are found in the tissue sample, the next step is to stage, or find out the extent of the disease. Various tests determine whether the cancer has spread and, if so, what parts of the body are affected. Because stomach cancer can spread to the liver, the pancreas, and other organs near the stomach as well as to the lungs, the doctor may order a CT scan, a PET scan, an endoscopic ultrasound exam, or other tests to check these areas. Blood tests for tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) may be ordered, as their levels correlate to extent of metastasis, especially to the liver, and the cure rate.

Staging may not be complete until after surgery. The surgeon removes nearby lymph nodes and possibly samples of tissue from other areas in the abdomen for examination by a pathologist.

The clinical stages of stomach cancer are:[18][19]
Stage 0. Limited to the inner lining of the stomach. Treatable by endoscopic mucosal resection when found very early (in routine screenings); otherwise by gastrectomy and lymphadenectomy without need for chemotherapy or radiation.
Stage I. Penetration to the second or third layers of the stomach (Stage 1A) or to the second layer and nearby lymph nodes (Stage 1B). Stage 1A is treated by surgery, including removal of the omentum. Stage 1B may be treated with chemotherapy (5-fluorouracil) and radiation therapy.
Stage II. Penetration to the second layer and more distant lymph nodes, or the third layer and only nearby lymph nodes, or all four layers but not the lymph nodes. Treated as for Stage I, sometimes with additional neoadjuvant chemotherapy.
Stage III. Penetration to the third layer and more distant lymph nodes, or penetration to the fourth layer and either nearby tissues or nearby or more distant lymph nodes. Treated as for Stage II; a cure is still possible in some cases.
Stage IV. Cancer has spread to nearby tissues and more distant lymph nodes, or has metastatized to other organs. A cure is very rarely possible at this stage. Some other techniques to prolong life or improve symptoms are used, including laser treatment, surgery, and/or stents to keep the digestive tract open, and chemotherapy by drugs such as 5-fluorouracil, cisplatin, epirubicin, etoposide, docetaxel, oxaliplatin, capecitabine, or irinotecan.

The TNM staging system is also used.[20]

In a study of open-access endoscopy in Scotland, patients were diagnosed 7% in Stage I 17% in Stage II, and 28% in Stage III.[21] A Minnesota population was diagnosed 10% in Stage I, 13% in Stage II, and 18% in Stage III.[22] However in a high-risk population in the Valdivia Province of southern Chile, only 5% of patients were diagnosed in the first two stages and 10% in stage III.[23]

Management [edit]

Cancer of the stomach is difficult to cure unless it is found in an early stage (before it has begun to spread). Unfortunately, because early stomach cancer causes few symptoms, the disease is usually advanced when the diagnosis is made. Treatment for stomach cancer may include surgery, chemotherapy, and/or radiation therapy. New treatment approaches such as biological therapy and improved ways of using current methods are being studied in clinical trials.[citation needed]

Surgery [edit]

Surgery is the most common treatment. The surgeon removes part or all of the stomach, as well as the surrounding lymph nodes, with the basic goal of removing all cancer and a margin of normal tissue. Depending on the extent of invasion and the location of the tumor, surgery may also include removal of part of the intestine or pancreas. Tumors in the lower part of the stomach may call for a Billroth I or Billroth II procedure.

Endoscopic mucosal resection (EMR)[24] is a treatment for early gastric cancer (tumor only involves the mucosa) that has been pioneered in Japan, but is also available in the United States at some centers. In this procedure, the tumor, together with the inner lining of stomach (mucosa), is removed from the wall of the stomach using an electrical wire loop through the endoscope. The advantage is that it is a much smaller operation than removing the stomach. Endoscopic submucosal dissection (ESD) is a similar technique pioneered in Japan, used to resect a large area of mucosa in one piece. If the pathologic examination of the resected specimen shows incomplete resection or deep invasion by tumor, the patient would need a formal stomach resection.

Surgical interventions are currently curative in less than 40% of cases, and, in cases of metastasis, may only be palliative.

Chemotherapy [edit]

The use of chemotherapy to treat stomach cancer has no firmly established standard of care. Unfortunately, stomach cancer has not been particularly sensitive to these drugs, and chemotherapy, if used, has usually served to palliatively reduce the size of the tumor, relieve symptoms of the disease and increase survival time. Some drugs used in stomach cancer treatment have included: 5-FU (fluorouracil) or its analog capecitabine, BCNU (carmustine), methyl-CCNU (Semustine), and doxorubicin (Adriamycin), as well as Mitomycin C, and more recently cisplatin and taxotere, often using drugs in various combinations. The relative benefits of these different drugs, alone and in combination, are unclear.[25] Clinical researchers have explored the benefits of giving chemotherapy before surgery to shrink the tumor, or as adjuvant therapy after surgery to destroy remaining cancer cells. Combination treatment with chemotherapy and radiation therapy has some activity in selected post surgical settings. For patients who have HER2 overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarcinoma, who have not received prior treatment for their metastatic disease, the US Food and Drug Administration granted approval (2010 October) for trastuzumab (Herceptin, Genentech, Inc.) in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil). This was based on an improvement of the median overall survival (OS) of 2.5 months[26] with trastuzumab plus chemotherapy treatment compared to chemotherapy alone (BO18255 ToGA trial). The combination of Herceptin with chemotherapy for treating metastatic gastric cancer was also sanctioned by the European regulatory authorities (2010 January).

Radiation [edit]

Radiation therapy (also called radiotherapy) is the use of high-energy rays to damage cancer cells and stop them from growing. When used, it is generally in combination with surgery and chemotherapy, or used only with chemotherapy in cases where the individual is unable to undergo surgery. Radiation therapy may be used to relieve pain or blockage by shrinking the tumor for palliation of incurable disease.

Multimodality therapy [edit]

While previous studies of multimodality therapy (combinations of surgery, chemotherapy and radiation therapy) gave mixed results, the Intergroup 0116 (SWOG 9008) study[27] showed a survival benefit to the combination of chemotherapy and radiation therapy in patients with nonmetastatic, completely resected gastric cancer. Patients were randomized after surgery to the standard group of observation alone, or the study arm of combination chemotherapy and radiation therapy. Those in the study arm receiving chemotherapy and radiation therapy survived on average 36 months; compared to 27 months with observation.

Epidemiology [edit]

Age-standardized death from stomach cancer per 100,000 inhabitants in 2004.[28]

no data

50

Stomach cancer is the fourth most common cancer worldwide with 930,000 cases diagnosed in 2002.[29] It is a disease with a high death rate (~800,000 per year) making it the second most common cause of cancer death worldwide after lung cancer.[1] It is more common in men and in developing countries.[29][30]

It represents roughly 2% (25,500 cases) of all new cancer cases yearly in the United States, but it is more common in other countries. It is the leading cancer type in Korea, with 20.8% of malignant neoplasms.

Metastasis occurs in 80-90% of individuals with stomach cancer, with a six month survival rate of 65% in those diagnosed in early stages and less than 15% of those diagnosed in late stages.

Less than 1 in every 50 people going to the doctor with indigestion have cancer.[31] Out of 10 million people in the Czech Republic, only 3 new cases of stomach cancer in people under 30 years of age in 1999 were diagnosed.[32] Other studies show that less than 5% of stomach cancers occur in people under 40 years of age with 81.1% of that 5% in the age-group of 30 to 39 and 18.9% in the age-group of 20 to 29.[33]

For Taiwan (statistic not shown on the above map), the mortality was 11.75 per 100,000 (1996).

Other animals [edit]

The stomach is a muscular organ of the gastrointestinal tract that holds food and begins the digestive process by secreting gastric juice. The most common cancers of the stomach are adenocarcinomas but other histological types have been reported. Signs vary but may include vomiting (especially if blood is present), weight loss, anemia, and lack of appetite. Bowel movements may be dark and tarry in nature. In order to determine whether cancer is present in the stomach, special X-rays and/or abdominal ultrasound may be performed. Gastroscopy, a test using an instrument called endoscope to examine the stomach, is a useful diagnostic tool that can also take samples of the suspected mass for histopathological analysis to confirm or rule out cancer. The most definitive method of cancer diagnosis is through open surgical biopsy.[34] Most stomach tumors are malignant with evidence of spread to lymph nodes or liver, making treatment difficult. Except for lymphoma, surgery is the most frequent treatment option for stomach cancers but it is associated with significant risks.

References [edit]

1.^ a b “Cancer (Fact sheet N°297)”. World Health Organization. February 2009. Retrieved 2009-05-11.
2.^ a b Tumors of the GI Tract at Merck Manual of Diagnosis and Therapy Professional Edition
3.^ a b “What Are The Risk Factors For Stomach Cancer(Website)”. American Cancer Society. Retrieved 2010-03-31.
4.^ Buckland G, Agudo A, Lujan L, Jakszyn P, Bueno-De-Mesquita HB, Palli D, Boeing H, Carneiro F, Krogh V (2009). “Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study”. American Journal of Clinical Nutrition 91 (2): 381–90. doi:10.3945/ajcn.2009.28209. PMID 20007304.
5.^ Nomura A, Grove JS, Stemmermann GN, Severson RK (1990). “Cigarette smoking and stomach cancer.”. Cancer Research 50 (21): 7084. PMID 2208177.
6.^ Trédaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A (August 1997). “Tobacco smoking and gastric cancer: Review and meta-analysis”. International Journal of Cancer 72 (4): 565–73. doi:10.1002/(SICI)1097-0215(19970807)72:43.0.CO;2-O. PMID 9259392.
7.^ Sung NY, Choi KS, Park EC, Park K, Lee SY, Lee AK, Choi IJ, Jung KW, Won YJ (2007). “Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study”. British Journal of Cancer 97 (5): 700–4. doi:10.1038/sj.bjc.6603893. PMC 2360367. PMID 17637680.
8.^ “Proceedings of the fourth Global Vaccine Research Forum”. Initiative for Vaccine Research team of the Department of Immunization, Vaccines and Biologicals. WHO. April 2004. Retrieved 2009-05-11. “Epidemiology of Helicobacter pylori and gastric cancer…”
9.^ Hatakeyama, M. & Higashi, H (2005). “Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis”. Cancer Science 96: 835–843. doi:10.1111/j.1349-7006.2005.00130.x. PMID 16367902.
10.^ Lee H-J, Yang H-K, Ahn Y-O (2002). “Gastric cancer in Korea”. Gastric Cancer 5 (3): 177–82. doi:10.1007/s101200200031. PMID 12378346.
11.^ Alonso-Amelot ME, Avendaño M (March 2002). “Human carcinogenesis and bracken fern: a review of the evidence”. Current Medicinal Chemistry 9 (6): 675–86. PMID 11945131.
12.^ Chandanos, Evangelos (December 2007). Estrogen in the development of esophageal and gastric adenocarcinoma (PDF) (Doctoral thesis). Karolinska Institutet. ISBN 978-91-7357-370-2.
13.^ Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J (2004). “Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria”. Journal of Medical Genetics 41 (7): 508–17. doi:10.1136/jmg.2004.018275. PMC 1735838. PMID 15235021.
14.^ Inoue H, Kudo S-, Shiokawa A (2005). “Technology Insight: laser-scanning confocal microscopy and endocytoscopy for cellular observation of the gastrointestinal tract”. Nature Clinical Practice Gastroenterology & Hepatology 2 (1): 31–7. doi:10.1038/ncpgasthep0072. PMID 16265098.
15.^ Pentenero M, Carrozzo M, Pagano M, Gandolfo S (2004). “Oral acanthosis nigricans, tripe palms and sign of leser-trelat in a patient with gastric adenocarcinoma”. International Journal of Dermatology 43 (7): 530–2. doi:10.1111/j.1365-4632.2004.02159.x. PMID 15230897.
16.^ Kumar; et al. (2010). Pathologic Basis of Disease (8th ed.). Saunders Elsevier. p. 784. ISBN 978-1-4160-3121-5.
17.^ Kumar 2010, p. 786
18.^ “Detailed Guide: Stomach Cancer Treatment Choices by Type and Stage of Stomach Cancer”. American Cancer Society. 2009-11-03.
19.^ Guy Slowik (2009-10). “What Are The Stages Of Stomach Cancer?”. ehealthmd.com.
20.^ “Detailed Guide: Stomach Cancer: How Is Stomach Cancer Staged?”. American Cancer Society.
21.^ Paterson HM, McCole D, Auld CD (2006). “Impact of open-access endoscopy on detection of early oesophageal and gastric cancer 1994–2003: population-based study”. Endoscopy 38 (5): 503–7. doi:10.1055/s-2006-925124. PMID 16767587.
22.^ Crane SJ, Locke GR, Harmsen WS, Zinsmeister AR, Romero Y, Talley NJ (2008). “Survival Trends in Patients With Gastric and Esophageal Adenocarcinomas: A Population-Based Study”. Mayo Clinic Proceedings 83 (10): 1087–1094. doi:10.4065/83.10.1087. PMC 2597541. PMID 18828967.
23.^ Heise K, Bertran E, Andia ME, Ferreccio C (2009). “Incidence and survival of stomach cancer in a high-risk population of Chile”. World Journal of Gastroenterology 15 (15): 1854–1862. doi:10.3748/wjg.15.1854. PMC 2670413. PMID 19370783.
24.^ Soetikno R, Kaltenbach T, Yeh R, Gotoda T (2005). “Endoscopic Mucosal Resection for Early Cancers of the Upper Gastrointestinal Tract”. Journal of Clinical Oncology 23 (20): 4490–8. doi:10.1200/JCO.2005.19.935. PMID 16002839.
25.^ Scartozzi M, Galizia E, Verdecchia L, Berardi R, Antognoli S, Chiorrini S, Cascinu S (2007). “Chemotherapy for advanced gastric cancer: across the years for a standard of care”. Expert Opinion on Pharmacotherapy 8 (6): 797–808. doi:10.1517/14656566.8.6.797. PMID 17425475.
26.^ Bang YJ, Van Cutsem E, Feyereislova A, et al. (August 2010). “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial”. Lancet 376 (9742): 687–97. doi:10.1016/S0140-6736(10)61121-X. PMID 20728210.
27.^ MacDonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL (2001). “Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction”. New England Journal of Medicine 345 (10): 725–30. doi:10.1056/NEJMoa010187. PMID 11547741.
28.^ “WHO Disease and injury country estimates”. World Health Organization. 2009. Retrieved Nov. 11, 2009.
29.^ a b Parkin DM, Bray F, Ferlay J, Pisani P (2005). “Global Cancer Statistics, 2002″. CA: A Cancer Journal for Clinicians 55 (2): 74–108. doi:10.3322/canjclin.55.2.74. PMID 15761078.
30.^ “Are the number of cancer cases increasing or decreasing in the world?”. WHO Online Q&A. WHO. 1 April 2008. Retrieved 2009-05-11.
31.^ “Guidance on Commissioning Cancer Services Improving Outcomes in Upper Gastro-intestinal Cancers”. NHS. Jan 2001.
32.^ Simsa J, Leffler J, Hoch J, Linke Z, Pádr R (2004). “Gastric cancer in young patients—is there any hope for them?” (PDF). Acta Chirurgica Belgica 104 (6): 673–6. PMID 15663273.[dead link]
33.^ “Gastric Cancer in Young Adults”. Revista Brasileira de Cancerologia 46 (3). Jul 2000.
34.^ Withrow SJ, MacEwen EG, ed. (2001). Small Animal Clinical Oncology (3rd ed.). W.B. Saunders Company.

External links [edit]

Wikimedia Commons has media related to: Stomach cancer

National Cancer Institute Gastric cancer treatment guidelines
GeneReview/NIH/UW entry on Hereditary Diffuse Gastric Cancer
Gastric Cancer Surgery

[hide]
v ·
t ·
e

Tumors: digestive system neoplasia (C15–C26/D12–D13, 150–159/211)

GI tract

Upper GI tract

Esophagus

Squamous cell carcinoma ·
Adenocarcinoma

Stomach

Gastric carcinoma ·
Signet ring cell carcinoma ·
Gastric lymphoma (MALT lymphoma)
·
Linitis plastica

Lower GI tract

Small intestine

Duodenal cancer (Adenocarcinoma)

Appendix

Carcinoid ·
Pseudomyxoma peritonei

Colon/rectum

colorectal polyp: Peutz–Jeghers syndrome ·
Juvenile polyposis syndrome ·
Familial adenomatous polyposis/Gardner’s syndrome ·
Cronkhite–Canada syndrome
neoplasm: Adenocarcinoma ·
Familial adenomatous polyposis ·
Hereditary nonpolyposis colorectal cancer

Anus

Squamous cell carcinoma

Upper and/or lower

Gastrointestinal stromal tumor ·
Krukenberg tumor (metastatic)

Accessory

Liver

malignant: Hepatocellular carcinoma (Fibrolamellar)
·
Hepatoblastoma
benign: Hepatocellular adenoma ·
Cavernous hemangioma
hyperplasia: Focal nodular hyperplasia ·
Nodular regenerative hyperplasia

Biliary tract

bile duct: Cholangiocarcinoma ·
Klatskin tumor
gallbladder: Gallbladder cancer

Pancreas

exocrine pancreas: Adenocarcinoma ·
Pancreatic ductal carcinoma
cystic neoplasms: Serous microcystic adenoma ·
Intraductal papillary mucinous neoplasm ·
Mucinous cystic neoplasm ·
Solid pseudopapillary neoplasm
Pancreatoblastoma

Peritoneum

Primary peritoneal carcinoma ·
Peritoneal mesothelioma ·
Desmoplastic small round cell tumor

M: DIG

anat (t, g, p)/phys/devp/enzy

noco/cong/tumr, sysi/epon

proc, drug (A2A/2B/3/4/5/6/7/14/16), blte

Categories: Gastrointestinal cancer
Abdomen

Patterns of peritoneal spread of tumor in the abdomen and pelvis.

Le O.

Source

Ott Le, Diagnostic Imaging, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, United States.

Abstract

The spread of tumor in the peritoneum can be understood, although it is a complex organ. A study of its embryology, anatomy and function is of clear benefit. It is formed from a network of folds, reflections, and potential spaces produced by the visceral and parietal peritoneum. These folds and reflections begin as a dorsal and ventral mesentery, supporting the primitive gut in early embryologic development. The dorsal mesentery connects the stomach and other organs to the posterior abdominal wall, while the ventral mesentery connects the stomach to the ventral abdominal wall. As the embryo develops, there is further organ growth, elongation, cavitation and rotation. The dorsal and ventral mesentery also develops along with the viscera, forming ligaments, mesenteries, omenta and potential spaces from the resulting reflections and folds. These ligaments, mesenteries, and omenta, support and nurture the organs of the peritoneum, providing a highway for arteries, veins, nerves and lymphatics. The potential spaces created from these folds and reflections of the visceral and parietal peritoneum are also important to realize. For example, the transverse mesocolon divides the peritoneal cavity into a supramesocolic and inframesocolic space in the abdomen and paravesicular spaces within the pelvis. The falciform ligament is well known in the supramesocolic space, dividing it further into a left and right compartment. Knowledge of the peritoneal vascular anatomy is beneficial in locating the spaces and ligaments about the peritoneum. For example, identifying the left gastric artery or vein will lead to the gastrohepatic ligament, which is part of the supramesocolic space. Besides serving a life sustaining role, the multiple compartments, ligaments, mesenteries and omenta within the peritoneum can also facilitate the spread of disease. Tumors can spread directly from one organ to another, seed metastatic deposits in the peritoneal cavity, and travel through the lymphatic or hematogenous route to invade other organs in the peritoneum.

KEYWORDS:

Abdomen, Pelvis, Peritoneal

PMID: 23671747 [PubMed - in process]

Supplemental Content

Save items

Add to FavoritesView more options

Recent activity

Clear Turn Off
Patterns of peritoneal spread of tumor in the abdomen and pelvis.

PubMed

stomach cancer (83947)
PubMed

See more…

You are here: NCBI > Literature > PubMed
Write to the Help Desk

Simple NCBI Directory

Getting Started

NCBI Education
NCBI Help Manual
NCBI Handbook
Training & Tutorials

Resources

Chemicals & Bioassays
Data & Software
DNA & RNA
Domains & Structures
Genes & Expression
Genetics & Medicine
Genomes & Maps
Homology
Literature
Proteins
Sequence Analysis
Taxonomy
Training & Tutorials
Variation

Popular

PubMed
Nucleotide
BLAST
PubMed Central
Gene
Bookshelf
Protein
OMIM
Genome
SNP
Structure

Featured

Genetic Testing Registry
PubMed Health
GenBank
Reference Sequences
Map Viewer
Human Genome
Mouse Genome
Influenza Virus
Primer-BLAST
Sequence Read Archive

NCBI Information

About NCBI
Research at NCBI
NCBI Newsletter
NCBI FTP Site
NCBI on Facebook
NCBI on Twitter
NCBI on YouTube

NLM

NIH

DHHS

USA.gov

Copyright | Disclaimer | Privacy | Browsers | Accessibility | Contact
National Center for Biotechnology Information, U.S. National Library of Medicine8600 Rockville Pike, BethesdaMD, 20894USA
Investigation of the role of 5-HT2 receptor subtypes in the control of the bladder and the urethra in the anaesthetized female rat.

Mbaki Y, Ramage AG
Department of Pharmacology, University College London, Hampstead Campus, Rowland Hill Street, London NW3 2PF, UK.

BACKGROUND AND PURPOSE: Micturition is controlled by central 5-HT-containing pathways. 5-HT2 receptors have been implicated in this system especially in control of the urethra, which is a drug target for treating urinary incontinence. This study investigates the role of each of the three subtypes of this receptor with emphasis on sphincter regulation. EXPERIMENTAL APPROACH: Recordings of urethral and bladder pressure, external urethral sphincter (EUS) EMG, as well as the micturition reflex induced by bladder distension along with blood pressure and heart rate were made in anaesthetized rats. The effects of agonists and antagonists for 5-HT2 receptor subtypes were studied on these variables. KEY RESULTS: The 5-HT2C agonists Ro 60-0175 [?], WAY 161503 and mCPP, i.v., activated the EUS, increased urethral pressure and inhibited the micturition reflex. The effects of Ro 60-0175 [?] on the EUS were blocked by the 5-HT2C antagonist SB 242084 and the 5-HT2A antagonists, ketanserin and MDL 100907 [?]. SB 242084 also blocked the inhibitory action on the reflex, while the 5-HT2B antagonist RS 127445 only blocked the increase in urethral pressure. The 5-HT2A receptor agonist DOI given i.v. or i.t. but not i.c.v. activated the EUS. CONCLUSIONS AND IMPLICATIONS: 5-HT2A/2C receptors located in the sacral spinal cord activate the EUS, while central 5-HT2C receptors inhibit the micturition reflex and 5-HT2B receptors, probably at the level of the urethra, increase urethral smooth muscle tone. Furthermore, 5-HT2B and 5-HT2C receptors do not seem to play an important role in the physiological regulation of micturition.

Br. J. Pharmacol. (2008)
PMID: 18604238 Fulltext – Related articles – Download citation

Alabama (AL)
•Birmingham, AL
•Mobile, AL

Alaska (AK)

Arizona (AZ)
•Mesa, AZ
•Phoenix, AZ
•Tucson, AZ

Arkansas (AR)
•Hot Springs, AR
•Little Rock, AR

California (CA)
•Anaheim, CA
•Bakersfield, CA
•Fresno, CA
•Long Beach, CA
•Los Angeles, CA
•Sacramento, CA
•San Diego, CA
•San Francisco, CA
•San Jose, CA

Colorado (CO)
•Denver, CO

Connecticut (CT)

Delaware (DE)

District of Columbia (DC)
•Washington, DC

Florida (FL)
•Jacksonville, FL
•Miami, FL
•Orlando, FL
•Saint Petersburg, FL
•Tampa, FL

Georgia (GA)
•Atlanta, GA
•Augusta, GA
•Columbus, GA

Hawaii (HI)
•Honolulu, HI

Idaho (ID)

Illinois (IL)
•Chicago, IL

Indiana (IN)
•Fort Wayne, IN
•Indianapolis, IN

Iowa (IA)
•Des Moines, IA

Kansas (KS)
•Overland Park, KS
•Wichita, KS

Kentucky (KY)
•Lexington, KY
•Louisville, KY

Louisiana (LA)
•Alexandria, LA
•Baton Rouge, LA
•Lafayette, LA
•Lake Charles, LA
•Monroe, LA
•New Orleans, LA
•Shreveport, LA

Maine (ME)

Maryland (MD)
•Baltimore, MD

Massachusetts (MA)
•Boston, MA
•Worcester, MA

Michigan (MI)
•Detroit, MI
•Grand Rapids, MI

Minnesota (MN)

Mississippi (MS)
•Jackson, MS
•Meridian, MS

Missouri (MO)
•Columbia, MO
•Kansas City, MO
•Saint Louis, MO

Montana (MT)

Nebraska (NE)
•Lincoln, NE
•Omaha, NE

Nevada (NV)
•Las Vegas, NV

New Hampshire (NH)

New Jersey (NJ)

New Mexico (NM)
•Albuquerque, NM

New York (NY)
•Albany, NY
•Bronx, NY
•Brooklyn, NY
•Buffalo, NY
•New York, NY

North Carolina (NC)
•Charlotte, NC

North Dakota (ND)

Ohio (OH)
•Akron, OH
•Cincinnati, OH
•Cleveland, OH
•Columbus, OH
•Dayton, OH
•Toledo, OH

Oklahoma (OK)
•Lawton, OK
•Oklahoma City, OK
•Tulsa, OK

Oregon (OR)
•Portland, OR

Pennsylvania (PA)
•Allentown, PA
•Philadelphia, PA
•Pittsburgh, PA

Rhode Island (RI)

South Carolina (SC)
•Charleston, SC
•Greenville, SC

South Dakota (SD)

Tennessee (TN)
•Chattanooga, TN
•Knoxville, TN
•Memphis, TN
•Nashville, TN

Texas (TX)
•Amarillo, TX
•Arlington, TX
•Austin, TX
•Corpus Christi, TX
•Dallas, TX
•El Paso, TX
•Fort Worth, TX
•Houston, TX
•Lubbock, TX
•Plano, TX
•San Antonio, TX
•Sugar Land, TX
•Tyler, TX

Utah (UT)
•Salt Lake City, UT

Vermont (VT)

Virginia (VA)
•Richmond, VA

Washington (WA)
•Seattle, WA

West Virginia (WV)

Wisconsin (WI)
•Green Bay, WI
•Madison, WI
•Milwaukee, WI

Wyoming (WY)

Family history and the risk of stomach and colorectal cancer

Carlo La Vecchia M.D.1,2,*,
Eva Negri Sc.D.1,
Antonella Gentile Ph.D.1,
Silvia Franceschi M.D.3

Article first published online: 29 JUN 2006

DOI: 10.1002/1097-0142(19920701)70:13.0.CO;2-I

Copyright © 1992 American Cancer Society

Issue

Cancer

Volume 70, Issue 1, pages 50–55, 1 July 1992

Additional Information(Show All)

How to CiteAuthor InformationPublication HistoryFunding Information

SEARCH

Search ScopeAll contentPublication titlesIn this journalIn this issueBy Citation
Search String
Advanced >
Saved Searches >

ARTICLE TOOLS
Get PDF (458K)
Save to My Profile
E-mail Link to this Article
Export Citation for this Article
Get Citation Alerts
Request Permissions

More Sharing ServicesShare|Share on citeulikeShare on connoteaShare on deliciousShare on http://www.mendeley.comShare on twitter

Abstract
References
Cited By

Get PDF (458K)

Keywords:

colorectal neoplasms;
family history;
risk;
stomach neoplasms

Abstract

Background. The role of a family history of selected neoplasms in first-degree relatives in the risk of gastrointestinal cancers has been investigated, but requires further quantification.

Methods. A case-control study was conducted in northern Italy on 628 histologically confirmed incident cases of stomach cancer, 766 cases of colon cancer, 456 cases of rectal cancer, and 1766 controls admitted to hospital for acute, nonneoplastic, non-digestive tract disorders.

Results. Significant associations were observed between a family history of gastric cancer and stomach cancer risk (relative risk [RR], 2.6), and between a family history of intestinal cancer and colon (RR, 2.4) and rectal cancer (RR, 1.7). There was a tendency for the risks to be above unity for a family history of stomach cancer and for a number of other cancer sites (including esophagus, intestines, liver, pancreas, gallbladder, and lung), and the RR were of borderline statistical significance for cancer of the liver and intestines. The RR for a family history of lung cancer was 1.5 for stomach, 1.2 for colon, and 1.3 for rectal cancer, with none of the estimates being significant. There was no consistent pattern of risk with reference to the type of first-degree relationship; the RR was similar for stomach cancer with reference to parents and siblings, and for colon and rectal cancer, it was only moderately higher with reference to siblings. Significant trends in risk with the number of first-degree relatives were observed for all three cancer sites investigated.

Conclusions. In terms of population attributable risk, approximately 8% of stomach cancers and 3% of colorectal cancers would be related to this familial component.

Get PDF (458K)
Content referenced by

http://en.wikipedia.org/wiki/Stomach_cancer

http://www.ncbi.nlm.nih.gov/pubmed?term=stomach%20cancer

http://www.ihop-net.org/UniPub/iHOP/index.html?search=stomach+&field=all&ncbi_tax_id=0&organism_syn=

http://www.healthgrades.com/hospital-directory

http://scholar.google.ca/scholar?hl=en&q=stomach+cancer&btnG=&as_sdt=1%2C5&as_sdtp=

Posted in Uncategorized | Leave a comment

Cancer of the Appendix Sarcoma


Appendix Cancer

Name l Define l Risk l Detect l Treatment l Stage/Grade l Followup l Mets/Recur l Link

Names – Synonyms

Appendix cancer, appendiceal cancer, see definition below for types

Definition

Appendiceal cancers are considered malignancies of the gastrointestinal system, accounting for about 1 in 200 gastrointestinal malignancies. The appendix (aka: vermiform process) is part of that system, although it has no known function or purpose in present day man.

Note: If you are seeking research for your appendiceal cancer in a book, the first place to look is the gastrointestinal section. You may not find anything because of it’s rarity. Between 1973 and 1998, 2117 appendiceal malignancies were reported to the United States SEER program. That’s less than 85 cases a year!

There are a number of non-cancerous tumors or nodules of the appendix; including adenoma (serrated, tubular, tubulovillous, villous), benign mesothelioma, cystadenoma (cystic adenoma), granular cell tumor, leiomyoma, lipoma, mucinous adenoma, mucinous cystadenoma (low grade appendiceal mucinous neoplasm), neurofibroma, neuroma, and polyp.

Borderline tumors, which may be malignant of benign, include fibrous histiocytic tumor, mucinous neoplasm of low malignant potential ( most commonly associated with pseudomyxoma peritonei), and mucinous neoplasm of uncertain malignant potential.

Malignancies of the appendix include adenocarcinoma, gastrointestinal stromal tumor (very rare), kaposi sarcoma, leiomyosarcoma, mixed cell (carcinoid & adenocarcinoma), mucinous adenocarcinoma (carcinoma), non-Hodgkin lymphoma (very rare), signet ring cell adenocarcinoma (carcinoma), small cell carcinoma, and undifferentiated carcinoma. Appendiceal carcinoids include endocrine/neuroendocrine {enterochromaffin (EC) (serotonin producing); non-argentaffin (L-Cell) (glucagon-like peptide)}, goblet cell carcinoma (adenocarcinoid), and tubular.

Conditions or syndromes that may coexist with a diagnosis of appendiceal tumor include disseminated peritoneal adenomucinosis, peritoneal carcinomatosis, and pseudomxoma peritonei

Risk Factors – Causes

Some familial risks have been reported for appendiceal carcinoids, such as the MEN1 syndrome. Gastritis, pernicious anemia, or Zollinger-Ellison syndrome may also predispose a person to carcinoid. Age may be a factor.

Detection

Intussusception, palpable mass, gastrointestinal bleeding, increasing abdominal girth, or secondary genitourinary complications may all be signs of an appendiceal tumor. Redness or a feeling of warmth in the face and neck, diarrhea, shortness of breath, fast heartbeat, tiredness, swelling of the feet and ankles, wheezing, pain or a feeling of fullness in the abdomen could be indicative of a carcinod or neuroendocrine tumor.

Blood tests, blood chemistry studies, and 24 hour urine tests might be used to rule out a carcinoid. Tumors that infiltrate large portions of the appendix may be seen on CT scan. Somatostatin receptor scintigraphy (SRS) may be used to diagnose carcinoids of the appendix.

Staging may include endoscopy, biopsy, xray, SRS, angiogram, PET and/or CT scans. Some appendix cancers are diagnosed after removal of the appendix for acute appendicitis. Sadly, many cancers of the appendix are diagnosed at autopsy.

Treatment

Treatment for cancers of the appendix are normally based on the involvement of the cancer. Localized, smaller, tumors are normally treated with surgery, alone. Appendiceal cancer that has moved out of the appendix may be treated with surgical procedures, cytoreductive surgery, and/or intraperitoneal hyperthermia.

Surgical techniques; such as ablation, fulguration, cryosurgery, ligation, or embolization; and radiotherapy, chemotherapy, and chemoembolization may also be used for carcinoids. Ethanol injection, hormone therapy, and biologic therapies might be used in conjunction with other treatments.

Stage – Grade

Carcinoid tumors are usually slow growing. Carcinoids are staged according to their involvement:
Localized – Encapsulated with the appendix.
Regional – In other areas of the gastrointestinal tract, lymph nodes, or surrounding tissue.
Metastatic – In areas outside of the gastrointestinal system.

Suggested Followups

Metastasis – Recurrence

Links

Appendix Cancer (Appendiceal) Support Forum

Gastrointestinal Kaposi sarcoma with appendiceal involvement.

Egwuonwu S, Gatto-Weis C, Miranda R, Casas Lde L.

Source

Department of Internal Medicine and Pathology, The University of Kansas Medical Center, Kansas City, Kansas, USA. Steveoge76@yahoo.com

Abstract

Kaposi sarcoma is a vascular tumor manifesting as nodular lesions on skin, mucous membranes, or internal organs. This is a case of a 42-year-old human immunodeficiency virus- (HIV) positive bisexual male, not on highly active antiretroviral therapy (HAART) since diagnosis four years ago. He presented with a three-day history of abdominal pains, fever, vomiting, and a one-week history of melena stools. Endoscopy revealed Kaposi sarcoma in the stomach and duodenum. Postendoscopy, he developed acute abdomen. Exploratory laparotomy revealed extensive Kaposi sarcoma of the gastrointestinal tract with appendiceal involvement. The patient underwent appendectomy and had an uneventful recovery. A review of the literature discusses appendiceal Kaposi sarcoma with appendicitis, a rare but critical manifestation of gastrointestinal Kaposi sarcoma.
Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis.

Takeo S, Arai H, Kusano N, Harada T, Furuya T, Kawauchi S, Oga A, Hirano T, Yoshida T, Okita K, Sasaki K.

Source

Department of Pathology, Yamaguchi University School of Medicine, Ube 755-8505, Japan. saori.t@po.cc.yamaguchi-u.ac.jp

Abstract

To identify amplified oncogenes involved in hepatocellular carcinomas (HCC), we applied a genomic DNA microarray spotted with 57 oncogenes to 20 HCCs. Aberrations in DNA copy number also were analyzed by comparative genomic hybridization (CGH) using an aliquot of DNA samples. In 5 of 20 HCCs, only 6 oncogenes (CCND1, FGF3/FGF4, SAS/CDK4, TERC, MET, and MYC) were amplified, whereas in the remaining 15 tumors no oncogenes were amplified. A comparison of DNA microarray and conventional CGH analyses showed that, although 5 of 6 amplified oncogenes shown by microarray were located in chromosomal regions shown by CGH to have increased DNA copy numbers, not all genes located in such chromosomal regions were affected. One of the amplified oncogenes (SAS/CDK4) was found in a chromosomal region that was undetected by CGH. We, therefore, conclude that amplification of the oncogenes examined in this series is not directly implicated in hepatocellular carcinogenesis.

PMID: 11675133 [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms

Alabama (AL)
•Birmingham, AL
•Mobile, AL

Alaska (AK)

Arizona (AZ)
•Mesa, AZ
•Phoenix, AZ
•Tucson, AZ

Arkansas (AR)
•Hot Springs, AR
•Little Rock, AR

California (CA)
•Anaheim, CA
•Bakersfield, CA
•Fresno, CA
•Long Beach, CA
•Los Angeles, CA
•Sacramento, CA
•San Diego, CA
•San Francisco, CA
•San Jose, CA

Colorado (CO)
•Denver, CO

Connecticut (CT)

Delaware (DE)

District of Columbia (DC)
•Washington, DC

Florida (FL)
•Jacksonville, FL
•Miami, FL
•Orlando, FL
•Saint Petersburg, FL
•Tampa, FL

Georgia (GA)
•Atlanta, GA
•Augusta, GA
•Columbus, GA

Hawaii (HI)
•Honolulu, HI

Idaho (ID)

Illinois (IL)
•Chicago, IL

Indiana (IN)
•Fort Wayne, IN
•Indianapolis, IN

Iowa (IA)
•Des Moines, IA

Kansas (KS)
•Overland Park, KS
•Wichita, KS

Kentucky (KY)
•Lexington, KY
•Louisville, KY

Louisiana (LA)
•Alexandria, LA
•Baton Rouge, LA
•Lafayette, LA
•Lake Charles, LA
•Monroe, LA
•New Orleans, LA
•Shreveport, LA

Maine (ME)

Maryland (MD)
•Baltimore, MD

Massachusetts (MA)
•Boston, MA
•Worcester, MA

Michigan (MI)
•Detroit, MI
•Grand Rapids, MI

Minnesota (MN)

Mississippi (MS)
•Jackson, MS
•Meridian, MS

Missouri (MO)
•Columbia, MO
•Kansas City, MO
•Saint Louis, MO

Montana (MT)

Nebraska (NE)
•Lincoln, NE
•Omaha, NE

Nevada (NV)
•Las Vegas, NV

New Hampshire (NH)

New Jersey (NJ)

New Mexico (NM)
•Albuquerque, NM

New York (NY)
•Albany, NY
•Bronx, NY
•Brooklyn, NY
•Buffalo, NY
•New York, NY

North Carolina (NC)
•Charlotte, NC

North Dakota (ND)

Ohio (OH)
•Akron, OH
•Cincinnati, OH
•Cleveland, OH
•Columbus, OH
•Dayton, OH
•Toledo, OH

Oklahoma (OK)
•Lawton, OK
•Oklahoma City, OK
•Tulsa, OK

Oregon (OR)
•Portland, OR

Pennsylvania (PA)
•Allentown, PA
•Philadelphia, PA
•Pittsburgh, PA

Rhode Island (RI)

South Carolina (SC)
•Charleston, SC
•Greenville, SC

South Dakota (SD)

Tennessee (TN)
•Chattanooga, TN
•Knoxville, TN
•Memphis, TN
•Nashville, TN

Texas (TX)
•Amarillo, TX
•Arlington, TX
•Austin, TX
•Corpus Christi, TX
•Dallas, TX
•El Paso, TX
•Fort Worth, TX
•Houston, TX
•Lubbock, TX
•Plano, TX
•San Antonio, TX
•Sugar Land, TX
•Tyler, TX

Utah (UT)
•Salt Lake City, UT

Vermont (VT)

Virginia (VA)
•Richmond, VA

Washington (WA)
•Seattle, WA

West Virginia (WV)

Wisconsin (WI)
•Green Bay, WI
•Madison, WI
•Milwaukee, WI

Wyoming (WY)

Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.

J M Coindre,
P Terrier,
N B Bui,
F Bonichon,
F Collin,
V Le Doussal,
A M Mandard,
M O Vilain,
J Jacquemier,
H Duplay,
X Sastre,
C Barlier,
M Henry-Amar,
J Macé-Lesech and
G Contesso

+ Author Affiliations

French Federation of Cancer Centers Sarcoma Group, Paris, France.

Abstract

PURPOSE To define the prognostic factors in adult patients with locally controlled soft tissue sarcoma (STS) and to determine which patients should be considered for adjuvant treatment.

PATIENTS AND METHODS Five hundred forty-six patients with a nonmetastatic and locally controlled STS, collected in a cooperative data base by the French Federation of Cancer Centers (FNCLCC) Sarcoma Group from 1980 and 1989, were studied. Histologic slides of all patients were collegially reviewed. Initial treatment consisted of complete tumor resection with amputation in only 4% of the patients. Adjuvant radiotherapy was administered to 57.9% and adjuvant chemotherapy to 31%. Relationships between tumor characteristics were analyzed, and univariate and multivariate analyses were performed using Cox models for the hazards rate of tumor mortality, development of distant metastasis, and strictly local recurrence.

RESULTS Unfavorable characteristics with an independent prognostic value for tumor mortality were: grade 3 (P = 3 x 10(-10)), male sex (P = 1.5 x 10(-5)), no adjuvant chemotherapy (P = 5.4 x 10(-5)), tumor size > or = 5 cm (P = 3.8 x 10(-3)), and deep location (P = 4.6 x 10(-3)). Unfavorable characteristics for the development of distant metastasis were: grade 3 (P = 4 x 10(-12)), no adjuvant chemotherapy (P = 6.4 x 10(-4)), tumor size > or = 10 cm (P = 9.8 x 10(-4)), and deep location (P = 1.3 x 10(-3)). For the development of local recurrence, the unfavorable characteristics were: no adjuvant radiotherapy (P = 3.6 x 10(-6)), poor surgery (local excision) (P = 2 x 10(-4)), grade 3 (P = 7.6 x 10(-4)), and deep location (P = 10(-2)). Grade, depth, and tumor size were used to define groups of patients according to the metastatic risk. Adjuvant chemotherapy was beneficial in terms of overall survival and metastasis-free survival in grade 3 tumor patients only. Despite worse characteristics concerning tumor depth, tumor-node-metastasis (TNM) and American Joint Committee (AJC)/International Union Against Cancer (UICC) classifications and grade in patients with adjuvant radiotherapy, the latter experienced significantly fewer local recurrences than patients with no radiotherapy.

CONCLUSION Grade, tumor depth, and tumor size could be used to select patients with a high metastatic risk, for which adjuvant chemotherapy could be beneficial.

CiteULike
Delicious
Digg
Facebook

Google+
Reddit

Content referenced by

http://www.rare-cancer.org/info/appendix-cancer.php

http://www.ncbi.nlm.nih.gov/pubmed?term=cancer%20of%20the%20appendix%20sarcoma

http://www.ihop-net.org/UniPub/iHOP/index.html?field=all&search=sarcoma&organism_id=0

http://www.healthgrades.com/hospital-directory

http://scholar.google.ca/scholar?hl=en&q=sarcoma+cancer+of+the+appendix&btnG=&as_sdt=1%2C5&as_sdtp=

Posted in Uncategorized | Leave a comment